text,labels
"GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19 SOUTH SAN FRANCISCO, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19.  ",1
"GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium SOUTH SAN FRANCISCO, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020.",1
"GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050 SOUTH SAN FRANCISCO, Calif., Aug.  10, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel technology for producing a new class of drug, which it calls ""recombinant hyperimmunes.""",1
"GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050 SOUTH SAN FRANCISCO, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), Waisman Biomanufacturing and Goodwin Biotechnology, Inc.",1
GigaGen Announces Publication in the Peer-Reviewed Journal mAbs Article Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge Platform Article Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge Platform,1
"Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences BERWYN, Pa., Dec.  15, 2020  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., presented her paper, “Targeting Increased Levels of Neurotoxic Proteins in Down Syndrome, Alzheimer’s and Parkinson’s Animals Normalized Axonal Transport, Cognition and Function,” at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.",1
"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report BERWYN, Pa., Dec.  17, 2020  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.",1
"GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology Article describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy Article describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy",1
"GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies SOUTH SAN FRANCISCO, May  25, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal BMC Biology. The preclinical data describes potential new avenues to overcome resistance to anti-PD-L1 therapies.",1
"GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564 --Reduced checkpoint inhibitor activity of GIGA-564 versus current anti-CTLA-4 inhibitors results in superior anti-tumor activity and lower toxicity in murine models ----Data supports advancement of GIGA-564 into the clinic for cancer indications-- SOUTH SAN FRANCISCO, Calif., July  14, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in bioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.",1
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19 First-in-human study evaluating recombinant hyperimmunes First-in-human study evaluating recombinant hyperimmunes,1
"GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates SOUTH SAN FRANCISCO, Calif., Sept.  30, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.",1
"GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development SOUTH SAN FRANCISCO, Calif., May  19, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.",1
"GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies SOUTH SAN FRANCISCO, Calif., July  28, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,” in the international, peer-reviewed journal Pathogens. This work showcases for the first time the GMP (good manufacturing practice) manufacturing and IND (Investigational New Drug)-enabling studies of its new class of drugs, recombinant polyclonal antibodies, describing the company’s recombinant polyclonal product that targets SARS-CoV-2, GIGA-2050.",0
"GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens SOUTH SAN FRANCISCO, Calif., Sept.  15, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.",1
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year,1
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye,1
"Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer SAN DIEGO and SUZHOU, China, Dec.  16, 2022  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC; liver cancer). The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and efficient combination development.",2
"Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mgkg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b2 Trial - No dose-limiting toxicities observed when ADG126 combined up to 10 mgkg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology -",2
"Quarterly Activities and Cashflow Report ADELAIDE, Australia, Jan.  30, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX  ASX BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 December 2022 (Quarter) and up to the date of this announcement include",1
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress Initiated Phase 2 proof-of-concept study of RZ402,1
"Bionomics’ Half-Year Report ADELAIDE, Australia, Feb.  23, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (ASX BNO, NASDAQ BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value.",2
"Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies",1
"Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD) ADELAIDE, Australia, March  08, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX  ASX BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators for serious central nervous system (CNS) disorders with high unmet medical need, today announced the release of a comprehensive analysis of the data from its Phase 2 PREVAIL study to evaluate the efficacy and safety of BNC210, a novel α7 nicotinic acetylcholine receptor negative allosteric modulator, for the acute treatment of Social Anxiety Disorder (SAD). These data support late-stage development of BNC210 in SAD.",1
"A.I. Coming to Certara’s D360 Scientific Informatics Software New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.",1
"Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments -- Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter -- -- Signed $67 Million in Net New Business Orders Resulting in a Backlog of $176 million, an Increase of 26% Year-Over-Year --",2
"Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April - Clinical posters detail results of dose escalation portion of phase 1b2 trials of ADG126 in combination with anti-PD-1 therapies, demonstrating benefits of SAFEbody precision masking technology -",1
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye,1
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update -- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 23 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients,1
"Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an αvβ3 small molecule drug conjugate (SMDC) in advanced solid tumors",1
"Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WALTHAM, Mass., March  31, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,700,000 shares of its common stock at a purchase price of $3.60 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.",0
Enochian BioSciences’ CEO Letter to Shareholders Turning the Page; A Promising Future Turning the Page; A Promising Future,2
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility,1
"ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023 PORTLAND, Maine, April  05, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2023, which ended March 31, 2023.",1
"Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS). IRVINE, Calif., April  17, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical diagnostic products, is pleased to announce that inFoods® IBS, a revolutionary new approach to alleviate Irritable Bowel Syndrome (IBS) symptoms, is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro Health offices in the future.",1
"Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic PDX mouse models across several tumor types VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic PDX mouse models across several tumor types",2
"Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023 BOSTON, April  17, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today presented preclinical data characterizing MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader designed for the treatment of MYC-driven solid tumors, including lung cancer. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL.",1
"Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in AdvancedMetastatic Solid Tumors - Results of dose escalation portion from phase 1b2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors -",2
"MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New York and virtually. ",1
Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) Topline results expected in Q3 2023 Topline results expected in Q3 2023,1
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year Asserts Certara’s leadership in advancing the development and approval of new drugs for patients Asserts Certara’s leadership in advancing the development and approval of new drugs for patients,1
"Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting NEW YORK, April  27, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID) reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neurology (AAN) from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The findings reaffirm soticlestat was generally safe and well tolerated. Soticlestat additionally showed an encouraging median seizure reduction in both conditions.",1
"Quarterly Activities and Cashflow Report ADELAIDE, Australia, April  28, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX  ASX BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 March 2023 (Quarter) and up to the date of this announcement include",1
"Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors NEW YORK, May  01, 2023  (GLOBE NEWSWIRE) --  Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, and Graviton Bioscience Corporation, a privately held early-stage drug development company specializing in therapeutics that inhibit RhoRho-associated coiled-coil containing protein kinase 2 (ROCK2), today announced a collaboration agreement to innovate novel medicines that they believe will significantly change the treatment paradigm for serious, rare neurological diseases.",1
"Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention – New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector –",1
"AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP) SAN DIEGO, May  02, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology. Patients with GPP who received a single dose of imsidolimab demonstrated a rapid and sustained improvement of symptoms and pustular eruptions of GPP flare within days after initiating treatment.",1
"MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has signed a collaboration agreement with SHL Medical, a world-leading provider of advanced drug delivery solutions, to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® sonelokimab.",1
"Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry WEST LAFAYETTE, Ind., May  04, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv’s Discovery and Safety Assessment business, telemetry allows for the continuous observation of ECG, respiratory rate and volume, blood pressure and other cardiovascular parameters during preclinical safety studies.",1
"Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate SAN DIEGO and SUZHOU, China, May  04, 2023  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate (ADC) candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.",1
"Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results – Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza –",1
"Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates NEW YORK, May  05, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter ended March 31, 2023.",0
"ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis SAN DIEGO, May  09, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the Pulmonology, Allergy-Drugs Advisory Committee (PADAC) meeting to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.",1
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights — Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in June –,2
Seer Reports First Quarter 2023 Financial Results Grew revenue 22% year-over-year with continued growth in installed base,1
"Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products FLORHAM PARK, N.J., May  10, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has been advised by Farouk, Maamoun Tamer & Co. (Tamer Group), the exclusive distributor for Celularity's branded Halal-Certified biomaterial products in the Kingdom of Saudi Arabia, that it expects to submit purchase orders through the end of 2023 in the range of $60 million to $80 million.",1
"Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update BOSTON, May  11, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended March 31, 2023.",2
RAPT Therapeutics Reports First Quarter 2023 Financial Results Company maintains strong cash position of $231.6 million Company maintains strong cash position of $231.6 million,1
"Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI – STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ",1
"Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma SOUTH SAN FRANCISCO, Calif., May  11, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023 the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML). NKX019 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target the B-cell antigen CD19.",1
"Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., May  11, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2023.",1
"ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023 PORTLAND, Maine, May  11, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2023.",0
"Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class αvβ3 small molecule drug conjugate (SMDC) for the treatment of solid tumors",1
"Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results Updates Select Full Year Fiscal 2023 Financial Guidance Updates Select Full Year Fiscal 2023 Financial Guidance",0
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023,1
"AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update SAN DIEGO, May  11, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.",0
"FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis SAN DIEGO, May  11, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drug Advisory Committee (PADAC) voted 166 in favor for adults, and 175 in favor for children (18 years of age and ≥30 kg), that available data support a favorable benefit-risk assessment for neffy in the treatment of severe allergic reaction (Type 1), including anaphylaxis,for adults and children who weigh more than 30kg.",1
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update,1
"Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update REDWOOD CITY, Calif., May  12, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended March 31, 2023, and provided a business update.",1
"Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 -",2
"ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions (Type I), Including Anaphylaxis",1
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023,1
"Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024",1
"Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023 VANCOUVER, British Columbia, May  16, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO MYCO) (OTC MYCOF) (FSE 0NFA) (""Mydecine"" or the ""Company""), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the three months ended March 31, 2023.",1
"XBiotech lance l'offre publique pour le rachat de ses parts à hauteur de 80 millions de dollars AUSTIN, Texas,  18 mai 2023  (GLOBE NEWSWIRE) --  XBiotech Inc. (NASDAQ  XBIT) (« XBiotech ») a annoncé aujourd'hui le commencement de son offre émettrice publique de rachat « à la hollandaise modifiée » pour le rachat de ses actions ordinaires à hauteur de 80 millions de dollars, ou pour un nombre d'actions ordinaires inférieur mais dûment soumises et non retirées, à un prix compris entre 3,80 dollars (inclus) et 4,00 dollars (inclus) par action ordinaire, payable au vendeur en numéraire, moins les retenues fiscales applicables et sans intérêt (l'« Offre »). L'Offre est présentée conformément aux modalités et sous réserve des conditions décrites dans une offre d'achat datée du 17 mai 2023, dans la lettre de transmission correspondante et sur le site Web créé aux fins de l'exécution de l'Offre. Le prix de clôture des actions ordinaires de XBiotech sur le NASDAQ Global Select Market au 17 mai 2023, le dernier jour de bourse complet avant le début de l'Offre, était de 3,48 dollars par action. L'Offre doit expirer à 17h00, heure de l'Est, le 15 juin 2023, sauf si l'Offre est reconduite.",0
"XBiotech startet Kaufangebot im Wert von bis zu 80.000.000 USD für seine Aktien AUSTIN, Texas, May  18, 2023  (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ XBIT) („Xbiotech“) gab heute bekannt, dass es ein Kaufangebot im Rahmen einer „modifizierten holländischen Auktion“ für den Erwerb seiner Stammaktien im Wert von bis zu 80.000.000 USD oder einer geringeren Anzahl von Stammaktien, die ordnungsgemäß angedient und nicht ordnungsgemäß zurückgezogen wurden, zu einem Preis von nicht mehr als 4,00 USD und nicht weniger als 3,80 USD pro Stammaktie an den Verkäufer in bar, abzüglich etwaiger geltender Quellensteuern und ohne Zinsen, gestartet hat (das „Angebot“). Das Angebot erfolgt zu den Bedingungen, die in einem Kaufangebot vom 17. Mai 2023, dem zugehörigen Begleitschreiben und der zum Zweck der Durchführung des Angebots eingerichteten Website beschrieben sind, und unterliegt diesen Bedingungen. Der Schlusskurs der XBiotech-Stammaktien am NASDAQ Global Select Market am 17. Mai 2023, dem letzten Handelstag vor Beginn des Angebots, betrug 3,48 USD je Aktie. Das Angebot endet planmäßig am 15. Juni 2023 um 1700 Uhr (Eastern Time), sofern es nicht verlängert wird.",0
"inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology NEWPORT BEACH, Calif., May  18, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome (IBS). The inFoods® IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test.  With this new finger stick blood collection option, any trained medical professional in the doctor’s office can collect the patient’s blood sample during their office visit and forward the sample to the Lab for processing. This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients.  The InFoods IBS test will continue to be available using blood collected from a patient’s arm (venipuncture) by a trained phlebotomist.",1
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and Cell Therapy demonstrate that therapy with placental-derived mesenchymal-like adherent stem cells (MLASCs) results in alterations in gene and protein signatures associated with inflammation and fistula formation in patients with Crohn’s disease,2
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment,0
"FDA genehmigt Phase-II-Studie zu Natrunix bei Patienten mit rheumatoider Arthritis XBiotech glaubt, dass der Wirkstoffkandidat Natrunix die Arthritisbehandlung revolutionieren könnte XBiotech glaubt, dass der Wirkstoffkandidat Natrunix die Arthritisbehandlung revolutionieren könnte",1
"La FDA autorise une étude de phase II pour Natrunix chez des patients souffrant d'arthrite rhumatoïde XBiotech estime que son médicament candidat, Natrunix, pourrait révolutionner le traitement contre l'arthrite XBiotech estime que son médicament candidat, Natrunix, pourrait révolutionner le traitement contre l'arthrite",1
"Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases BOSTON, May  23, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.",1
"Celularity Announces $45 Million Purchase Order,  First Middle East Private Label Agreement For  Celularity’s Halal-Certified Biomaterial Products FLORHAM PARK, N.J., May  23, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has received a $45 million purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store (Jamjoom). Dr. Walid Swelim will serve as marketing manager for promotion and distribution of the products. This marks the first purchase order received by Celularity under its recently announced expansion into the Middle East market, as part of Celularity’s global market strategy.",2
"Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WALTHAM, Mass., May  23, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,256,269 shares of common stock and Series B warrants to purchase up to 3,256,269 shares of common stock, at a purchase price of $3.071 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules.",0
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers -FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response,1
"Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting - SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mgkg dose –",1
"Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting ADELAIDE, Australia and CAMBRIDGE, Mass., May  30, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX  ASX BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators for serious central nervous system (CNS) disorders with a high unmet medical need, today announced it will present data on BNC210 for the treatment of Social Anxiety Disorder (SAD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place Tuesday, May 30, 2023, through Friday, June 2, 2023, in Miami Beach, Florida.",1
"PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) BOSTON, May  30, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding their Investigational New Drug Application (IND) to initiate a Phase 1 study of PGN-EDODM1 in patients with Myotonic Dystrophy Type 1 (DM1). The FDA indicated its intention to provide an official clinical hold letter to PepGen stating the reasons for the clinical hold within 30 days.",0
"scPharmaceuticals to Present at the Jefferies Healthcare Conference BURLINGTON, Mass., May  31, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.",1
"Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split NEWTON, Mass., June  01, 2023  (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.",2
Seer Launches the Proteograph XT Assay Kit Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale,1
"Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improve the safety of ASC-based cell therapy ",1
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers,1
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023 – Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV – – Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV – ,1
"Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome",2
"Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review LOS ANGELES, June  08, 2023  (GLOBE NEWSWIRE) -- (NASDAQ ENOB).  Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in earlymid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024.",1
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure,1
"PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 BOSTON, June  13, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that while it awaits receipt of an official clinical hold letter from the U.S. Food and Drug Administration (FDA), the Company is withdrawing its prior guidance with respect to the timeline for initiating a Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the first half of 2023 in any geography.",0
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients,1
"ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility PORTLAND, Maine, June  15, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the approval by Gorham Savings Bank (GSB) and the Finance Authority of Maine (FAME) of the principal terms of a $3 million debt facility with the Company.",1
"ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023 Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023",1
"Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients IRVINE, Calif., June  21, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ BMRA), a global biomedical company leading the way in innovative diagnostic solutions, announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system that includes an artificial Intelligence (AI) claim aimed at assisting individuals to protect themselves against potential adverse reactions to specific food ingredients. Among other things, the patent claims focus on systems, algorithms and methods to help patients avoid potentially harmful food items based on their unique medical data.",1
"Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023 -- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Million in Net New Business Orders Resulting in a Record-High Backlog of $191 Million --",0
"scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes BURLINGTON, Mass., June  23, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it expects to be added to the small cap Russell 2000® and broad market Russell 3000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.",1
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D – Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) and higher rates of HBsAg loss compared to antivirals or immunomodulators alone –,1
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis -  Study did not meet the primary endpoint-  Pamrevlumab was generally safe and well tolerated-  ZEPHYRUS-2 Phase 3 study will be discontinued-  Company to implement plan to extend cash runway into 2026,0
"Ovid Therapeutics Added to Russell 3000® Index NEW YORK, June  26, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that the company was added to the Russell 3000® Index, effective after the U.S. market opens on June 26, 2023, as part of the 2023 Russell indexes annual reconstitution.",1
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering ,1
"Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program Call scheduled for Tuesday, June 27, 2023 at 800 a.m. ET Call scheduled for Tuesday, June 27, 2023 at 800 a.m. ET",1
"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance SAN DIEGO and TORONTO, June  26, 2023  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ APTO, TSX APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it meets compliance with the Nasdaq’s minimum bid price requirement.",1
"Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., June  27, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced positive updated data from its Phase 1 study of NKX101 to treat patients with relapsed or refractory (rr) acute myeloid leukemia (AML). NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells.",0
"Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025",1
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares,1
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens,1
"Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer NEW YORK, June  28, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs. The Company also announced changes to its administrative functions intended to enhance efficiency and reduce costs.",0
"MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting LA JOLLA, Calif., June  29, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that Principal Investigator, Lara Ray, PhD, Professor, Department of Psychology, University of California Los Angeles (UCLA) presented the results of the Phase 2b trial of MN-166 (ibudilast) in alcohol use disorder (AUD) at the 46th Annual Research Society on Alcoholism (RSA) Scientific Meeting held June 24 - 28, 2023, in Bellevue, Washington.",1
"Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects",1
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 AC Immune Showcasing Precision Medicine Programs at AAIC 2023,1
"C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer WATERTOWN, Mass., July  05, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for CFT8919, an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients.",2
"ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023 PORTLAND, Maine, July  11, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023.",1
"22nd Century Group (XXII) Announces New Agreement with Hub, Inc. to Expand Midwest Distribution Enhances Reach for Regional, Specialty and Tribal Retail Channels Enhances Reach for Regional, Specialty and Tribal Retail Channels",1
"22nd Century Group (XXII) VLN® Products Now Selling in Montana C-Stores Town Pump, #1 Chain in Montana, Selling VLN® Products in More Than 80 Stores Across the State",1
"C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., July  17, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 351,000 shares of the Company’s common stock to two new employees (the “Inducement Grants”), with grants made on July 10 and July 17, 2023 (the “Grant Dates”). The Inducement Grants were granted as inducements material to these individuals entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"A Cigarette to Help Californians Smoke Less 22nd Century Group, Inc. Launches Reduced Nicotine VLN® King Cigarettes in California, VLN Will Be Sold at #1 U.S. Convenience Store Chain and Other Responsible Retail Locations With 95% less nicotine than a traditional cigarette, VLN® cigarettes help existing adult smokers reduce their nicotine consumption and dependence With 95% less nicotine than a traditional cigarette, VLN® cigarettes help existing adult smokers reduce their nicotine consumption and dependence",1
"Celularity Human Placental-Derived  Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering",1
"scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., July  19, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on July 3, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 26,250 shares of its common stock to seven new employees.",1
"Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness SAN FRANCISCO, July  20, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified.",0
"22nd Century Group (XXII) Regains Compliance with Nasdaq Listing Standards BUFFALO, N.Y., July  20, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hempcannabis and hops, today announced notification that it has regained compliance with Nasdaq listing requirements.",1
"Mydecine Innovations Group Provides Corporate Update VANCOUVER, British Columbia, July  21, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEOMYCO) (OTCMYCOF) (FSE0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that John Ross, the Company’s current Chief Financial Officer has been appointed as Corporate Secretary, effective immediately.",1
"AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively",0
"Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX) ADELAIDE, Australia and CAMBRIDGE, Mass., July  25, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (ASXBNO, NASDAQBNOX) (Bionomics or the Company) a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has submitted a formal request to the Australian Securities Exchange (“ASX”) to be removed from the official list of the ASX, in keeping with the Company’s ongoing transformation to a U.S. focused organization. The main consequence of an ASX delisting for shareholders is that, from the time the proposed ASX delisting is scheduled to take effect on August 28, 2023, Bionomics Shares will no longer be quoted or traded on the ASX, and will only be tradable in the form of American Depositary Shares on the NASDAQ Global Market (NASDAQ) under the symbol BNOX.",0
"InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th -Conference call and webcast to be held at 830 a.m. EDT-",0
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts,1
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma 55% objective response rate; 23% complete response rate in locally advanced cSCC,1
"Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications FLORHAM PARK, N.J. and TAMPA, Fla., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Verséa Ophthalmics will distribute Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.",2
"Celularity Inc. Announces $3 Million Registered Direct Offering FLORHAM PARK, N.J., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined purchase price of $0.35 per share and accompanying warrant (together the “Securities”), pursuant to a registered direct offering resulting in total gross proceeds of approximately $3 million before deducting placement agent commissions and other estimated offering expenses. The warrants will have an exercise price of $0.35, will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date. The closing of the offering and sale of the Securities is expected to occur on or about July 31, 2023, subject to the satisfaction of customary closing conditions.",2
"Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents TORONTO, July  28, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has filed a provisional patent application titled “Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a chemical warfare agent.”",0
"Quarterly Activities and Cashflow Report ADELAIDE, Australia, and CAMBRIDGE, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX  ASX BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 30 June 2023 (Quarter) and up to the date of this announcement include",1
"Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market WALTHAM, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,236,248 shares of common stock and Series B warrants to purchase up to 3,236,248 shares of common stock, at a purchase price of $3.09 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants, in a registered direct offering priced at-the-market.",0
"AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMRMSI-H Primary Advanced or Recurrent Endometrial Cancer SAN DIEGO, July  31, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the Sept. 23, 2023 Prescription Drug User Fee Act action date.",1
scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion Company also announces issuance of key patents covering development of alternate formulations of furosemide Company also announces issuance of key patents covering development of alternate formulations of furosemide,1
"Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the second quarter ended June 30, 2023.",0
"CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test IRVINE, Calif., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA) (the “Company”) today announced that CVS Pharmacy has begun in-store sales rollout of the Company’s EZ Detect™ colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy retail system. Biomerica has shipped the EZ Detect product to CVS Health distribution centers in the US, and the product is projected to be on store shelves in September. The Company is also working with CVS Health to introduce an additional Biomerica product to be sold in CVS pharmacies.  ",2
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023,1
"Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates - Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and pERKpMEK suppression consistent with deep cyclic inhibition of the MAPK pathway -",1
"NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results BELTSVILLE, Md., Aug.  03, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported second quarter 2023 financial results.",1
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results – Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 –,1
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update,2
"Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates NEW YORK, Aug.  04, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.",1
"FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45",1
"Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023",1
"ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023 Conference Call Scheduled for Friday, August 11, 2023 at 900 AM ET Conference Call Scheduled for Friday, August 11, 2023 at 900 AM ET",1
"FibroGen Reports Second Quarter 2023 Financial Results SAN FRANCISCO, Aug.  07, 2023  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today reported financial results for the second quarter 2023 and provided an update on the Company’s recent developments.",1
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3;Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway,1
"AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update SAN DIEGO, Aug.  07, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.",1
"C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared",1
"InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –",0
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments – Phase 2 open-label CONNECT1-EDO51 study open in Canada –,1
"XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial AUSTIN, Texas, Aug.  08, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA).",1
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results Data from the Phase 1 dose escalation portion of the Phase 12 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023,1
"Seer Reports Second Quarter 2023 Financial Results Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies",0
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update Patient Screening Completed in Part 2 of Phase 1b2a Trial of BX004 with patient enrollment expected to exceed original estimates,2
"Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model BOSTON, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics (NASDAQELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of preclinical data demonstrating its lymph node-targeting Amphiphile (AMP) adjuvant, AMP-CpG, combined with cell surface-associated viral protein EBV gp350 and EBVpoly protein, elicited a potent and durable immune response to Epstein-Barr virus (EBV) in Human Leukocyte Antigen expressing mice. The data was published in Nature Communications and can be accessed here.",1
"AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer LOS ANGELES, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQRENB) (formerly NASDAQ ENOB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has executed a binding, exclusive letter of intent to merge a subsidiary with the cutting-edge health AI company GEDi Cube Intl Ltd. The combined company would aim to accelerate diagnosis, enhance treatment effectiveness, discover new therapies, and expand access to life-saving technologies for cancer and other diseases.",2
"XBiotech gibt ersten mit der neuartigen Natrunix-Therapie behandelten Patienten in einer klinischen Phase-II-Studie zu rheumatoider Arthritis (RA) bekannt AUSTIN, Texas, Aug.  09, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc.(NASDAQ XBIT) hat heute mit der Behandlung des ersten Patienten in einer doppelblinden, placebokontrollierten, randomisierten klinischen Studie der Phase II begonnen, um Natrunix als neue Behandlung für Arthritis zu untersuchen. Natrunix blockiert eine der Hauptursachen für Entzündungen, die zu Schmerzen und Gelenkzerstörung bei rheumatoider Arthritis (RA) führen.",1
"XBiotech annonce la première administration du nouveau traitement Natrunix à un patient lors d'un essai clinique de phase II sur l'arthrite rhumatoïde (AR) AUSTIN, Texas,  09 août 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ  XBIT) a débuté aujourd'hui le traitement du premier patient dans le cadre d'une étude clinique randomisée de phase II en double aveugle et contrôlée par placebo visant à évaluer Natrunix en tant que nouveau traitement pour l'arthrite. Natrunix bloque une cause clé de l'inflammation impliquée dans la douleur et la destruction articulaire de l'arthrite rhumatoïde (AR).",1
Certara Reports Second Quarter 2023 Financial Results Provides Update to Full Year 2023 Financial Guidance Provides Update to Full Year 2023 Financial Guidance,1
"MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update ZUG, Switzerland, August 10, 2023 – MoonLake Immunotherapeutics (NASDAQMLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2023.",1
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update  ,1
"Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023.",1
"HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights NEW YORK and VIENNA, Austria, Aug.  10, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.",1
"Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update BOSTON, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended June 30, 2023.",1
"Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.",0
"Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights – Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting, including data supporting 3 mgkg as the appropriate dose for each PROC combination cohort –",1
"ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates ARS continues engagement with U.S. FDA on final labeling and post-marketing commitments for the neffy® new drug application; PDUFA target action date set for September 19, 2023",1
scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $1.6 million,1
"Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results SAN DIEGO, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2023 financial results.",2
Aptose Reports Results for the Second Quarter 2023             ─ CRc Response Rate 50% with TuspetinibVenetoclax Doublet in Evaluable Patients ─,1
"Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the Optejet®",1
"ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023 PORTLAND, Maine, Aug.  10, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023.",1
"Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Enrollment is underway for REFRaME-O1, the Phase 23 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer -",1
RAPT Therapeutics Reports Second Quarter 2023 Financial Results Company maintains strong cash position of $205 million Company maintains strong cash position of $205 million,0
"Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates BOSTON, Aug.  11, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.",1
"Entera Bio Announces Q2 2023 Financial Results and Corporate Updates JERUSALEM, Aug.  11, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the second quarter ended June 30, 2023.",1
"Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update REDWOOD CITY, Calif., Aug.  11, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended June 30, 2023, and provided a business update.",2
"22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results BUFFALO, N.Y., Aug.  14, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hempcannabis and hops, today reported results for the Second quarter ended June 30, 2023, and provided an update on recent business highlights. The Company will host a live audio webcast today at 800 a.m. ET.",0
Humacyte Second Quarter 2023 Financial Results and Business Update – Completed Enrollment in Phase 23 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line Results on Track for Q3 2023 –,1
"Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023",1
"Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 ",1
"MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe LA JOLLA, Calif., Aug.  14, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH).",1
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update EscharEx® Phase III study protocol FDAEMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders,2
"MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe LA JOLLA, Calif., Aug.  15, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced it has received a Decision to Grant from the European Patent Office for a new patent which covers MN-001 (tipelukast) for the treatment of scleroderma andor systemic sclerosis.",1
"Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery",1
"Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown",2
"Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting JERUSALEM, Aug.  16, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada.",2
"MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe LA JOLLA, Calif., Aug.  16, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.",1
"MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology LA JOLLA, Calif., Aug.  17, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada. The poster will be presented by MediciNova’s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.",1
"Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer LOS ANGELES, Aug.  21, 2023  (GLOBE NEWSWIRE) -- (NASDAQ RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information (httpsgedicube.comnews).",2
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates Completed upsized initial public offering raising $96.4 million in gross proceeds,1
"Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development TORONTO, Aug.  22, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has initiated the development of a next generation formulation of Bucillamine for the potential treatment of public health medical emergencies including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. In addition, the Company may explore the use of the novel Bucillamine formulation as a potent antioxidant and anti-inflammatory treatment for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.",2
Vincerx Pharma Announces FDA Clearance of IND for VIP943 Phase 1 trial expected to begin in early Q4 2023,2
"Elicio Therapeutics Reports Inducement Grants BOSTON, Aug.  22, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on August 21, 2023, the Company’s board of directors approved the grant of 72,980 inducement stock options to two new employees, as an inducement material to each employee entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210 ADELAIDE, Australia, and CAMBRIDGE, Mass., Aug.  23, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX  ASX BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD.",2
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators  by the US Patent and Trademark Office Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients,2
"AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache IRVINE, Calif., Aug.  24, 2023  (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application No. 17006,685, titled “Neurotoxin Compositions for Use in Treating Headache” (the “Application”), which involves the Company’s lead asset, ABP-450 (prabotulinumtoxinA) injection. The soon to issue patent will provide protection in the United States for the claimed methods of use of ABP-450 into 2041.",2
"Biomerica Reports Fiscal 2023 Year End Results IRVINE, Calif., Aug.  25, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2023 financial results.",1
"AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress® IRVINE, Calif., Aug.  29, 2023  (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced the presentation of positive results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD), a chronic and debilitating neurologic condition affecting the muscles of the neck, at the International Parkinson and Movement Disorders Society Congress® (IP-MDS), which is being held at the Bella Center in Copenhagen, Denmark, from August 27 – 31, 2023. The data was previously released by the Company in September 2022.",2
Certara Simcyp™ Group Awarded Two New Grants from US FDA Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations,1
"FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy – Study did not meet the primary endpoint –",0
"XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer AUSTIN, Texas, Aug.  30, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase III randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer.",1
"Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort LOS ANGELES, Aug.  30, 2023  (GLOBE NEWSWIRE) -- (NASDAQ RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials.",1
"Mydecine Announces Conditional Approval of CSE Listing VANCOUVER, British Columbia, Aug.  30, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEOMYCO) (OTC MYCOF) (FSE 0NFA) (""Mydecine"" or the ""Company""), is pleased to announce that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the ""CSE"") subject to fulfilling customary CSE requirements. The Company anticipates that trading will commence immediately upon receipt of voluntarily delisting approval from the NEO Exchange with a trading date to be provided in due course. The Company’s trading symbol “MYCO” will remain the same.",1
"XBiotech gibt den Abschluss der Rekrutierung von Patientinnen für Phase II der placebokontrollierten, multizentrischen klinischen Studie zu Natrunix bei Bauchspeicheldrüsenkrebs bekannt AUSTIN, Texas, Aug.  31, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. gab heute den Abschluss der Rekrutierung für den Phase-II-Teil seiner 1-BETTER-Studie bekannt, bei der es sich um eine randomisierte, doppelblinde, placebokontrollierte klinische Studie der Phase III zur Beurteilung von Natrunix in Kombination mit Chemotherapie für die Behandlung von Bauchspeicheldrüsenkrebs handelt.",1
"XBiotech annonce l'achèvement du recrutement concernant son étude multicentrique contrôlée par placebo de phase II pour Natrunix dans la lutte contre le cancer du pancréas AUSTIN, Texas,  31 août 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. a annoncé aujourd'hui avoir achevé le recrutement concernant la phase II de 1-BETTER, son étude clinique randomisée, en double aveugle et contrôlée par placebo de phase III pour Natrunix en combinaison avec une chimiothérapie pour le traitement du cancer du pancréas.",1
"Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update - Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy –",1
"InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 TEL AVIV, Israel, and MIAMI, Aug.  31, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting (VIVA23), which is being held October 30 through November 2 in Las Vegas.",1
"22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets BUFFALO, N.Y., Sept.  05, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal advisors, has initiated a process to evaluate strategic alternatives with respect to the Company’s tobacco assets. The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements, alternate financing strategies and other options.",1
"Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer BOSTON, Sept.  05, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that additional data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster presentation at the upcoming AACR Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023. These data are in addition to the interim data Elicio presented at the ASCO Annual Meeting earlier this year.",1
"C4 Therapeutics Announces Chief Financial Officer Succession WATERTOWN, Mass., Sept.  05, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023. She will succeed Lauren White, who will be leaving C4T to pursue a new role with a commercial-stage pharmaceutical company.",1
"Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions RADNOR, Pa., Sept.  05, 2023  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in an oral poster presentation at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10.",1
"Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease BELTSVILLE, Md., Sept.  05, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, reduced bone loss and enhanced bone formation and quality following immobilization in an experimental animal model of acute spinal cord injury (SCI), at the 2023 Military Health System Research Symposium (MHSRS).",2
"MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11",1
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical — TUSVEN doublet continues safe and effective in AML patients who failed prior venetoclax — — TUSVEN doublet continues safe and effective in AML patients who failed prior venetoclax —,2
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences - EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide -,1
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1),1
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate Study met 5 of 6 primary endpoints,1
"Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines BOSTON, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has been awarded a $2.6 million grant from the GI Research Foundation in Chicago to fund research for two therapeutic cancer vaccines, ELI-007 and ELI-008. This $2.6 million grant is an addition to the $2.8 million that it awarded Elicio in September 2022. Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations. Both vaccines have been designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) platform that “educates” T cells on how to target particular antigens, such as mutated proteins in cancer.",2
"BiomX to Present Data from Ongoing Phase 1b2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023 CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept.  07, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis (“CF”) at European Respiratory Society (ERS) International Congress 2023, which is being held September 9-13, 2023, in Milan, Italy. The abstract was submitted as a Late-Breaking Abstract and selected for oral presentation at the conference.",1
"Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023 -- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million --",1
"NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen BELTSVILLE, Md., Sept.  07, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a review article in the online journal Frontiers in Immunology, highlighting the need for targeting tumor collagen in the extracellular matrix (ECM) in the tumor microenvironment to enhance anti-tumor immunity.",1
"Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference -Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage- -Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage-",2
BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological Association Annual Meeting,1
"Humacyte Announces Positive Top Line Results from Phase 23 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma -- Single-arm clinical trial was a success and showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks -- -- BLA planned to be filed with FDA in 4th Quarter 2023 --",2
"22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023 First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023",2
"HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) NEW YORK and VIENNA, Sept.  12, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 100,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. The award was granted as an inducement material to the employees’s acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $ 1.00 per share. The options have a ten year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal quarterly installments for three years thereafter, subject to the employee’s continued service with HOOKIPA on each such vesting date. The options are subject to the terms and conditions of HOOKIPA’s 2023 Inducement Plan approved by the Board of Directors in April 2023 and the terms and conditions of award agreements covering the grants.",1
"A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC • Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore",1
"Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes JERUSALEM, Sept.  12, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology.",1
Adaptive Announces Launch of Epic Integration for clonoSEQ® The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers,1
"Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept.  14, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced an update on the company’s α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) collaboration with MSD (known as Merck & Co., Inc., Rahway NJ, USA in the US and Canada). Data for MK-4334, a novel clinical candidate developed by MSD and derived from Bionomics’ original α7 nAChR PAM candidate (BNC375), was recently presented at the Society for Chemical Industry (SCI) and Royal Society of Chemistry (RSC) 22nd Medicinal Chemistry Symposium, held in Cambridge, UK, September 10-13, 2023.",0
"Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 Phase 1 trial enrolling patients with relapsedrefractory AML, MDS and B-cell ALL Phase 1 trial enrolling patients with relapsedrefractory AML, MDS and B-cell ALL",2
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023,1
"Aptose to Present at the Cantor Global Healthcare Conference SAN DIEGO and TORONTO, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ APTO, TSX APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.",1
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀ Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale,1
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives Company advancing plans to expand the FUROSCIX franchise to include an 80mg1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients,1
"Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms MARLBOROUGH, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platform upgrades. Enhancements to the PhenoCycler-Fusion 2.0 System allow customers to process twice as many samples per week, making it the highest throughput spatial discovery platform on the market. The PhenoImager 2.0 platform delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument. With an unprecedented ability to perform whole-slide spatial biology at scale, Akoya’s customers can accelerate progress towards new discoveries, identification of clinically relevant biomarkers, and development of novel spatial signatures.",1
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines,1
"Mydecine Innovations Announces Closing of Prospectus Supplement Financing VANCOUVER, British Columbia, Sept.  19, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEOMYCO) (OTCMYCOF) (FSE0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,7500,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,7500,000.",1
"FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under allergen-induced allergic rhinitis conditions",1
"Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV – Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –",1
Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe Company to Lead Symposiums at ICCS and ESCCA Company to Lead Symposiums at ICCS and ESCCA,1
"PolyPid Announces Reverse Share Split PETACH TIKVA, Israel, Sept.  20, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated into one (1) Ordinary Share.",2
"Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing VANCOUVER, British Columbia, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEOMYCO) (OTCMYCOF) (FSE0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023 and September 19, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,750,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,750,000. A previous news release incorrectly stated that the Company issued 18,7500,000 Shares for aggregate gross proceeds of $3,7500,000.",1
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- andor full- thickness thermal burns Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- andor full- thickness thermal burns,2
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally,0
"LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan TOKYO and CAMBRIDGE, Mass., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters Tokyo, CEO Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq BIIB, Corporate headquarters Cambridge, Massachusetts, CEO Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI® Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD).",1
"Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer CAMBRIDGE, Mass., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Deardorf’s employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Ms. Deardorf’s continued service relationship with Editas Medicine through the applicable vesting dates.",1
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution,1
"Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis NEW YORK, Sept.  26, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, six to ten new clinical trial sites will be recruited.",1
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events,2
"BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease CARSON CITY, Nev., Sept.  26, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the last patient has completed the last visit at week 30 in its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s Disease (AD).",2
"Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer NEEDHAM, Mass., Sept.  26, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced updated activity data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage IIIIV non-small cell lung cancer (NSCLC), who have an inadequate response to front line anti-PD(L)1 therapy. These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al. J Clin Onc 2022;402295-2306). The aim of the CAN-2409 immunotherapy antitumor strategy is to raise the tail on the survival curve by increasing the number of long survivors beyond 10-13 months.",1
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 12 Adult Trial for the Treatment of Rett Syndrome Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring Committee (IDMC) review,0
"Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide",1
"Biogen Completes Acquisition of Reata Pharmaceuticals CAMBRIDGE, Mass., Sept.  26, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs.",1
"XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke AUSTIN, Texas, Sept.  26, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin.",1
"NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease BELTSVILLE, Md., Sept.  26, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, including neuroinflammatory disease, today announced the presentation of preclinical data relating to NC181, a novel humanized antibody targeting ApoE4, for the treatment of Alzheimer’s disease (AD), at the 2nd Annual Neurodegeneration Targets, Drug Discovery for Progressive Central Nervous System Disorders conference.",1
"XBiotech meldet Abschluss der Rekrutierung von Teilnehmern in klinischer Phase-I-Studie zu Hutrukin, einem neuartigen Therapiekandidaten bei Schlaganfällen, bekannt AUSTIN, Texas, Sept.  27, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ XBIT) gibt bekannt, dass Hutrukin von XBiotech als bahnbrechende Therapie zur Verringerung von Hirnschäden nach einem Schlaganfall entwickelt wird. Der letzte Teilnehmer einer randomisierten, offenen, placebokontrollierten klinischen Phase-I-Dosiseskalationsstudie wurde rekrutiert. XBiotech hat Hutrukin entdeckt, stellt es her und führt diese klinische Studie durch.",1
"XBiotech annonce l'achèvement du recrutement dans son essai clinique de phase I concernant Hutrukin, un nouveau traitement candidat pour l'AVC AUSTIN, Texas,  27 sept. 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ  XBIT) annonce qu'Hutrukin est en cours de développement par XBiotech en tant que traitement révolutionnaire pour la réduction des lésions cérébrales après un accident vasculaire cérébral (AVC). Le dernier sujet a été recruté dans l'étude clinique de phase I, contrôlée par placebo, ouverte et randomisée, avec escalade de la dose. XBiotech a découvert, fabrique et mène actuellement cette étude clinique sur Hutrukin.",1
"Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States",1
"Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting NEEDHAM, Mass., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the Company will present three posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 in San Diego, CA and virtually.",1
"Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma SAN MATEO, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that its license partner, Ascletis Bioscience Co. Ltd. (Ascletis), has enrolled 120 patients in its Phase 3 registration clinical trial of denifanstat combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). Ascletis anticipates that this number of study subjects will provide sufficient events for its planned interim analysis of progression-free survival (PFS). Denifanstat is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). Sagimet licensed the rights to develop and commercialize denifanstat in the People’s Republic of China, Hong Kong, Macau and Taiwan to Ascletis in January 2019.",1
"Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date VANCOUVER, British Columbia, Sept.  27, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEOMYCO) (OTCMYCOF) (FSE0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce expected admission of its common shares to begin trading on the Access Segment of the AQSE Growth Market in the UK is expected to take place on October 10th, 2023. The AQSE Growth Market is a multilateral trading facility operated by Aquis Stock Exchange. A copy of the application announcement can be accessed at the following link httpsaqx-web-prod-s3-public-read.s3.eu-west-2.amazonaws.com20230926_Application_Announcement_1_5533c9b702.pdf",1
"MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced the results of the nonclinical studies conducted under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.",1
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.,2
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564 Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development,1
"Capricor Therapeutics Announces $23 Million Registered Direct Offering SAN DIEGO, Sept.  29, 2023  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $5.70 per share. Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance. The combined offering price per share of common stock and accompanying warrant is $4.66. The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.",0
"Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discovery",1
"FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA® CAMBRIDGE, Mass., Sept.  29, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis.",1
"Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept.  29, 2023  (GLOBE NEWSWIRE) --  Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Nicole Davarpanah, M.D., J.D., a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 330,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of September 29, 2023. The stock option has an exercise price of $0.94 per share, which is equal to the closing price of Cidara’s common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 14 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of Cidara’s 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.",1
"NKGen Biotech, Inc. Announces Closing of Business Combination Company to Commence Trading on Nasdaq under Ticker Symbol “NKGN” on Monday, October 2, 2023 Company to Commence Trading on Nasdaq under Ticker Symbol “NKGN” on Monday, October 2, 2023",0
"AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD",1
"Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine",1
"Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds WALTHAM, Mass., Oct.  02, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,734,105 shares of common stock, each having an exercise price of $4.075 per share, issued by Checkpoint on December 16, 2022 and (ii) Series A warrants to purchase up to an aggregate of 1,428,572 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,428,572 shares of common stock issued by Checkpoint on February 22, 2023, each having an exercise price of $5.00 per share, at a reduced exercise price of $1.76 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-251005) and Form S-3 (File No. 333-270474), respectively. The gross proceeds to Checkpoint from the exercise of the warrants are expected to be approximately $11.13 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the offering is expected to occur on or about October 4, 2023, subject to satisfaction of customary closing conditions.",0
"Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQREGN) and Intellia Therapeutics, Inc. (NASDAQNTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This builds on the success of the companies’ existing collaboration and continues to combine both companies’ deep biology and technology expertise. The collaboration will leverage Regeneron’s proprietary antibody-targeted adeno-associated virus (AAV) vectors and delivery systems and Intellia’s proprietary Nme2 CRISPRCas9 (Nme2Cas9) systems adapted for viral vector delivery and designed to precisely modify a target gene.",1
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19,1
"Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology SAN DIEGO, Oct.  03, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the publication of its full pharmacokinetic and pharmacodynamic results from one of its four primary registration studies of neffy (epinephrine nasal spray) in the Journal of Allergy and Clinical Immunology (JACI). JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology. The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.",1
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time,1
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress,1
"Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening of fibrosis",1
"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 12 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 Management to host conference call and webcast on October 13 at 430 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host conference call and webcast on October 13 at 430 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope",1
"MediciNova Receives Gene Therapy Milestone Payment LA JOLLA, Calif., Oct.  04, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.",1
"scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., Oct.  05, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on October 2, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 52,500 shares of its common stock to 14 new employees comprised of sales representatives.",1
"Oncternal Therapeutics Announces First Patient Dosed in Phase 12 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer SAN DIEGO, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 12 dose escalationdose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.",1
Immunocore announces upcoming presentation and posters at ESMO 2023 Immunocore announces upcoming presentation and posters at ESMO 2023,1
"ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray) SAN DIEGO, Oct.  06, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.",1
"Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet® In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions",1
"MediWound Deploys NexoBrid® for Emergency Supply YAVNE, Israel, Oct.  09, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.",1
"Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile.",0
"Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 415pm ET115pm PT on Wednesday, Oct. 25.",0
"Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins 22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo",0
Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress “VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH),1
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society -24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy-,1
"MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada LA JOLLA, Calif., Oct.  10, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).",1
"BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II SUNNYVALE, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces completion of enrollment in its CardiAMP Heart Failure Trial and initiation of a discussion with the FDA on a second pivotal study protocol adapted for the responders in the initial trial with the objective of gaining FDA marketing approval.",1
"MediWound Announces Collaboration with 3M on EscharEx® Phase III Study MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers",1
"PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule PETACH TIKVA, Israel, Oct.  11, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC (""Nasdaq"") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share.",1
"C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023",1
"Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting BOSTON, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and ELI-008. ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, are being evaluated in studies funded by a grant from the Gastro-Intestinal (GI) Research Foundation with the aim of developing multivalent cancer vaccines targeting several mutations.",1
"Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism REDWOOD CITY, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results following administration of RZ358 to a patient with refractory hypoglycemia due to tumor-mediated hyperinsulinism (tmHI) on a compassionate-use basis, under its expanded access program (EAP). ",1
"electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology ROCKAWAY, N.J., Oct.  11, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS.",1
"Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023 SAN DIEGO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023. The conference is taking place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.",1
"Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development TORONTO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.",1
"Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress SAN DIEGO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phase 2b study in moderate to severe atopic dermatitis.",1
"Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors LOS ANGELES, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors. Beyond this board position, Mr. Miller will also take on an advisory role, contributing to the company's strategy and business development efforts. Renovaro Biosciences has recently signed a definitive agreement to combine with GEDiCube, a UK-based medical AI company specializing in early detection and remissions of cancer, and expedited drug discovery (Renovaro Press Release) (GEDiCube press release). GEDiCube intends to rebrand as Renovaro.AI.",1
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress,1
"Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK VANCOUVER, British Columbia, Oct.  12, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (NEOMYCO) (AQSE MYIG) (OTC MYCOF) (FSE 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces that it has completed its admission to the Access segment of the AQSE Growth Market (“AQSE”) and that trading commenced at 800 A.M. GMT on Tuesday, 10 October 2023 (""Admission"") under the ticker ""MYIG"".",1
"PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) – Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mgkg, 10 mgkg and 20 mgkg –",1
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market,2
"BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award Award recognizes Dr. Short’s contribution to science innovation Award recognizes Dr. Short’s contribution to science innovation",1
"Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 23 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 23 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients",2
"TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting NEW YORK, Oct.  12, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to the presentation is included below.",1
"Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference Vir Biotechnology is participating in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25th",1
"Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference – Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer",1
Biomerica Reports First Quarter 2024 Financial Results Biomerica Reports First Quarter 2024 Financial Results.  Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024,1
"Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) NEW YORK, Oct.  13, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP). Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS.",2
"Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema CAMBRIDGE, Mass., Oct.  13, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.",1
"Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1) SAN DIEGO and CAMBRIDGE, England, Oct.  13, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, and Mundipharma today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1",1
"Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 12 KB-0742 Study at AACR-NCI-EORTC Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors",2
REPEAT - Biomerica Reports First Quarter 2024 Financial Results Biomerica Reports First Quarter 2024 Financial Results.  Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024,1
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 Late-breaking poster presentation at ASN’s Kidney Week 2023 - - -Poster presentation at AHA’s Scientific Sessions 2023,1
"Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab NEW YORK, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program.   This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023.",2
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference Aptose to present TUSVEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to VEN.,1
"Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701 NORWOOD, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate (ADC) targeting nectin-4 was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston on October 14th 2023.",1
"Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease CAMBRIDGE,  Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD).",1
"Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting JERUSALEM, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. Both posters will be available on the Company’s website, www.enterabio.com.",1
"Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the successful and favorable outcomes of an End-of-Phase 2 meeting (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its lead asset BNC210 for the acute treatment of Social Anxiety Disorder (SAD) into Phase 3 registrational studies based on the recently completed Phase 2 PREVAIL dataset.",2
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model -Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease- -Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-,0
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMVHIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration,1
"22nd Century Announces Proposed Public Offering BUFFALO, N.Y., Oct.  16, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hempcannabis and hops advanced plant technologies, today announced that it intends to offer and sell in a “best efforts” public offering shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock. All of the shares of common stock (or common stock equivalents) and warrants in the offering are to be offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.",0
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases,0
"Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure TORONTO, Oct.  17, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure. The DRDC will fund the research project, which is expected to begin in early Q1-2024.",1
"Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023 NORWOOD, Mass., Oct.  17, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for oral presentation at the 11th annual Obesity Journal Symposium, held during the 2023 Obesity Week Conference in Dallas, Texas October 14-17, 2023. In addition, the work has also been selected as a late breaking poster. ",0
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism,2
"NKGen Biotech Presents Interim Phase I Trial Data at the  XXVI World Congress of Neurology (WCN) Annual Meeting 2023 SANTA ANA, Calif., Oct.  17, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the XXVI World Congress of Neurology (WCN) Annual Meeting in Montreal, QC, Canada and online.",1
"Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility Avid completes construction of cell and gene theapy facility bringing total revenue generating capacity to up to ~$400 Million annually",1
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting,2
"22nd Century Announces Pricing of $5.25 Million Public Offering BUFFALO, N.Y., Oct.  17, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hempcannabis and hops advanced plant technologies, today announced the pricing of its previously announced public offering of 10,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 20,000,000 shares of common stock, at a combined public offering price of $0.525 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.525 per share, are immediately exercisable and will expire five years following the date of issuance. The offering is expected to close on or about October 19, 2023, subject to the satisfaction of customary closing conditions.",0
"Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures MARLBOROUGH, Mass., Oct.  17, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The University of Queensland’s Frazer Institute have comprehensively mapped the spatial proteome of head and neck squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial phenotyping. Spatial phenotyping consists of whole-slide imaging of tissue sections at single-cell resolution to visualize and quantitate biomarker expression and reveal how cells interact and organize across the entire tissue landscape.",2
"Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment NEW YORK, Oct.  18, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis. The U.S. Food and Drug Administration (FDA) has allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab, a groundbreaking treatment developed by Tiziana Life Sciences. Delivery Device Training materials have been developed and refined in collaboration with the FDA, and patients will be trained in the use of the nasal device in accordance with these materials.",2
"Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy. The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is expected to initiate by year-end 2023.",1
"HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences NEW YORK and VIENNA, Austria, Oct.  18, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that The Journal of Infectious Diseases has published preclinical data on HB-400, an investigational therapeutic vaccine for chronic hepatitis B developed in collaboration with Gilead Sciences, Inc. (HB-400 is also referenced as GS-2829 and GS-6779.) The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.",1
"Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026 NEW YORK and SAN DIEGO, Oct.  18, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, and Ligand Pharmaceuticals Incorporated (NASDAQ LGND) today announced that Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat. In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.",1
"Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma",1
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia,1
"Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 NEEDHAM, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment.",2
"Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting CAMBRIDGE, Mass., Oct.  19, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass. The presentations will advance the understanding of Alzheimer’s disease with data on different treatment approaches, predictive analysis of disease progression, and clinical meaningfulness of amyloid removal for patients and their caregivers.",1
"BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD CARSON CITY, Nev., Oct.  19, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease will be presented during an oral presentation at the upcoming 16th Clinical Trials on Alzheimer's Disease (CTAD), to be held in Boston, MA from October 24-27, 2023.",1
"NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference SANTA ANA, Calif., Oct.  19, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation on a final report of a Phase I dose escalation study of SNK01 in subjects with Alzheimer’s Disease, at the 16th Clinical Trials on Alzheimer’s Disease Annual Meeting to be held in Boston, MA, USA from October 24–27, 2023.",0
"Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13",1
"Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults -- Company Expects to Initiate VAX-31 Phase 12 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 12 Study Expected in the Second Half of 2024 --",1
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023,1
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer Media Release ,0
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress Highlights advantages of IMUNON’s PlaCCine modality over current commercial vaccines,2
Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia,1
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress In vitro data demonstrated the miRARE control element downregulates MECP2 transgene and protein expression in response to cellular levels of MeCP2 in cell culture models,1
NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease NKGen’s neurodegenerative program continues to advance with dosing in the Phase 12a clinical trial anticipated to commence by year-end 2023,2
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial  at ESMO Congress 2023 Media Release,1
"Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023 SAN MATEO, Calif., Oct.  24, 2023  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announces the acceptance of two abstracts, one of which is a late-breaking poster, at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to be held November 10-14, 2023 in Boston, MA.",1
Immutep receives ~A$1.13 million R&D Tax Incentive Media Release (Code ASX IMM; NASDAQ IMMP) ,2
22nd Century Group (XXII) Reduces Debt by $8.1 Million 37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets 37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets,1
"New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease CAMBRIDGE, Mass., Oct.  25, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD). The data showed favorable trends on multiple exploratory endpoints of cognition and activities of daily living in AD (n=46), building upon prior results which showed a reduction of tau protein in the cerebral spinal fluid (CSF t-tau) and tau positron emission tomography (PET) across brain regions. The late-breaking results were presented at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting held in Boston, MA from October 24-27.",1
"Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients CARSON CITY, Nev., Oct.  25, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced that blinded data on cognitive, biomarker and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease (AD) were presented today as an oral presentation at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) in Boston, MA,",0
"Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV",1
Mydecine Provides Q4 2023 Business Update Mydecine is pleased to address its shareholders and provide a general update on the company's progress.,1
NKGen Biotech Presented Phase I Clinical Trial Data at the  16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference 90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks,1
Latest Research Evaluating VASCEPA®VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 -- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- -- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting --,1
"22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB BUFFALO, N.Y., Oct.  26, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hempcannabis and hops, announced that it supports the recent move by the US Food and Drug Administration to send final rules aimed at banning menthol in cigarettes and banning flavored cigars to the White House Office of Management and Budget for review, a key regulatory step toward the rules becoming federal policy.",1
"Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer SAN DIEGO, Oct.  26, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).",2
"Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules",1
"MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria LA JOLLA, Calif., Oct.  26, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova’s assignment agreement with Genzyme Corporation.",1
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic PRESS RELEASE,0
"Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 12 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 12 study at leading international sarcoma meeting",2
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis,0
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUSVEN in Heavily Pre-treated RR AML Patients,0
"TransCode Therapeutics Withdraws Public Offering BOSTON, Oct.  30, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief that current market conditions were not conducive for an offering on terms that would be in the best interests of the Company's stockholders.",2
"CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD) ZUG, Switzerland and BOSTON, Oct.  31, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock.",1
Immutep Quarterly Activities Report Q1 FY24 Media Release ,1
"X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024",2
"CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease -Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)-",1
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting - Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools -,1
"Amarin Reports Third Quarter 2023 Financial Results -- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 --  -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million --",0
"C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights Portfolio Decision to Prioritize Ongoing Phase 12 Trials of CFT7455, an IKZF13 Degrader, and CFT1946, a BRAF V600 Degrader",2
"TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm",2
"Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services",1
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure,2
"Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, will present data for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma and cutaneous melanoma at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting (1st – 5th November) and the Society for Melanoma Research (SMR) Congress (6th – 9th November).",1
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing  Rule 5635(c)(4) BOSTON, Nov.  01, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on October 31, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 454,500 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights – PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 –",2
"AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023",1
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production Anticipates having product available to ship in January 2024 Anticipates having product available to ship in January 2024,1
"Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting CAMBRIDGE, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today presented additional interim results from its ongoing Phase 1 study of NTLA-2001, an investigational, in vivo CRISPRCas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. Results were presented in an oral presentation at the 4th International ATTR Amyloidosis Meeting, held Nov. 2–3 in Madrid, Spain.",2
"Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting NORWOOD, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody were presented as posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in San Diego, CA November 1-5, 2023.",1
"Pacira BioSciences Reports Third Quarter 2023 Financial Results -- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- ",1
"Immutep to Participate in November Investor Events SYDNEY, AUSTRALIA, Nov.  02, 2023  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (""Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will participate in the following upcoming investor events in November",1
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants,1
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose’s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023,1
"Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 100 p.m. ET",1
"Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 12 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 12 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting",0
"Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding",1
"Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 12 Study Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 12 study",1
"NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results BELTSVILLE, Md., Nov.  02, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported third quarter 2023 financial results.",1
"Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update SAN DIEGO, Nov.  02, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update.",1
"Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results SAN DIEGO, Nov.  02, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an update on its corporate activities and product pipeline.",2
Editas Medicine Announces Third Quarter 2023 Results and Business Updates Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar,2
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update,0
"Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates NEW YORK, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.",1
"IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting NEW YORK, Nov.  03, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (Abstract # 637 in Exhibit Halls A and B1). The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies.",2
"Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023 - MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mgkg every three weeks plus pembrolizumab –",1
"Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting SAN DIEGO, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA.",1
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer Media Release ,1
"Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer NEEDHAM, Mass., Nov.  03, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced initial positive interim survival and immunological biomarker data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug) together with standard of care (SoC) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.",0
"RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC - Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI)",1
"HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023 NEW YORK and VIENNA, Austria, Nov.  03, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced updated Phase 1 clinical, biomarker and translational data on HB-200 as a monotherapy in heavily pretreated patients with recurrentmetastatic Human Papillomavirus 16-positive (HPV16+) head and neck cancer. The data show HB-200 monotherapy induced robust, high-quality and durable tumor-specific T cell responses, which showed a trend of clinical benefit measured by a 44 percent disease control rate in a difficult-to-treat patient population. The data were presented in a poster presentation (abstract #679) at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.",1
"Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting BOSTON, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced promising updated preliminary translational data from the ongoing Phase 1 (AMPLIFY-201) study of its lead cancer vaccine candidate, ELI-002, in patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers, and new preclinical data on vaccine candidates, ELI-007 and ELI-008.",1
"Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC NEEDHAM, Mass., Nov.  04, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today will present two posters during the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego focused on the enLIGHTEN™ Discovery Platform.",2
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023 -CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose-,1
"BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD) Columbia University-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024",1
InspireMD Reports Third Quarter 2023 Financial Results and Provides  Business Update - Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –,1
"22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results BUFFALO, N.Y., Nov.  06, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hempcannabis and hops, today reported results for the third quarter ended September 30, 2023, and provided an update on recent business highlights.",1
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test Potential world-first patented biomarker for long COVID,1
"GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023 Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA)        ",1
"IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting NEW YORK, Nov.  06, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.",1
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase IIIII Trial in Metastatic Breast Cancer Media Release,0
"FibroGen Reports Third Quarter 2023 Financial Results SAN FRANCISCO, Nov.  06, 2023  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company’s recent developments.",2
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update -- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 --   -- Received FDA Clearance of VAX-31 Adult IND Application; Phase 12 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024 -- ,1
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile,1
"CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results -Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD-",1
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update,2
"Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline SEATTLE, Nov.  07, 2023  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies.",1
"electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum ROCKAWAY, N.J., Nov.  07, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.",1
"Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update NORWOOD, Mass., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the third quarter of 2023.",0
"IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023 LAWRENCEVILLE, N.J., Nov.  07, 2023  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 1000 a.m. ET on Tuesday, November 14, 2023 to discuss financial results for the third quarter and nine-months ended September 30, 2023 and provide an update on its clinical development of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.",0
22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities,1
"Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to",1
"Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023",0
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update – On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 –,1
"Cytek Biosciences Reports Third Quarter 2023 Financial Results FREMONT, Calif., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023.",0
"Anaptys Named a BioSpace 2024 Best Places to Work Winner SAN DIEGO, Nov.  07, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category.",1
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections,2
"BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2 trial1",1
"MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients",1
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments - Continuing to open CONNECT1-EDO51 trial sites in Canada -,0
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities,0
"Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups IRVINE, Calif., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using the Company's revolutionary inFoods® IBS Product. This expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for Irritable Bowel Syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters. These new groups join Gastro Health, a group with 390 GI physicians which was the Company's first large physician group customer. In addition, several additional Gastro Health office locations have started using the inFoods IBS therapy for their IBS patients.",2
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500 Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics,0
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’ The Cytek® Aurora™ CS system has been selected as the “Cell Sorting Product of the Year” in the third annual BioTech Breakthrough Awards program.,0
"22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores Adds another 500+ stores Adds another 500+ stores",1
"Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance Q3 2023 revenue $25.2 million, 34% yy growth Reiterating FY 2023 revenue guidance range of $95-98 million",1
"electroCore Announces Third Quarter 2023 Financial Results Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022",2
Certara Reports Third Quarter 2023 Financial Results Reiterates Full Year 2023 Financial Guidance Reiterates Full Year 2023 Financial Guidance,1
"BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results SUNNYVALE, Calif., Nov.  08, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2023 and filed its quarterly report on Form 10-Q for the three and nine months ended June 30, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 430 PM ET today in which it will discuss business highlights.  Following management’s formal remarks, there will be a question-and-answer session.",2
"Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update BERWYN, Pa., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments.",1
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights – Positive interim data from Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safety profile and encouraging anti-tumor activity that compares favorably to PLD as a monotherapy; expect to complete enrollment in this expansion cohort in the fourth quarter of 2023 –,0
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update,1
"HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights NEW YORK and VIENNA, Austria, Nov.  09, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the third quarter of 2023.",1
"Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2023.",0
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma Media Release,1
"Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update REDWOOD CITY, Calif., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced results for the fiscal quarter ended September 30, 2023, and provided a business update.",0
"Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.",0
"Vaxcyte Doses First Participants in Phase 12 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults -- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 --",1
"ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting",1
"Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis JERUSALEM, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone and Mineral Research (ASBMR) has announced that the SABRE (Strategy to Advance BMD as a Regulatory Endpoint) project team has submitted to the U.S. Food and Drug Administration (FDA) its full qualification plan to use the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs.",2
"IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update NEW YORK, Nov.  09, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.",1
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024,1
"Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results SAN DIEGO, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2023 financial results.",2
"Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., Nov.  09, 2023  (GLOBE NEWSWIRE) --  Nkarta, Inc. (Nasdaq NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2023.",1
"Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update SEATTLE, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2023.",0
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 12a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 -,1
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC,1
"Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates WARRINGTON, Pa., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2023 and provided key business updates.",1
"Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates BOSTON, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX)(“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate and clinical updates.",1
"Fortress Biotech Announces Launch of Proposed Public Offering MIAMI, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has commenced a public offering, subject to market and other conditions, to offer and sell units, consisting of (i) one share of common stock (or pre-funded warrant in lieu thereof) and (ii) one warrant to purchase one share of common stock. All of the shares of common stock, pre-funded warrants and accompanying warrants are being offered by Fortress.",1
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications —  EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — ,1
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks,2
"Fortress Biotech Announces Pricing of $10.0 Million Public Offering MIAMI, Nov.  10, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the pricing of its public offering of an aggregate of 5,885,000 units, at a public offering price of $1.70 per unit, consisting of (i) one share of common stock (or one pre-funded warrant in lieu thereof) and (ii) one warrant to purchase one share of common stock, immediately exercisable at a price of $1.70 per share and expiring five years from the date of issuance.",0
"Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023 Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fibrosis, while semaglutide alone did not significantly improve fibrosis",1
"Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023 Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASHMASH",1
"Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients",2
"Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results Company Prioritizes Greatest Near-term Value-Driving Programs ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ",1
"Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update -- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov.  13, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.",1
RAPT Therapeutics Reports Third Quarter 2023 Financial Results Company maintains strong cash position of $184.8 million Company maintains strong cash position of $184.8 million,1
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024,1
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023 Data Show that BIV201 in Combination with Standard of Care (SOC) is Well Tolerated with No Major Difference in Treatment-Emergent Adverse Events (TEAEs) Compared to SOC Alone,1
"Rezolute Reports First Quarter Fiscal 2024 Results REDWOOD CITY, Calif., Nov.  13, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023.",2
"Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals",1
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 12 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences,1
"ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023 PORTLAND, Maine, Nov.  13, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023.",1
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome,1
"Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation",1
"Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsedrefractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 -",1
"Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 ",1
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update Analysis of Part 2 data from Phase 1b2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month,1
"Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort",1
"BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure SUNNYVALE, Calif., Nov.  14, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.",2
"Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema CAMBRIDGE, Mass., Nov.  14, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.",2
"Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development JERUSALEM, Nov.  14, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter ended September 30th, 2023.",1
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update,1
"IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones",0
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis (Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation),0
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023 Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens,0
"Fortress Biotech Announces Closing of $10.0 Million Public Offering MIAMI, Nov.  14, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced public offering of an aggregate of 5,885,000 units, consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $1.70 per unit. The warrants are immediately exercisable at a price of $1.70 per share and expire five years from the date of issuance.",2
"Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update -Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy-",2
"Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023",2
"TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update BOSTON, Nov.  14, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2023, and recent business progress.",1
"NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights – SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease, expect to initiate Phase IIIa by year end",0
Dr. Alan Kivitz leitet XBiotechs Natrunix-Programm für rheumatoide Arthritis (Multizentrische Phase-II-Studie schreitet mit großer Erwartung gut voran) (Multizentrische Phase-II-Studie schreitet mit großer Erwartung gut voran),1
"Le Dr Alan Kivitz prend la tête du programme Natrunix, conduit par XBiotech dans le traitement de la polyarthrite rhumatoïde (L’étude clinique multicentrique de phase II progresse bien et suscite de vives attentes) (L’étude clinique multicentrique de phase II progresse bien et suscite de vives attentes)",1
"Oculis Reports Q3 2023 Financial Results and Provides Company Update ZUG, Switzerland and BOSTON, Nov.  15, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced third quarter financial results for the period ended September 30, 2023, and an overview of the Company’s progress.",1
"INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon. The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon.",2
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering,1
"NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML BELTSVILLE, Md., Nov.  15, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “LAIR-1 Agonism as a Therapy for Acute Myeloid Leukemia” in the Journal of Clinical Investigation. The data demonstrate that NC525 induces cell death in acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs) through leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) agonism by driving a unique apoptotic signaling pathway.",1
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program,2
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update,1
"BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov.  16, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about November 20, 2023, subject to the satisfaction of customary closing conditions.",0
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma – Presentations included results from Phase 23 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine –,1
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Nov.  17, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on November 16, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees.",1
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months,0
"HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus NEW YORK and VIENNA, Austria, Nov.  20, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter.",0
"Cidara Therapeutics Named as a San Diego Metro Area Top Workplace SAN DIEGO, Nov.  20, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has been named a Top Workplace by The San Diego Union-Tribune. Cidara was among the top 100 companies and organizations included in the 2023 Top Workplace list.",1
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand,1
"Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development TORONTO, Nov.  21, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.",0
"Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing LOS ANGELES, Nov.  21, 2023  (GLOBE NEWSWIRE) --  Immix Biopharma, Inc. (NasdaqIMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101). With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsedrefractory AL Amyloidosis to the United States. Favorable tolerability enables potential expansion into autoimmune indications.",1
"Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.",1
"Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht LOS ANGELES, Nov.  22, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (NasdaqIMMX) („ImmixBio“, „Unternehmen“, „wir“ oder „uns“), ein biopharmazeutisches Unternehmen im klinischen Stadium, das personalisierte Therapien für die Onkologie und Immunologie vorantreibt, gab heute bekannt, dass die U.S. Food and Drug Administration (FDA) den IND-Antrag (Investigational New Drug) für BCMA CAR-T NXC-201 (ehemals HBI0101) genehmigt hat. Mit dieser Freigabe wird NEXICART-2 (NCT06097832) die Studien mit NXC-201 bei rezidivierterrefraktärer AL-Amyloidose auf die Vereinigten Staaten ausweiten. Gute Verträglichkeit ermöglicht eine potenzielle Ausweitung auf Autoimmunindikationen.",1
"La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains LOS ANGELES,  22 nov. 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq  IMMX), ci-après « ImmixBio », la « Société », « Nous » ou « Notre », une société biopharmaceutique au stade clinique qui développe des thérapies d’oncologie et d’immunologie personnalisées, annonce ce jour que l’administration américaine des denrées alimentaires et des médicaments, la Food and Drug Administration (ou FDA) a autorisé sa demande d’essai clinique pour BCMA CAR-T NXC-201, anciennement HBI0101. À l’appui de cette validation, NEXICART-2 (essai clinique NCT06097832) va poursuivre sur le sol américain les essais sur le NXC-201 dans le traitement de l’amylose AL en rechute ou réfractaire aux États-Unis. Un profil de tolérance favorable permettrait d’étendre le traitement aux maladies auto-immunes.",1
"Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial SYDNEY, AUSTRALIA, Nov.  22, 2023  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (""Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003 trial has been expanded to four sites across Germany including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim. This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and doublet chemotherapy for first line treatment of non-squamous non-small cell lung cancer (NSCLC).",1
"Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for RelapsedRefractory AL Amyloidosis Virtual Event to be held on November 29, 2023 at 415 p.m. ET Virtual Event to be held on November 29, 2023 at 415 p.m. ET",1
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions Study to enroll 15 acute stroke patients across three U.S. sites Study to enroll 15 acute stroke patients across three U.S. sites,0
"Kraig Biocraft Laboratories Strengthens Spider Silk Production Operations with Sericulture Experts from India ANN ARBOR, Mich., Nov.  27, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announced its continued investment into building its world-class team with the addition of leading sericulture consultants from India. Before joining Kraig, these individuals spent more than 30 years in senior-level positions overseeing all aspects of India's silk production on a national scale.",0
"Annovis Bio Announces Full Enrollment of Its Phase IIIII Alzheimer’s Disease Trial, Exceeding Original Projections BERWYN, Pa., Nov.  27, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) and developing novel and transformative therapies, announced that AD phase IIIII study of its lead compound buntanetap has exceeded full enrollment. ",1
"INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease Boca Raton, Florida, Nov.  27, 2023  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the patient’s innate immune system to combat disease, announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spain to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™.  ",1
"RAPT Therapeutics Announces Publication of Phase 1a1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy SOUTH SAN FRANCISCO, Calif., Nov.  27, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that results from its previously disclosed Phase 1a1b clinical trial of zelnecirnon (formerly RPT193) were published in Allergy. The Phase 1a portion of the trial was a standard single and multiple dose-escalation study in 72 healthy volunteers. The Phase 1b portion of the trial was a randomized, double-blind, placebo-controlled study examining zelnecirnon as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).",1
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) —Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injuryinflammation and fibrosis in NASH patients with fibrosis stage F2-F3—,0
"Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates -- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial Manufacturing Strategy as Lead PCV Candidate, VAX-24, Advances into Phase 3 --",1
"Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals SAN DIEGO, Nov.  27, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ CNTA) blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.",1
22nd Century Group Enters into Agreement to Sell HempCannabis Franchise Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements,2
"SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors – Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life –",1
"C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in RelapsedRefractory Multiple Myeloma WATERTOWN, Mass., Nov.  28, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that it will host a webcast on Tuesday, December 12, 2023 at 430 PM ET to present new Phase 1 dose escalation data for relapsed refractory multiple myeloma from the ongoing Phase 12 clinical trial of CFT7455, a MonoDAC™ degrader of IKZF13, for the potential treatment of relapsedrefractory multiple myeloma and relapsedrefractory non-Hodgkin’s lymphoma.",1
"Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit SAN MATEO, Calif., Nov.  28, 2023  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, will present preclinical data at the 7th Obesity and NASH Drug Development Summit on November 28, 2023, in Boston. The presentation details an evaluation of Sagimet’s FASN inhibitor alone or in combination with semaglutide in a preclinical mouse model of nonalcoholic steatohepatitis (NASH), using an artificial intelligence (AI) based digital pathology platform (FibroNestTM, Pharmanest Inc., Princeton, USA) to assess fibrosis.",0
"Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409 NEEDHAM, Mass., Nov.  28, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN™ Discovery Platform, while reducing the Company’s workforce and expenses associated with enabling commercial readiness of CAN-2409. The Company expects to present initial activity and biomarker data for repeated injections of CAN-3110 in recurrent high-grade glioma in the second half of 2024 and new data for the second drug candidate based on the enLIGHTEN™ Discovery Platform in Q3 2024. The Company plans to continue to collect clinical data for key readouts for CAN-2409 in non-small cell lung cancer (NSCLC), with topline overall survival data of the open label phase 2 clinical trial expected in Q2 2024; pancreatic cancer, with an update on overall survival based on an interim analysis of the randomized, open label clinical trial in Q2 2024; and prostate cancer, with topline data for both fully enrolled randomized, blinded, placebo-controlled phase 2 and phase 3 clinical trials in Q4 2024.",1
"Mydecine Announces Update Regarding the Special Access Program DENVER, Nov.  28, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEOMYCO) (OTCMYCOF) (FSE0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statements made in the Company’s news release of January 13, 2022 (the “Prior Release”) wherein the Company announced it would be launching the Special Access Support and Supply Program (“SASSP”) to provide products and services to physicians, clinics, and hospitals in Canada who are looking to treat patients through psychedelic-assisted psychotherapy.",1
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV11 and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain in a predefined subgroup of patients with reduced lung function2,0
"INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the tumor killing immunology of the tumor microenvironment.",1
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 12 Adult Trial to Include Adolescent Rett Syndrome Patients Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 12 adult trial in Canada,1
"BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints",0
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast,1
"Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform JERUSALEM, Nov.  29, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic (PK) and early pharmacodynamic (PD) profile of current and several next generation compositions of its oral peptide platform (NCT05965167).",1
"Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis NEW YORK, Nov.  30, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System Expanded Access (EA) Program. A total of ten patients are now being followed in the EA Program.",1
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress Preclinical data on dual CD73PD-1 targeting DFC to be presented for the first time Preclinical data on dual CD73PD-1 targeting DFC to be presented for the first time,1
"TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules BOSTON, Nov.  30, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.",0
"BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023 CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov.  30, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 1200 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infections. To register for the event, please click here.",2
Biora Therapeutics Announces FDA Clearance of IND Application for DrugDevice Combination BT-600 Targeting Treatment of Ulcerative Colitis BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon,2
"Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) NEW YORK, Dec.  01, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec.  01, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on December 1, 2023 (the “Grant Date”), ORIC granted a total of 23,080 non-qualified stock options and 3,840 restricted stock units to three new non-executive employees who began their employment with ORIC in November 2023.",1
"89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 —Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology—",2
"22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction Newly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce Costs Newly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce Costs",0
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing  Rule 5635(c)(4) BOSTON, Dec.  04, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on November 30, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 114,500 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules BOSTON, Dec.  04, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common stock priced at-the-market under Nasdaq rules.",1
"SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock STAMFORD, Conn., Dec.  04, 2023  (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock in the offering.",0
"CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease -Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70-",1
"VAX-24 Phase 12 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate -- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards --",1
"SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock STAMFORD, Conn., Dec.  05, 2023  (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being sold by SpringWorks. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $275.0 million. The offering is expected to close on or about December 7, 2023, subject to the satisfaction of customary closing conditions. In addition, SpringWorks has granted the underwriters a 30-day option to purchase up to an additional 1,422,413 shares of its common stock at the public offering price, less underwriting discounts and commissions.",0
"Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting Data supporting clonoSEQ’s clinical and research utility, as well as insights based on analysis of real-world experience, will be featured at ASH.",1
"Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease BERWYN, Pa., Dec.  05, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024.",2
"IN8bio to Host Investor Call at 830 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia NEW YORK, Dec.  05, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the Company will host a conference call on Tuesday, December 12, 2023 at 830 am ET. The event will highlight data presented at the ASH 65th Annual Meeting in a poster presentation on December 11, 2023 starting at 600 pm PT. The Company’s INB-100 trial is focused on investigating the potential of harnessing donor-derived allogeneic gamma-delta T cells for the treatment of patients with hematological malignancies following hematopoietic bone marrow transplantation (HSCT).",1
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints,1
"Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance Upcoming PDUFA goal date of January 3, 2024",1
"TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium BOSTON, Dec.  05, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at this year’s San Antonio Breast Cancer Symposium scheduled to take place December 5-9 in San Antonio, TX.",1
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers,0
"Kraig Biocraft Laboratories Prepares for Silk Production Season ANN ARBOR, Mich., Dec.  06, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announced that its senior management team is en route to Vietnam to prepare for the spring rearing season. They will meet with the team from its wholly owned Vietnamese subsidiary, Prodigy Textiles, third party contractors, and government officials, including provincial leadership.",1
"Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China SAN DIEGO, Dec.  06, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company, along with Mundipharma, has completed enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis.",1
"BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023 SAN DIEGO, Dec.  06, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day on Wednesday, December 13, 2023 at 1000 AM ET. To register, click here.",1
"Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting ADELAIDE, Australia and CAMBRIDGE, Mass., Dec.  06, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the presentation of data on the psychometric validity and reliability of SUDS as an outcome measure in assessing anxiety in SAD clinical trials at the 2023 American College of Neuropsychopharmacology Annual Meeting taking place December 3 – 6 in Tampa, Florida.",1
"Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones",1
"Inotiv, Inc. Announces Plan to Insource North American Transportation Operations WEST LAFAYETTE, Ind., Dec.  06, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will be partnering with Vanguard Supply Chain Solutions LLC, the Company’s current provider of transportation services, to enable the in-house integration of Inotiv’s North American transportation operations.",1
"89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants SAN FRANCISCO, Dec.  06, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.",0
"MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe LA JOLLA, Calif., Dec.  06, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced it has received a Notice of Decision to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).",1
"Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease ZUG, Switzerland and BOSTON, Dec.  07, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces First Patient First Visit (FPFV) in its Phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ innovative anti-TNFα biologic eye drop, for the treatment of Dry Eye Disease (DED).",2
"89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants SAN FRANCISCO, Dec.  07, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25 and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 1,081,081 shares of its common stock at a public offering price of $9.249. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,432,432 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $150.0 million. The offering is expected to close on or about December 11, 2023, subject to the satisfaction of customary closing conditions.",2
"Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress First in class, multi-specific CD73PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses",1
Immutep Receives A$2.6 million R&D Tax Incentive from French Government Media Release,1
"Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting SEATTLE, Dec.  09, 2023  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data demonstrating the expanding use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® test in assessing minimal residual disease (MRD) in blood cancer patient care and in clinical trials. The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California.",0
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models.,0
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx – NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI monotherapy also recommended as the only preferred regimen in subsequent lines of therapy –,1
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases,1
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations,2
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis --Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- ,1
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in RelapsedRefractory AL Amyloidosis Patients at ASH 2023  ,1
"Initial Phase 1 Dose Escalation Data for ORIC-533 in RelapsedRefractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients",1
"Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of 40%",1
"IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia NEW YORK, Dec.  11, 2023  (GLOBE NEWSWIRE) --  IN8bio, Inc. (Nasdaq INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced positive updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies. The data, which will be presented in a poster presentation at the 65th ASH Annual Meeting & Exposition this evening, demonstrated that 100% of evaluable leukemia patients (n=10) treated remained alive, progression-free, and in durable complete remission (CR) as of November 3, 2023. The Company believes this data indicate the curative potential of INB-100 to provide durable relapse free periods for high-risk or relapsed AML and other hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). The CRs to date, combined with INB-100’s benefitrisk profile are encouraging for the treatment of hematological malignancies and the trial is being expanded by ten patients at Dose Level (DL) 2, the recommended Phase 2 dose (RP2D). Additional expansion patient enrollment is on-going and updated data is expected to be presented at medical meetings in 2024.",2
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with RelapsedRefractory CBFGLIS Presented at ASH 2023 – Complete remission seen in 42% of patients with CBFGLIS AML with ≥5% blasts and 75% of pediatric patients with CBFGLIS AML with 5% blasts; treatment with luvelta was either alone or in combination –,1
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today Company to review BXCL502 and other potential emerging pipeline candidates  ,1
"C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets",2
"89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN FRANCISCO, Dec.  12, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its previously announced upsized underwritten public offering of 17,567,567 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 2,432,432 shares, at a public offering price of $9.25 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 1,081,081 shares of its common stock, at a purchase price of $9.249 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to the company, before deducting underwriting discounts and commissions and other offering expenses payable by the company, were approximately $172.5 million.",0
"Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer NEEDHAM, Mass., Dec.  12, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.",2
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine – Expect to announce topline data in Q3 2024 –,1
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma – BLA supported by results from Phase 23 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime trauma injuries in Ukraine –,1
"electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology ROCKAWAY, N.J., Dec.  12, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.",1
"GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tumors The Phase 1 trial will be conducted by researchers from the National Cancer Institute as part of a Cooperative Research and Development Agreement (CRADA)",1
Immuneering Announces FDA Clearance of IND Application for Phase 12a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations Immuneering Announces FDA Clearance of IND Application for Phase 12a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations,0
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland,1
"TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138 TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer",2
"Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 AB Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients – Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)marrow complete response (mCR) rate of 64% –",2
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) Plans to report topline data mid-second quarter 2024 Plans to report topline data mid-second quarter 2024,1
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel),2
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies Combined Certara-Applied Biomath organization establishes the life sciences industry’s largest quantitative systems pharmacology center.,1
"ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD",1
"NextCure Provides Year-End Clinical Pipeline Updates BELTSVILLE, Md., Dec.  14, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline.",0
"Kraig Biocraft Laboratories Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk ANN ARBOR, Mich., Dec.  14, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announces the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk. Silk from this production cycle was processed into finished reeled raw silk and happily received on site by the Company’s Senior management this week.",1
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025,1
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial,1
AC Immune Announces Pricing of Underwritten Offering of Common Shares AC Immune Announces Pricing of Underwritten Offering of Common Shares ,1
"CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease CAMBRIDGE, Mass., Dec.  15, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS® (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in people aged 16 years and older. If approved by the European Commission (EC), SKYCLARYS will be the first treatment authorized within the European Union for this rare, genetic, progressive neuromuscular disease.1 If approved, omaveloxolone will be marketed as SKYCLARYS.",1
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound MYCO announces it has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office for MYCO-005 compound,1
"Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine TORONTO, Dec.  18, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a collaboration agreement with Attwill Medical Solutions LP (“AMS”) for the clinical and commercial development of the Company’s next-generation lyophilized formulation of Bucillamine.",1
"U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab",0
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASHMASH (F2-F3) to be Reported in March 2024,0
"BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes SUNNYVALE, Calif., Dec.  18, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Japan Pharmaceutical and Medical Device Agency (PMDA) minutes support the Company’s understanding that CardiAMP autologous cell therapy may be approved for the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) based on follow-up data from the patients currently enrolled in the CardiAMP Heart Failure Trial (CardiAMP HF) that will be available in Q4 2024.",1
"Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population IRVINE, Calif., Dec.  18, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test (K232892), a new product that is designed to detect the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population. H. pylori infection is a disease which affects half the population of the world.",2
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3,2
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.,0
"Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU NORWOOD, Mass., Dec.  18, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held January 25-27, 2024 in San Francisco, CA and online. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting nectin-4, that contains a third generation, site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Pre-clinical data demonstrating differentiation from enfortumab vedotin was recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.",1
"PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) - Safety, transcript splicing correction and clinical outcome measures data at 5 mgkg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical trial expected in 2024 -",2
"Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board  ",0
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial. ,0
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate Phase 1b portion of phase 1b2 lanraplenib study in patients with relapsedrefractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2,0
"Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Dec.  18, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that, on December 14, 2023, three new employees were awarded grants of options to purchase an aggregate of 240,000 shares of voting common stock (the “Options”). Each Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to such employee’s employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of each Option is $0.49. Each Option will vest over four years, with 25% of the total number of shares vesting on the one year anniversary of the date of commencement of such employee’s employment with Jasper and 148th of the total number of shares subject to each Option vesting monthly thereafter, subject in each case to such employee’s continued service to Jasper on each vesting date.",2
"Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis NEW YORK, Dec.  19, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).   Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status Scale (EDSS), QoL assessments, and the Modified Fatigue Impact Scale (MFIS), which assess parameters that are essential to a patient’s everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images is an integral component of this study.",2
"BioCardia Doses First Patient in CardiALLO Phase III Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction SUNNYVALE, Calif., Dec.  19, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase III trial for the treatment of patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction (HFrEF).",1
"Kraig Biocraft Laboratories Announces Successful Production Test Utilizing a Two Strain Hybrid System ANN ARBOR, Mich., Dec.  19, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announces that it has successfully completed the first pilot production test using a new two strain hybrid system.",1
"Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission CAMBRIDGE, Mass., Dec.  19, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.",1
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.,1
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees,1
"Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery ZUG, Switzerland, and BOSTON, Dec.  20, 2023  (GLOBE NEWSWIRE) --  Oculis Holding AG (Nasdaq OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced First Patient First Visit (FPFV) in OCS-01 Phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the Phase 3 OPTIMIZE-2 trial is intended to support the Company’s NDA submission to the Food and Drug Administration (FDA). If approved, OCS-01 has the potential to be the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.",1
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke,1
"Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease MIAMI, Dec.  20, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announces additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.",2
"Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity",1
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians,1
"Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock BRISBANE, Calif., Dec.  20, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock. The shares of common stock are being sold at a price of $2.88 per share and the pre-funded warrants are being sold at a price of $2.879 per share.",1
"HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences NEW YORK and VIENNA, Austria, Dec.  21, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Gilead Sciences (‘Gilead’) has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share.",2
"NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury BELTSVILLE, Md., Dec.  21, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats” in JMBR Plus, a journal of the American Society for Bone and Mineral Research (ASBMR). The data demonstrated that NC605, a novel anti-Siglec-15 (S15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.",0
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer Media Release,1
"Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MIAMI, Dec.  21, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.62 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,355,301 shares of its common stock. The warrants will have an exercise price $1.62 per share, will become exercisable immediately upon issuance and have a term of five and one-half (5.5) years from the date of issuance. The offering is expected to close on or about December 26, 2023, subject to the satisfaction of customary closing conditions.",0
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers On track to report topline data by the end of 2024,1
"MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement",1
"Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants AUSTIN, TX and DURHAM, NC, Dec.  21, 2023  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “company”) (NASDAQ STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the pricing of a registered offering of 4,651,163 shares of common stock, par value $0.0001 (the “common stock”), at a price of $6.45 per share, which is priced at the closing price on Nasdaq for the common stock on December 20, 2023. In addition to the shares sold in the registered offering, Shattuck announced the concurrent pricing of a private placement of pre-funded warrants to purchase 3,100,823 shares of common stock at a purchase price of $6.4499 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Shattuck from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50 million. The offering is expected to close on or about December 26, 2023, subject to customary closing conditions.",2
"Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry The new Cytek Orion reagent cocktail preparation system simplifies & accelerates laboratory workflow, assures consistent experimental results & saves time.",1
"UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MIAMI, Dec.  21, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.745 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,355,301 shares of its common stock. The warrants will have an exercise price $1.62 per share, will become exercisable immediately upon issuance and have a term of five and one-half (5.5) years from the date of issuance. The offering is expected to close on or about December 22, 2023, subject to the satisfaction of customary closing conditions.",1
"Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension – Topline data from confirmatory Launch-HTN trial expected in 2H 2025 –",1
"Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults SAN DIEGO, Dec.  22, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) today announced REZZAYO (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.",2
"Elicio Therapeutics Announces $7.0 Million Private Placement Financing BOSTON, Dec.  22, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC. GKCC, LLC is an entity controlled by a member of Elicio’s Board of Directors. Gross proceeds of the private placement are expected to be approximately $7.0 million, before deducting expenses. The private placement is expected to close on December 22, 2023, subject to the satisfaction of customary closing conditions.",2
"Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MIAMI, Dec.  22, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,355,301 shares of its Class A common stock (“common stock”) at a purchase price of $1.745 per share and associated warrant. In a concurrent private placement, Longeveron issued unregistered warrants to purchase up to an aggregate of 1,355,301 shares of its common stock. The warrants have an exercise price of $1.62 per share, are exercisable immediately upon issuance and have a term of five and one-half (5.5) years from the date of issuance.",1
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Dec.  22, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on December 21, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 44,175 shares of Iovance’s common stock to four new non-executive employees.",1
"Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025 JERUSALEM, Dec.  26, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors. The Company issued and sold 7,916,879 units at a price of $0.835 per unit, each consisting of one ordinary share of Entera (or one pre-funded warrant in lieu thereof), and one five-year warrant. Gross proceeds to Entera, before offering expenses, were approximately $6.6 million, extending the Company’s cash runway into 2025.",2
electroCore Expands Intellectual Property Portfolio electroCore Granted Two New U.S. Patents electroCore Granted Two New U.S. Patents,1
"Oncternal Therapeutics Updates the Status of its Phase 12 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma SAN DIEGO, Dec.  26, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalationdose expansion Phase 12 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.",0
"Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv – Innovative design enables five-minute pegfilgrastim delivery time –",2
"Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer SAN CARLOS, Calif., Dec.  27, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC).",0
"NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 12a clinical trial in moderate Alzheimer’s Disease patients",2
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million,1
"NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 12a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease NKGen Biotech’s autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease (“AD”) in its Phase 1 dose-escalation safety trial.",0
"Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MIAMI, Dec.  29, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has entered into a definitive agreement for the issuance and sale of 3,303,305   shares of its common stock and warrants to purchase up to 3,303,305   shares of common stock at a combined offering price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, are immediately exercisable, and will expire five years following the date of issuance.",0
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform Biora's BioJet™ drug delivery platform exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study.,0
"INmune Bio Announces First Patient Dosed in a Phase 12 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer Boca Raton, Florida, Jan.  02, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight  disease, dosed the first patient in the Phase III trial in men with metastatic castration-resistant prostate cancer (mCRPC) on December 27, 2023. INKmune™ is a biologic therapy given as out-patient therapy without the need for pre-medication or cytokine support. ",1
"Jasper Therapeutics, Inc. Announces Reverse Stock Split REDWOOD CITY, Calif., Jan.  02, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding voting common stock that will become effective at 1201 a.m. Eastern Time on Thursday, January 4, 2024. Jasper’s voting common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, January 4, 2024.",0
Coherus Announces U.S. Launch of LOQTORZI™ – Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy –,1
"Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference JUPITER, Fla., Jan.  02, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following events during the J.P. Morgan 42nd Annual Healthcare Conference in January 2024.",1
"Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan.  02, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager.",1
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator The new preclinical data further supports istaroxime clinical data from three Phase 2 studies,1
"BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders SUNNYVALE, Calif., Jan.  03, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, issues the following letter to shareholders",1
"Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule JERUSALEM, Jan.  03, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 27, 2023, it received an extension of 180 calendar days from the Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Bid Price Requirement”). The Nasdaq determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the Bid Price Requirement.",0
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases,1
"Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively. These numbers do not include revenue from other sources, including research contracts such as the Company’s previously announced multi-year research collaboration services agreement with Regeneron.",2
"Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MIAMI, Jan.  03, 2024  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced registered direct offering. The company issued 3,303,305 shares of its common stock and warrants to purchase up to 3,303,305 shares of common stock at a combined offering price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, are immediately exercisable, and will expire five years following the date of issuance.",1
"Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium - Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -",2
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress Reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting,1
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer Media Release,2
"IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals NEW YORK, Jan.  04, 2024  (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024.",1
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 -,1
"TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives An Open Letter to Shareholders of TransCode Therapeutics, Inc.",0
"Oncternal Therapeutics Announces Reverse Stock Split SAN DIEGO, Jan.  04, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the company's common stock. The reverse stock split will become effective at 1201 a.m. Eastern time on January 8, 2024. The company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the same symbol (ONCT) when the market opens on January 8, 2024 with the new CUSIP number 68236P206.",1
"XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus AUSTIN, Texas, Jan.  04, 2024  (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024.",1
"Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care",1
"Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare FLORHAM PARK, N.J., Jan.  04, 2024  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dentaloral healthcare applications. A copy of BioCellgraft’s announcement of the agreement can be accessed here httpswww.prweb.comreleasesbiocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html.",0
"Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise -- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 12 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following Successful End-of-Phase 2 Meeting with FDA, Company Planning for Initiation of VAX-24 Adult Phase 3 Pivotal, Non-Inferiority Study in Second Half of 2024; Topline Data Expected in Second Half of 2025 --",1
"Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones CAMBRIDGE, Mass., Jan.  04, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced its strategic priorities through 2026 and key anticipated 2024 milestones that support the company’s mission to transform the lives of patients and bring forth a new era in medicine.",1
"C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals WATERTOWN, Mass., Jan.  04, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the closing of the previously announced $25 million stock purchase agreement with a wholly-owned subsidiary of Betta Pharmaceuticals Co. Ltd (Betta) (300558.SZ), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China. This investment was completed at $4.49 per share. The purchase price represents a 25% premium over the 60-trading-day volume weighted average through the date that was two business days prior to the entry into the stock purchase agreement on May 29, 2023.",1
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million,1
"Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer",1
PolyPid Announces Private Placement for $16 Million in Gross Proceeds Financing Led by Leading U.S. Life Sciences-focused Investors Financing Led by Leading U.S. Life Sciences-focused Investors,0
"Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues TAMPA, Fla., Jan.  04, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023, compared with $666.8 million for the year ended December 31, 2022.",1
"XBiotech entame la construction d’un nouveau centre de recherche et développement sur son campus de 19 hectares AUSTIN, Texas,  05 janv. 2024  (GLOBE NEWSWIRE) -- La société XBiotech Inc. a annoncé, ce jour, qu’elle prévoyait d’agrandir son siège social sur le campus avec la construction d’un nouveau centre de recherche et développement à la pointe de la technologie. XBiotech a reçu l’approbation de la ville d’Austin pour commencer l’excavation en vue de la préparation du site et les travaux de terrassement devraient commencer au 1er trimestre 2024.",1
"XBiotech beginnt mit dem Bau der neuen F&E-Anlage auf seinem 19 Hektar großen Campus AUSTIN, Texas, Jan.  05, 2024  (GLOBE NEWSWIRE) -- XBiotech Inc. gab heute sein Vorhaben bekannt, seinen Campus-Hauptsitz durch eine neue, moderne Forschungs- und Entwicklungsanlage zu erweitern. XBiotech erhielt die Genehmigung der Stadt Austin für die Aushubarbeiten zur Standort- und Bodenvorbereitung, die voraussichtlich im ersten Quartal 2024 beginnen werden.",1
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist,1
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Jan.  05, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that, on January 2, 2024, Taysha's Board of Directors granted Meredith Schultz, M.D., M.S., an option to purchase 257,700 shares of the Company's common stock in connection with her employment as Taysha’s new Senior Vice President, Clinical Development and Medical Affairs. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to Ms. Schultz entering into employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",0
"Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones - EU Clinical Trials authorized for Phase 1b2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively",1
"CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook ZUG, Switzerland and BOSTON, Jan.  08, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.",1
"Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients NEW YORK, Jan.  08, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients (10 total) are planned to be available in late January.",1
"Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 AUSTIN, TX and DURHAM, NC, Jan.  08, 2024  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024.",1
"PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping - Preliminary data from the 5 mgkg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024 including initial safety, exon 51 skipping and dystrophin protein production data -",2
"Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600 SADMAD study to evaluate safety and PKPD of BT-600 drug-device combination, including concentrations in colon tissue",2
"ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life 10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination development",1
"Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostate Cancer SAN DIEGO, Jan.  08, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 12 study of ONCT-534, its dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). The last two patients were enrolled into the third dosing cohort, to receive ONCT-534 at a dose of 160 mg taken orally each day. The study utilizes an adaptive Bayesian Optimal Interval (BOIN) design, under which the first two dosing cohorts treated one patient each at 40 mg ONCT-534 per day and 80 mg ONCT-534 per day, respectively. The decision to proceed to dose level 3 was confirmed by the study’s Safety Review Committee (SRC).",2
"Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results FREMONT, Calif., Jan.  08, 2024  (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023.",1
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance            ,2
"ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 PORTLAND, Maine, Jan.  08, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended December 31, 2023.",1
"Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002 BOSTON, Jan.  09, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of data from the Phase 1 (AMPLIFY-201) study of ELI-002 2P in Nature Medicine. The paper, “Lymph Node Targeted, mKRAS-specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer The phase 1 AMPLIFY-201 Trial”, details expanded and updated results originally presented at the 2023 American Society of Clinical Oncology (“ASCO”) Annual Meeting and the 2023 AACR Special Conference on Pancreatic Cancer.",1
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases US IND filing targeted for mid-2024 US IND filing targeted for mid-2024,0
"MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.",1
"Kraig Biocraft Laboratories Joins Vietnam Sericulture Association ANN ARBOR, Mich., Jan.  09, 2024  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announces its Vietnamese subsidiary, Prodigy Textiles (""Prodigy""), has joined the Vietnam Sericulture Association (""VSA"").",1
"electroCore Expands Intellectual Property Portfolio ROCKAWAY, N.J., Jan.  09, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).",1
"Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601) NORWOOD, Mass., Jan.  09, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo. The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.",2
Mainz Biomed Provides Year-End Corporate Review 2023 Mainz Biomed Provides Year-End Corporate Review 2023,2
"C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials",1
"TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively",1
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024 -- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million --,2
"Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine TORONTO, Jan.  10, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo. The New Bucillamine has the potential to unlock the therapeutic utility of Bucillamine for treating public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.",1
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 12 Pediatric Trial in Rett Syndrome Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome,1
"Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries DALLAS, Jan.  11, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDMDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients.",2
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split TransCode Announces Reverse Stock Split,1
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium,1
"Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference WALTHAM, Mass., Jan.  11, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 400 p.m. EST.",1
"Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study BOSTON, Jan.  11, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase 2 (AMPLIFY-7P) study of ELI-002 7P as an adjuvant monotherapy in KRAS mutated pancreatic ductal adenocarcinoma (“PDAC”).",1
"Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada TORONTO, Jan.  16, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The Company and the DRDC have finalized the research protocol and expect the project to be completed by the end of Q2-2024.",2
"Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007",0
"Biora Therapeutics Provides Outlook for 2024 Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.",1
"Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD Accelerating Healthcare With Award-Winning AI Big Steps Forward In 2023 And The Early Days Of 2024 Accelerating Healthcare With Award-Winning AI Big Steps Forward In 2023 And The Early Days Of 2024",1
"Biomerica Reports Second Quarter 2024 Financial Results IRVINE, Calif., Jan.  16, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2024 ended November 30, 2023.",0
"Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management SOUTH SAN FRANCISCO, Calif., Jan.  16, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.",1
"CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia - Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment-",1
"Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Data from first tranche of MSS CRC patients treated with ADG126 10 mgkg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy -",1
"MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China LA JOLLA, Calif., Jan.  17, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced it has received a Notice of Grant from the Chinese Patent Office for a new patent which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.",1
"Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China  Asia Pacific Region Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for products in the licensed territory",0
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries Cytek Biosciences has signed an agreement with The Centre for Genomic Regulation and the Pompeu Fabra University to accelerate scientific discoveries.,1
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies,1
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies,1
"T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients LEXINGTON, Mass., Jan.  18, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for pneumonia patients. The Pneumonia Direct Pilot study is a prospective, observational, diagnostic, feasibility study to determine the accuracy of multiple pathogen- and host-directed tests for the diagnosis of ventilator-associated pneumonia (VAP). Under the direction of Kimberly Hanson, M.D., University of Utah, the study seeks to explore new approaches for diagnosing VAP along with more comprehensive detection of antibiotic-resistant infections. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen and host-directed testing approaches.",1
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering,0
"Celularity Releases CEO Letter to Shareholders FLORHAM PARK, N.J., Jan.  18, 2024  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here.",1
"NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders BELTSVILLE, Md., Jan.  18, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease (COPD), at the Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy.",1
"Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium – Data demonstrate early activity with casdozokitugatezolizumabbevacizumab; 38% objective response rate including three complete responses – ",2
"AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference – Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated 12 to 16 weeks post treatment –",1
"Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -",1
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Jan.  19, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on January 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 51,375 shares of Iovance’s common stock to six new non-executive employees.",1
"Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal – Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 830 a.m. Eastern Time –",0
"Bionomics Provides a Review of 2023 and of 2024 Plans Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration (FDA) anticipated in Q2’24.",0
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2F3 NASH Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis,2
AC Immune to Regain Global Rights to Crenezumab and Semorinemab AC Immune to Regain Global Rights to Crenezumab and Semorinemab,1
"Kraig Biocraft Laboratories Targets Vertical Markets for its Spider Silk and Shares Planned Applications ANN ARBOR, Mich., Jan.  22, 2024  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB KBLB) (""the Company""), shares an update on near-term commercial applications and opportunities for recombinant spider silk as the Company prepares for expanding production in 2024. Spider silk has long been prized for its unique blend of chemical and mechanical properties, including strength and elasticity.",1
"Amarin Chairman & CEO Issue Letter to Shareholders DUBLIN, Ireland and BRIDGEWATER, N.J., Jan.  22, 2024  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQAMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders",0
"ORIC Pharmaceuticals Announces $125 Million Private Placement Financing Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech",2
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering TransCode Therapeutics closes public offering,1
"Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism REDWOOD CITY, Calif., Jan.  23, 2024  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). The Innovation Passport designation was granted based on the substantial unmet medical need in this condition and the potential for RZ358 to benefit patients as evidenced by the Phase 2 RIZE study in congenital HI, which safely demonstrated significant improvements in hypoglycemia events.",1
"Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU NORWOOD, Mass., Jan.  23, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (CRB-701) has been released, and the corresponding up-to-date data will be presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data referred to in the abstract dates to September of 2023; the upcoming presentation will include data as of December 2023. The study is being conducted by Corbus’s partner CSPC Pharmaceutical Group in China. ASCO GU will be held January 25-27, 2024 in San Francisco, CA and online.",1
"Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock SAN MATEO, Calif., Jan.  23, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common stock. All of the shares in the proposed offering are to be sold by Sagimet. In addition, Sagimet expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its Series A common stock in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",1
"Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement MALVERN, Pa., Jan.  24, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.",0
"CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b - Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -",1
"Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products LOS ANGELES, CA, Jan.  24, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, NasdaqIMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products",1
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 -Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic-,2
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN,1
"FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 23 Adaptive Platform Trial for Metastatic Pancreatic Cancer SAN FRANCISCO, Jan.  25, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM Phase 23 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline data from this registration study is anticipated in the second quarter of 2024.",1
"Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company WARRINGTON, Pa., Jan.  25, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that the Company entered an Exchange and Termination Agreement with affiliates of Deerfield Management Company (collectively, “Deerfield”) pursuant to which Deerfield has agreed to terminate its rights under the Company’s 2017 Exchange and Termination Agreement to receive up to $15,000,000 in development and commercial milestone payments associated with AEROSURF®, an acute pulmonary drugdevice combination intended to treat premature infants with respiratory distress syndrome. Windtree out-licensed global rights to AEROSURF® in 2022.",2
"Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million amended and restated senior secured loan agreement with an existing lender, Resorts World Inc Pte Ltd. Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million amended and restated senior secured loan agreement with an existing lender, Resorts World Inc Pte Ltd.",1
"Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors BOSTON, Jan.  25, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (“AACR”). These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.",2
"Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock SAN MATEO, Calif., Jan.  25, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the pricing of its underwritten public offering of 9,000,000 shares of its Series A common stock at a public offering price of $12.50 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $112.5 million. In addition, Sagimet has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its Series A common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by Sagimet. The offering is expected to close on January 30, 2024, subject to the satisfaction of customary closing conditions.",2
"CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024 NORWOOD, Mass., Jan.  26, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), today announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner CSPC Pharmaceutical Group at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors. The study opened for enrollment in January 2023 and data through December 2023 from the first eighteen participants reflective of the first six dose cohorts (0.2-3.6mgkg) will be shared.",2
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical,0
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™ U.S. patent allowance impacts Aging-related Frailty patients receiving vaccines and builds upon a growing patent estate protecting the use of Lomecel-B™ U.S. patent allowance impacts Aging-related Frailty patients receiving vaccines and builds upon a growing patent estate protecting the use of Lomecel-B™,0
"Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market WALTHAM, Mass., Jan.  29, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 7,756,233 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.805 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock. The warrants will have an exercise price of $1.68 per share, will be exercisable immediately upon issuance and will expire five years following the issuance date.",2
"HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs NEW YORK and VIENNA, Austria, Jan.  29, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company will focus its resources in two strategic areas (1) prioritize the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and (2) its two Gilead-partnered infectious disease cure programs for hepatitis B and human immunodeficiency virus.",0
"Vaxcyte Completes Enrollment of Phase 12 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older -- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 12 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in the U.S. Adult Population --",1
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer,2
"Spectral Submits Application for UKCA Mark Classification DALLAS, Jan.  29, 2024  (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (NASD MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the submission of an application in the United Kingdom for its predictive software DeepView AI®-Burn to be registered as UK Conformity Assessed (UKCA) for burn wound use in the UK.",1
Immunocore Announces Proposed Convertible Senior Notes Offering Immunocore Announces Proposed Convertible Senior Notes Offering,0
"Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults SAN DIEGO, Jan.  29, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults.",2
Kraig Biocraft Laboratories Signs Pivotal MOU in Vietnam's Silk Production Capital Kraig Labs(OTCQBKBLB) MOU with Vietnam Sericulture Assn(VSA) & Lam Dong Agro-Forestry Res Exp Cntr(LAREC) to enhance and expand silk production in VNM,2
Immutep Quarterly Activities Report Q2 FY24 Media Release,2
"Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio MALVERN, Pa., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications. This application follows the U.S. Provisional Application No. 63440,890 which was filed on January 24, 2023.",1
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program  The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final patient is enrolled.  ,1
"Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants SAN CARLOS, Calif., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",1
"Corbus Pharmaceuticals Announces Proposed Public Offering NORWOOD, Mass., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.",2
Immunocore Prices Upsized Convertible Senior Notes Offering Immunocore Prices Upsized Convertible Senior Notes Offering ,1
"Vaxcyte Announces Pricing of $750 Million Public Offering SAN CARLOS, Calif., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $750.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,757,812 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.",1
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325DB-1305    ,1
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325DB-1305     ,1
"InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework TEL AVIV, Israel and MIAMI, Jan.  31, 2024  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation (MDR) regulatory framework. MDR replaced the previous MDD framework, which had governed the approval and marketing of medical devices in the EU until May of 2021.",1
"Biogen to Realign Resources for Alzheimer's Disease Franchise CAMBRIDGE, Mass., Jan.  31, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth. The company will continue to advance LEQEMBI® (lecanemab-irmb), the first anti-amyloid beta treatment with FDA traditional approval in the United States, and will accelerate development of potential new treatment modalities, including its ASO targeting tau (BIIB080) and an oral small molecule inhibitor of tau aggregation (BIIB113). The company will discontinue the development and commercialization of ADUHELM® (aducanumab-avwa) 100 mgmL injection for intravenous use and will terminate the ENVISION clinical study. This decision is not related to any safety or efficacy concerns. A large portion of the resources released resulting from termination of the ADUHELM program will be redeployed in Biogen’s AD franchise.",1
"Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives WARRINGTON, Pa., Jan.  31, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value.",0
"Corbus Pharmaceuticals Announces Pricing of Public Offering NORWOOD, Mass., Jan.  31, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 648,750 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Corbus. The offering is expected to close on or about February 2, 2024, subject to customary closing conditions.",2
"Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option Aptose closes previously announced public offering and private placement",1
"Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market",2
"Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine CAMBRIDGE, Mass., Jan.  31, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim results from the Phase 1 portion of the Phase 12 study of NTLA-2002 were published online in the New England Journal of Medicine (NEJM). NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.",1
"Revive Therapeutics Explores the Use of Bucillamine for Long COVID TORONTO, Feb.  01, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company aims to advance the clinical development of Bucillamine by leveraging the published research and existing data from its previous Phase 3 clinical trial (the “Study”) and is preparing a clinical package that includes a proposed Phase 23 clinical protocol for long COVID to present to the FDA and international health regulatory bodies.",2
"Immuneering Announces Participation in February Investor Conferences CAMBRIDGE, Mass., Feb.  01, 2024  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq IMRX), a clinical-stage oncology company seeking to develop universal-RASRAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company’s pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.",1
"Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research WARRINGTON, Pa., Feb.  01, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. Windtree personnel from its offices in Taipei, Taiwan will participate in the collaboration.",1
"Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb.  01, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science.",1
"Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline  Continuing the substantial growth trajectory that began during 2023, for the first quarter 2024 and the full year 2024, Celularity expects triple-digit percentage increases in combined net sales of its advanced biomaterial product and biobanking businesses compared to the first quarter 2023 and the full year 2023.",2
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Feb.  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 575,942 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Feb.  02, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that, on January 31, 2024, three new employees were awarded grants of options to purchase an aggregate of 12,000 shares of voting common stock (the “Options”). Each Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to such employee’s employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of each Option is $11.78. Each Option will vest over four years, with 25% of the total number of shares vesting on the one year anniversary of the date of commencement of such employee’s employment with Jasper and 148th of the total number of shares subject to each Option vesting monthly thereafter, subject in each case to such employee’s continued service to Jasper on each vesting date.",1
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Feb.  02, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that, on February 1, 2024, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 180,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",0
"Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares NORWOOD, Mass., Feb.  02, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb.  02, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 1, 2024 (the “Grant Date”), ORIC granted a total of 12,500 non-qualified stock options and 2,100 restricted stock units to two new non-executive employees who began their employment with ORIC in January 2024.",1
"Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN CARLOS, Calif., Feb.  02, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,695,312 shares of common stock at a public offering price of $64.00 per share and pre-funded warrants to purchase 781,250 shares of common stock at a public offering price of $63.999 per underlying share. This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.",1
"FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 SAN FRANCISCO, Feb.  05, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 1030 AM ET. To register, click here.",2
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine Aligns with Company’s strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer’s patients ,2
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge —  Data served as foundation for current vaccine candidate for planned Phase 2 research,1
Candel Therapeutics Sets Path to Success Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts Candel Therapeutics Sets Path to Success Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts,0
"Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting REDWOOD CITY, Calif., Feb.  05, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.",1
"Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP - Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduced by ~70% -",1
"Spectral AI Announces Publication of Letter to Shareholders DALLAS, Feb.  05, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the publication of a Letter to Shareholders from the Company’s CEO and Co-founder, Wensheng Fan, and Chairman of the Board, Richard Cotton.",1
"Immix Biopharma Announces Proposed Public Offering of Common Stock LOS ANGELES, Feb.  05, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.    ",0
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Feb.  05, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 28,400 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on the later of February 2, 2024 and the employee’s commencement of employment with the Company (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA® Human proof of concept portion of the trial expected to begin in H1 2024; led by Georgetown Lombardi Comprehensive Cancer Center,1
"Kraig Biocraft Laboratories Announces Creation of Production Ready Spider Silk Hybrid BAM 1 Kraig Labs (OTCQB KBLB) creates BAM 1, a new recombinant spider silk superfiber hybrid",1
"electroCore Expands Intellectual Property Portfolio ROCKAWAY, N.J., Feb.  06, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).",1
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies,1
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY,1
"Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company JUPITER, Fla., Feb.  06, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform. Under the agreement, research and development activities will be funded by the collaborator.",1
"Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock REDWOOD CITY, Calif., Feb.  06, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (“Jasper”), a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten offering of 3,900,000 shares of its common stock. Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for continued advancement of its preclinical and clinical development programs of briquilimab in mast-cell driven diseases such as CSU and Chronic Inducible Urticaria (CIndU), as well as general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. All of the shares of common stock are being offered by Jasper. The offering is expected to close on or about February 8, 2024, subject to the satisfaction of customary closing conditions.",2
"INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024 Boca Raton, Florida, Feb.  06, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 1030AM EST.  The webcast will feature RJ Tesi, MD, CEO, CJ Barnum, PhD, head of Neuroscience, and Malu Tansey, PhD, Professor of Neuroscience and Neurology, Norman and Susan Fixel Chair in Parkinson’s Disease, Director, Parkinson’s Foundation Research Center of Excellence, University of Florida.",1
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Feb.  06, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 33,750 restricted stock units of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of February 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Sutro Biopharma to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb.  06, 2024  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.",1
"PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock BOSTON, Feb.  07, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 7,530,000 shares of its common stock at a price to the public of $10.635 per share. The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen. The offering is expected to close on or about February 9, 2024, subject to customary closing conditions.",2
"Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. TAMPA, Fla., Feb.  07, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc. Effective January 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for EXPAREL® (bupivacaine liposome injectable suspension).",0
"Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024 The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024",2
"Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement COPENHAGEN, Denmark, Feb.  07, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).",1
"U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize LEXINGTON, Mass., Feb.  07, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation (“Cohen Foundation”) have selected T2 Biosystems as a Phase 2 winner in the LymeX Diagnostics Prize, a prize competition to accelerate the development of Lyme disease diagnostics. As a Phase 2 winner, T2 Biosystems will receive $265,000.",1
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis European Orphan Drug Designation (“ODD”) qualifies NXC-201 for,1
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update - First quarter fiscal 2024 revenue up 10.3% to $135.5 million,1
"Theriva Biologics anuncia la recomendación positiva del Comité independiente para la monitorización de los datos de Datos de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico El comité independiente para la monitorización de los datos (IDMC) ha recomendado la continuación de VIRAGE sin que se plantearan problemas de seguridad; VIRAGE está en vías de finalizar la inscripción en el primer semestre de 2024 El comité independiente para la monitorización de los datos (IDMC) ha recomendado la continuación de VIRAGE sin que se plantearan problemas de seguridad; VIRAGE está en vías de finalizar la inscripción en el primer semestre de 2024",1
"BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme MAINZ, Deutschland und LONDON, Vereinigtes Königreich, 8. Februar 2024 – BioNTech SE (Nasdaq BNTX, „BioNTech“), ein Immuntherapie-Unternehmen der nächsten Generation, das bei der Entwicklung von Therapien gegen Krebs und anderer schwerer Erkrankungen Pionierarbeit leistet, und Autolus Therapeutics plc (Nasdaq AUTL, „Autolus“), ein biopharmazeutisches Unternehmen im klinischen Stadium, das programmierbare T-Zelltherapien der nächsten Generation entwickelt, gaben heute eine strategische Kollaboration bekannt, die darauf abzielt, die autologen CAR-T-Programme beider Unternehmen vorbehaltlich behördlicher Genehmigungen in Richtung Marktzulassung voranzutreiben. Im Zusammenhang mit der strategischen Kollaboration schlossen die Unternehmen eine Lizenz- und Optionsvereinbarung sowie einen Wertpapierkaufvertrag ab.",1
"BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs MAINZ, Germany and LONDON, United Kingdom, February 8, 2024 – BioNTech SE (Nasdaq BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc (Nasdaq AUTL, “Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations. In connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement.",1
"Evaxion erfüllt wieder die Anforderungen der Nasdaq an den Mindestangebotspreis KOPENHAGEN, Dänemark, Feb.  08, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von KI-gestützten Immuntherapien (AI-Immunology™) spezialisiert hat, hat heute bekanntgegeben, dass es am 5. Februar 2024 ein Benachrichtigungsschreiben der Abteilung für Zulassungsqualifikationen von The Nasdaq Stock Market LLC („Nasdaq“) erhalten hat, in dem festgestellt wird, dass das Unternehmen die Mindestangebotspreisanforderung gemäß Nasdaq Listing Rule 5550(a)(2) wieder erfüllt hat.",2
"Evaxion répond de nouveau aux exigences du Nasdaq en matière de prix minimum de l'offre COPENHAGUE, Danemark,  08 févr. 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ  EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement de vaccins à partir de sa plateforme IA-Immunology™, à annoncé aujourd'hui avoir reçu le 5 février 2024 un avis en provenance du département chargé de l'admissibilité à la cote du Nasdaq (ci-après « Nasdaq ») indiquant que la Société répondait de nouveau aux exigences en matière de prix minimum de l'offre suivant les dispositions du Règlement Nasdaq 5550(a)(2).",2
"BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA SUNNYVALE, Calif., Feb.  08, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chronic myocardial ischemia as potential indications for its biotherapeutic candidates autologous CardiAMP® cell therapy and allogeneic CardiALLO™ cell therapy.",0
"Mineralys Therapeutics Announces $120 Million Private Placement Financing RADNOR, Pa., Feb.  08, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.",2
"Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)  - Interim data from additional MSS CRC patients dosed at 10 mgkg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -",1
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform,1
"MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU) Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU)",2
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial Approximately 40 Centers Currently Open,0
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability,2
"Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO SAN DIEGO, Feb.  12, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.",2
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel Increases number of bacteria species detected with addition of Acinetobacter baumannii Increases number of bacteria species detected with addition of Acinetobacter baumannii,2
"Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia CAMBRIDGE, Mass., Feb.  12, 2024  (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. SKYCLARYS is the first treatment approved within the European Union for this rare, genetic, progressive neurodegenerative disease.1",1
"European Commission Approves First CRISPRCas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)  —Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment—",0
"Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases AUSTIN, TX and DURHAM, NC, Feb.  13, 2024  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to generate novel bifunctional fusion proteins targeting certain pathways in autoimmune and inflammatory diseases.",1
"Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi",1
"Kraig Biocraft Laboratories Announces New Spider Silk Production Facility in Vietnam's Silk Capital Kraig Labs (OTCQBKBLB) has taken possession of its new recombinant spider silk production center in Lam Dong, Vietnam",2
"CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma NEEDHAM, Mass., Feb.  13, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate – for the treatment of patients with recurrent high-grade glioma (HGG) to improve overall survival.",2
"RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations SOUTH SAN FRANCISCO, Calif., Feb.  13, 2024  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.",0
"Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing JUPITER, Fla. and LELAND, N.C., Feb.  13, 2024  (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila). Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.",1
CRISPR Therapeutics Announces $280 Million Registered Direct Offering - Led by new investor EcoR1 Capital and SR One with participation from existing and new investors -,0
"BioXcel Therapeutics Announces Termination of Proposed Public Offering NEW HAVEN, Conn., Feb.  13, 2024  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on February 8, 2024. As a result of such termination, no securities of the Company are being sold pursuant to the offering.",2
"AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine LOS ANGELES, Feb.  13, 2024  (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ RENB) announced today that it completed its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, and a new era in healthcare innovation. The two subsidiaries will be under the parent organization, which was renamed Renovaro Inc.",1
"Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy. ",1
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025,1
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections,1
"Annovis Bio Announces Last Patient Last Visit in the Phase IIIII Study of Buntanetap in Alzheimer’s Disease MALVERN, Pa., Feb.  14, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase IIIII study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD). ",1
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy,1
"Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease -Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery",2
"Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis CAMBRIDGE, Mass. and MENLO PARK, Calif., Feb.  15, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF). CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestive systems and other organs. CF can result in life-threatening infections, respiratory failure and other serious complications.",1
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy – Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –,1
"Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy. ",0
"Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs DALLAS, Feb.  15, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.",1
"T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity LEXINGTON, Mass., Feb.  15, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a definitive agreement to convert $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity upon stockholder approval.",0
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales,0
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy,1
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Feb.  16, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on February 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees.",2
"Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock SAN CARLOS, Calif., Feb.  20, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of $9.15 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $211 million. The offering is expected to close on or about February 22, 2024, subject to customary closing conditions.",0
Kraig Biocraft Laboratories Announces New Premium Spider Silk and Pima Cotton Composite Yarn Kraig Labs (OTCQBKBLB) creates the first yarn combining premium spider silk with Pima Cotton,1
"TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, Feb.  20, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29 – March 2, 2024, in West Palm Beach, Florida. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentations are outlined below.",1
"Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD COPENHAGEN, Denmark, Feb.  20, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (""Evaxion"" or the ""Company""), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.",1
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic,2
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer – Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma –,1
"PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 BOSTON, Feb.  20, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PGN-EDODM1, an investigational candidate for the treatment of myotonic dystrophy type 1 (DM1). “Receiving Fast Track designation from the FDA for PGN-EDODM1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the DM1 community,” said James McArthur, Ph.D., President and CEO of PepGen. “Patients with DM1 currently have no available treatment options that target the root cause of the disease, which leads to progressive neuromuscular symptoms and reduction in life expectancy. Following robust preclinical data, we are now evaluating PGN-EDODM1 in the ongoing FREEDOM-DM1 Phase 1 trial and expect to report preliminary data later this year. We believe that PGN-EDODM1 has the potential to be disease-modifying and improve outcomes for patients living with DM1.”",1
"Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization -Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024-",2
"ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection",1
"Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb.  20, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on February 16, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",2
"Evaxion gibt den erfolgreichen Abschluss der ersten Phasen der laufenden Impfstoff-Zusammenarbeit mit MSD bekannt KOPENHAGEN, Dänemark, Feb.  21, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges TechBio-Unternehmen, das sich auf die Entwicklung von AI-Immunology™-gestützten Impfstoffen spezialisiert hat, gibt den erfolgreichen Abschluss der ersten Phasen seiner Impfstoff-Zusammenarbeit mit MSD (Handelsname von Merck & Co., Inc., Rahway, NJ, USA) bekannt. Das Impfstoffentwicklungsprojekt kombiniert die einzigartigen Kompetenzen und das Fachwissen beider Unternehmen.",1
"Evaxion annonce le succès des phases initiales de sa collaboration actuelle avec MSD dans le domaine des vaccins COPENHAGUE, Danemark,  21 févr. 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ  EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement de vaccins alimentés par AI-Immunology™, annonce le succès des phases initiales de sa collaboration avec MSD dans le domaine des vaccins (marque déposée de Merck & Co, Inc, Rahway, NJ, États-Unis). Le projet de développement du vaccin associe les capacités et le savoir-faire uniques des deux organisations.",1
"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain —",1
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy,1
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare,1
"Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions JUPITER, Fla. and NES-ZIONA, Israel, Feb.  21, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"" or the ""Company"") (NASDAQ DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.",2
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv – Innovative design enables five-minute pegfilgrastim-cbqv delivery time –,1
"Immix Biopharma 12 Month Review Progress Update LOS ANGELES, Feb.  21, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.",1
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results  and Corporate Update on March 6 MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6,1
AC Immune Announces Upcoming Presentations at ADPD™ 2024 AC Immune Announces Upcoming Presentations at ADPD™ 2024,1
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024,1
"Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., Feb.  22, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2023.",0
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality,1
"Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024 DALLAS, Feb.  22, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI®-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United Kingdom.",1
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®,2
"Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions JUPITER, Fla. and NES-ZIONA, Israel, Feb.  23, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"" or the ""Company"") (NASDAQ DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.",1
"Dyadic מקדמת שיתוף פעולה עם המכון הביולוגי הישראלי (IIBR) להתמקדות באיומים ביולוגיים ופתרונות למחלות מתפתחות יופיטר, פלורידה ונס-ציונה, ישראל, Feb.  23, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc (""דיאדיק"" או ""החברה"") (נאסד""ק DYAI), חברת ביוטכנולוגיה גלובלית המתמחה בפלטפורמות מיקרוביאליות מתקדמות לפיתוח חלבונים וייצור ביולוגי ומתן מענה לצרכים קליניים, והמכון למחקר ביולוגי (IIBR) הודיעו כי קידמו את שיתוף הפעולה עם המכון למחקר ביולוגי (IIBR) והזרוע המסחרית שלו Life Science Research Israel (LSRI), כדי להתמקד בפתרונות מתפתחים למחלות. שותפות זו נועדה למנף את המומחיות של Dyadic בפלטפורמות מיקרוביאליות לייצור ביולוגי של חלבונים בקנה מידה גמיש ואת יכולות גילוי הנוגדנים והאנטיגנים של המכון כדי לפתח ולייצר פתרונות חדשניים לטיפול במחלות מתפתחות ובאיומים ביולוגיים פוטנציאליים. באמצעות שיתוף פעולה זה, שני הצדדים פועלים לפיתוח טיפולים וחיסונים יעילים למאבק באתגרי הבריאות העולמיים מתוך כוונה למסחור עתידי (נכון להיום, המסגרת אינה מחייבת וכפופה לביצוע הסכם מחייב שיידון על ידי הצדדים) באמצעות יוזמות שיתוף פעולה של רישוי חוץ.",1
"Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP CAMBRIDGE, Mass., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene. If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).",1
"Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting REDWOOD CITY, Calif., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.",1
"Celularity Announces 1-for-10 Reverse Stock Split FLORHAM PARK, N.J., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, to be effective at 500 p.m. Eastern Standard Time, Wednesday, February 28, 2024. Celularity’s Class A common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Thursday, February 29, 2024, under the current trading symbol, “CELU.” The reverse stock split was approved by Celularity’s stockholders on February 22, 2024, and is intended to increase the per share trading price of its Class A common stock to enable Celularity to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.",0
"Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date. One Executive Vice President level executive was granted an option to purchase 150,000 shares; and two additional non-officer employees were granted options to purchase an aggregate of 20,000 shares.",1
"TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy) Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country",1
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101,1
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS),1
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600 Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.,2
"ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study SAN DIEGO, Feb.  26, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced positive efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy (epinephrine nasal spray), an investigational new drug. The trial met its primary endpoints with both 1 mg and 2 mg neffy demonstrating statistically significant and clinically meaningful changes from baseline in itch, hives, urticaria and erythema scores as early as 5 minutes after dosing. Urticaria is a skin disorder that causes itchy hives andor angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.",2
"Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN",1
"FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place ",0
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results •  Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024,0
"SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates – Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 –",2
Kraig Biocraft Laboratories Establishes Homozygosity and Confirms BAM 1 Hybrid Optimized Ahead of Spring Production Trials Kraig Labs (OTCQB KBLB) achieves homozygosity for the spider silk gene in both of the parental strains for its new BAM 1 production hybrid.,2
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy) Newly issued patents extend exclusivity of ublituximab through 2042 Newly issued patents extend exclusivity of ublituximab through 2042,1
"Annovis Bio Announces Participation in Forum Discussion at ADPD™ 2024 MALVERN, Pa., Feb.  27, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (ADPD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. ",1
"Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community",1
"Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy SAN DIEGO, Feb.  27, 2024  (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March. In the upcoming meeting with the FDA, the Company intends to discuss its proposed chemistry, manufacturing and controls (CMC) plans for commercial launch, if approved which may enable opportunities to expedite the pathway to a Biologics License Application (BLA) submission. The Company has previously been granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designations for the use of CAP-1002 in Duchenne muscular dystrophy (DMD) and these designations enable sponsors to work closely with the FDA and receive its guidance on potential expedited pathways for approval.",2
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 12 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer Trial will evaluate the effect of this combination therapy on minimal residual disease,0
"Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- VAX-31 Adult Program Phase 12 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults --",1
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC ,1
"ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 PORTLAND, Maine, Feb.  27, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023.",1
Longeveron Reports Year-End 2023 Results and Provides Corporate Update Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome,1
"Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments ZUG, Switzerland, and BOSTON, Feb.  28, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today provides updates at its in-person and virtual R&D Day on continued progress in advancing its late-stage clinical trials and strengthening the organization with additional senior appointments to its management and advisory teams.",1
"TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively",2
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates Company aligned with FDA that RUBY is a single Phase 123 trial,2
"TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference WALTHAM, Mass., Feb.  28, 2024  (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference being held at the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 910 a.m. Eastern Time.",1
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update Immunocore reports fourth quarter and full year 2023 financial results and provides a business update,1
"Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform JUPITER, Fla. and BUNNIK, the Netherlands, Feb.  28, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health today announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV (“Rabian”), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists. The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform. This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.",0
"Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S. PALO ALTO, Calif., Feb.  28, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a major initiative with a leading national pharmacy chain to stock GLOPERBA® in most of their stores throughout the U.S.  GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is expected to launch in the U.S. in first half of 2024. The increase of GLOPERBA® manufacturing is to meet its potential demand and increased stocking needs in its distribution center.",2
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.,0
"Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer",0
Arcutis Announces Proposed Public Offering Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock,0
"Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Feb.  29, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2023.",2
"Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million -- -- Company Reports Fourth Quarter 2023 Total Operating Expense of $50 Million ---- Initiated Shareholder Approval Process to Execute a Share Repurchase Program of up to $50 Million by the End of the Second Quarter 2024 ---- Company to Host Conference Call Today at 800 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb.  29, 2024  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQAMRN), today announced financial results for the quarter and year ended December 31, 2023 and provided an update on the Company’s operations.",0
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results — Record revenues of $675 million in 2023 —,1
"Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH Investor webcast on Monday, March 4 at 800 a.m. ET to present clinical data Investor webcast on Monday, March 4 at 800 a.m. ET to present clinical data",2
"MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10",1
"Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company’s request to initiate dose escalation; dosing of first patient in cohort two (high dose, n=3) expected in Q2 2024",1
"SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role functioning, and quality of life Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role functioning, and quality of life",1
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality,1
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data,1
"89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates – Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively –",1
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights - Announced positive topline data from the ongoing Phase 1AB clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting –,1
Certara Reports Fourth Quarter 2023 Financial Results Provides Full Year 2024 Financial Guidance Provides Full Year 2024 Financial Guidance,1
"Scilex Holding Company Announces $10 Million Bought Deal Offering PALO ALTO, Calif., Feb.  29, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into an underwriting agreement with Rodman & Renshaw LLC and StockBlock Securities LLC, as underwriters, pursuant to which the underwriters have agreed to purchase on a firm commitment basis 5,882,353 shares of common stock of the Company and accompanying common warrants (the “Common Warrants”) to purchase up to 5,882,353 shares of common stock, at a price to the public of $1.70 per share and accompanying Common Warrant, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.",1
"TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, March  01, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below.",1
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 12a trial of IMM-1-104 expected in March 2024 -,1
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened,2
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, March  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on February 29, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 1,524,112 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March  01, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 1, 2024 (the “Grant Date”), ORIC granted a total of 3,600 non-qualified stock options and 600 restricted stock units to one new non-executive employee who began their employment with ORIC in February 2024.",1
"Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., March  01, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences",1
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March  01, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on March 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",2
"BioVie Inc. Announces Pricing of Public Offering CARSON CITY, Nev., March  04, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.50 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $21 million, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on March 6, 2024, subject to satisfaction of customary closing conditions.",0
"Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study       50mg (75%, p0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%)",2
"SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN STAMFORD, Conn., March  04, 2024  (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).",1
"Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer SAN CARLOS, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold placed on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC).   In collaboration with the FDA and an independent data monitoring committee, Iovance developed additional safety measures and monitoring. Upon reviewing this proposal, the FDA has cleared Iovance to resume patient enrollment in IOV-LUN-202.",2
"PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy BOSTON, March  04, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has authorized its Clinical Trial Application (CTA) to initiate the CONNECT2-EDO51 Phase 2 clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) amenable to an exon 51-skipping approach.",1
"C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline",2
"Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter and year ended December 31, 2023, and reported recent corporate developments.",2
"BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure SUNNYVALE, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, today announced positive interim results from the Phase III randomized controlled trial of its CardiAMP® autologous cell therapy in 110 randomized patients with advanced chronic heart failure at a mean 20-month follow-up, (CardiAMP HF). Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. The data was presented today by Amish Raval, MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting.",0
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024,1
"NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference SANTA ANA, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (NK) cell therapeutics, today announced the acceptance of an abstract for presentation on the effect of SNK01 NK cell therapy on CSF proteins, plasma proteins, and cognitive function in patients with advanced Alzheimer’s disease. The data will be presented at the Tau2024 Global Conference, held March 25-26, 2024, virtually and at The Westin Washington, DC Downtown in Washington, D.C.",2
"Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose by the End of 2025 -- -- VAX-24, a 24-Valent Pneumococcal Conjugate Vaccine (PCV), is Designed to Cover More Serotypes Than Any Infant Pneumococcal Vaccine On-Market or in U.S. Clinics Today --",1
"Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease",2
Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates Redesigned website reflects the Company's expanded pipeline of non-opioid pain management products and links to its recent publications and news Redesigned website reflects the Company's expanded pipeline of non-opioid pain management products and links to its recent publications and news,0
"Akero Therapeutics Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",0
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery,0
"Immutep Announces First Clinical Data from 90mg Dosing of Efti SYDNEY, AUSTRALIA, March  05, 2024  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase IIIII trial.",2
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™  Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy.,1
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic,1
"NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances BELTSVILLE, Md., March  05, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “The FLRT3-UNC5B Checkpoint Pathway Inhibits T Cell-Based Cancer Immunotherapies” in the journal Science Advances, published by the American Association for the Advancement of Science. The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.",1
"Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024 PALO ALTO, Calif., March  05, 2024  (GLOBE NEWSWIRE) --  Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced expected plans to launch Gloperba, its novel liquid colchicine formulation, in the first half of 2024 with a launch price of $595 per 150ml bottle. Gloperba is the only FDA approved liquid formulation of colchicine for the prophylaxis of acute gout flares. Over 70% of gout patients have chronic kidney disease and many suffer from gastrointestinal sensitivity, necessitating a lower dose of colchicine than the standard 0.6 mg tablet or capsule. Gloperba is expected to be the first liquid colchicine formulation that allows healthcare providers to prescribe precision dosing in at-risk patient populations, and thereby help mitigate against severe toxicity in patients. Healthcare providers can now safely and effectively manage such patients at doses below 0.6 mg once or twice daily, which is the standard dose for prophylaxis. In patients who are treated at lower doses than 0.6 mg, the 150 ml bottle of Gloperba is expected to last more than 30 days, delivering additional value to patients.",0
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., March  05, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 12,000 restricted stock units of Arcutis’ common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 4, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering PALO ALTO, Calif., March  05, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced public offering of 5,882,353 shares of common stock of the Company and accompanying common warrants (the “Common Warrants”) to purchase up to 5,882,353 shares of common stock, at a combined public offering price of $1.70, less underwriting discounts and commissions.",1
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024,2
Immunocore presented two posters at CROI 2024 Immunocore presented two posters at CROI 2024,1
"C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis",1
"ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March  05, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts have been accepted for presentation, including two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, CA.",1
"Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting SAN MATEO, Calif. and CAMBRIDGE, Mass., March  05, 2024  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.",2
"Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 CAMBRIDGE, Mass., March  05, 2024  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RASRAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.",1
"BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024 MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 800 a.m. ET (200 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.",1
"BioNTech veröffentlicht am 20. März 2024 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2023 und informiert über operativen Fortschritt MAINZ, Deutschland, 06. März 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech” oder „das Unternehmen“) wird am Mittwoch, den 20. März 2023, die Ergebnisse für das vierte Quartal und das Geschäftsjahr 2023 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 1400 Uhr MEZ (800 Uhr Eastern Time) eine Telefonkonferenz samt Webcast für Investoren, Finanzanalysten sowie die allgemeine Öffentlichkeit durchführen, um die Finanzergebnisse sowie ein Unternehmensupdate zu präsentieren. ",1
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 -,1
Kraig Biocraft Laboratories Preparing Additional Business Investment License to Advance its Business Operations Kraig Labs (OTCQBKBLB) expects to submit its second business investment application in Vietnam as part of the planned expansion of its business operations,2
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism),1
"BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”)",2
"New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy CAMBRIDGE, Mass., March  06, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec). The new data show that plasma neurofilament light chain (NfL) levels, an objective biomarker of axonal injury and neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA. These data will be presented at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 3-6, 2024).",1
"Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024 Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC) Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC)",1
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy,2
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results,1
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments - Enrollment completed for PGN-EDO51 5 mgkg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mgkg dose cohort in mid-2024 –,1
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress,1
"Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 TUSTIN, Calif., March  06, 2024  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQCDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024.",0
"Avid Bioservices Announces Proposed Private Placement of Convertible Notes TUSTIN, Calif., March  06, 2024  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQCDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 (the “2029 Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The company expects to price the Offering before open of market on March 7, 2024.",0
"BioVie Inc. Announces Closing of Public Offering CARSON CITY, Nev., March  06, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced best efforts public offering of 15,000,000 shares of its common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock (“Pre-funded Warrants”)and warrants to purchase up to 10,500,000 shares of common stock (the ""Common Warrants"") at a combined public offering price of $1.00 per share (or Pre-funded Warrant) and associated Common Warrant. The Common Warrants have an exercise price of $1.50 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are approximately $21,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.",1
"Avid Bioservices Announces Pricing of Private Placement of Convertible Notes TUSTIN, Calif., March  06, 2024  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQCDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the offering, the company entered into private placement purchase agreements with the several purchasers, each of whom is a “qualified institutional buyer” within the meaning of Rule 144A promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the offering is subject to customary closing conditions and is expected to take place on March 12, 2024.",0
"BioNTech Announces Planned Retirement of Sean Marett Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech. As of July 1, 2024, Sean Marett will continue as a specialist advisor to the Company at least until the end of the year. A new Chief Commercial Officer will be announced by the end of March 2024. Sean Marett’s responsibilities as Chief Business Officer are beeing gradually transferred to James Ryan, Ph.D., Chief Legal Officer, who will also take on the role of Chief Business Officer of BioNTech at the end of the transition phase and upon Sean Marett’s retirement.",1
"BioNTech gibt geplanten Ruhestand von Sean Marett bekannt MAINZ, Deutschland, 7. März, 2024 – BioNTech SE (Nasdaq BNTX, „BioNTech” oder “das Unternehmen”) gab heute bekannt, dass Sean Marett, Chief Business and Commercial Officer, in den Ruhestand gehen und damit wie geplant aus dem Vorstand von BioNTech ausscheiden wird. Ab dem 1. Juli 2024 wird Sean Marett dem Unternehmen mindestens bis Ende des Jahres als Fachberater zur Verfügung stehen. BioNTech wird bis Ende März 2024 die Nachfolge für die Rolle des Chief Commercial Officer bekanntgegeben. Sean Maretts Verantwortlichkeiten als Chief Business Officer werden schrittweise auf Dr. James Ryan, Chief Legal Officer, übertragen, der nach Abschluss der Übergangsphase und nach Sean Maretts Ausscheiden die Rolle des Chief Business Officer von BioNTech übernehmen wird.",1
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Company maintains solid cash position of $158.9 million Company maintains solid cash position of $158.9 million,1
"Spectral AI Announces Intellectual Property Subsidiary to Focus on the Broader AI Healthcare Ecosystem DALLAS, March  07, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI ecosystem, with a specific emphasis on healthcare.",1
"Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024 Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024",2
"Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health",1
"Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, March  07, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.",1
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway Company to assess KB-0742 at planned new dose schedule in ongoing phase 12 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025,0
"Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions Cytek Biosciences has opened a 50,000-square-foot facility in Wuxi, China to meet the growing worldwide demand for comprehensive cell analysis solutions",1
"TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, March  08, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at httpswww.aan.commsaPublicEventsIndex49. Details of the upcoming presentations are outlined below.",1
"Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results NEW YORK, March  08, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.",1
"Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., March  08, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,650,000 shares of common stock in this offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.",1
"89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, March  08, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 10,800 shares of the Company’s common stock to a new employee (the “Inducement Grant”) on March 6, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to this individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates JERUSALEM, March  08, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.",1
"QIAGEN announces Form 20-F annual report filing for 2023 results Venlo, the Netherlands, March  11, 2024  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE QGEN; Frankfurt Prime Standard QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.",1
"Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3IL-1β Pathway Inhibitor Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7-Directed Molecular Glue Degrader",1
"BioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-Kandidaten MAINZ, Deutschland, 11. März 2024 – BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom 5. bis 10. April 2024 in San Diego, Kalifornien, stattfindet, klinische Studiendaten für ausgewählte Kandidaten aus ihrer Onkologie-Pipeline präsentieren. Die Daten-Updates werden im Rahmen von Vorträgen und Poster-Präsentationen vorgestellt und umfassen Prüfpräparate aus BioNTechs mRNA-basierten Krebsimpfstoffansätzen sowie innovative Ansätze für Antikörper-Wirkstoff-Konjugate (antibody-drug conjugates, „ADCs“). ",1
"BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The oral and poster presentations will feature BioNTech’s investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches.",1
BioVie Announces Pipeline Update and Near-Term Clinical Priorities Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority,1
"Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset Monetization of legacy asset brings in $3 million in nondilutive capital; note exchange brings in another $2.8 million in capital, reduces net debt",1
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors - First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) -,1
"Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization JUNIPER, Fla., March  11, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"" or the ""Company"") (NASDAQ DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, announced today that it entered into a securities purchase agreement on March 8, 2024, pursuant to which, the Company has sold and issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 (the “Convertible Notes”) in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The purchasers of the Convertible Notes include immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company’s outstanding common stock, (collectively, the “Purchasers”).",0
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment,1
"CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The corrected release follows",0
"ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies",1
"Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update SAN DIEGO, March  11, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.",1
"MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology LA JOLLA, Calif., March  12, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 (ibudilast) in a chlorine gas-induced acute lung injury (CIALI) model at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah.",1
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure study,1
"Revive Therapeutics Provides Corporate Update TORONTO, March  12, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.",0
Kraig Biocraft Laboratories Senior Management travels to Vietnam for Launch of Spring Trials Kraig Labs (OTCQBKBLB) management will be in Vietnam this week to oversee BAM-1 production launch and its planned commercial expansion,1
"Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b3 trial will significantly shorten bexotegrast’s time to Phase 3 data",1
"Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors Former Chairman, CEO and Founder of ChemoCentryx, Inc. Former Chairman, CEO and Founder of ChemoCentryx, Inc.",1
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis —Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients—,1
"Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System In the past six months, the Company has announced over $149 million of non-dilutive financing from the US Government for the DeepView™ Wound Imaging System In the past six months, the Company has announced over $149 million of non-dilutive financing from the US Government for the DeepView™ Wound Imaging System",2
"Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update NORWOOD, Mass., March  12, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.",2
Mainz Biomed Presents ColoAlert® at UDH Congress 2024 Leading the Way in Evidence-Based Cancer Screening Innovations Mainz Biomed Presents ColoAlert® at UDH Congress 2024 Leading the Way in Evidence-Based Cancer Screening Innovations,1
"T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement LEXINGTON, Mass., March  12, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq Stock Market, subject to the Company demonstrating compliance with Nasdaq's market value of listed securities (“Market Value”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) on or before May 20, 2024.",2
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering ,1
"IMUNON Announces Leadership Change Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged. ",1
"NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals EMERYVILLE, Calif. and NEW YORK, March  13, 2024  (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American NBY) and Eyenovia, Inc. (Nasdaq EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel. Eyenovia will market NovaBay’s prescription Avenova® Antimicrobial Lid & Lash Solution through its Mydcombi and Clobetasol sales representatives strategically located across the U.S.",1
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee -- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --,1
"BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options",1
"PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy BOSTON, March  13, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year.",2
"Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 12 Clinical Trial Evaluating the Safety and Efficacy of OCU410 MALVERN, Pa., March  13, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 12 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age related macular degeneration (dAMD). GA affects approximately 1 million people in the United States alone.",2
"INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy  ",1
IMUNON Files IND Application to Begin Human Testing of IMNN-101 Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA ,0
"Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases BARCELONA, Spain and WATERTOWN, Mass., March  13, 2024  (GLOBE NEWSWIRE) -- Almirall, S.A. (BMEALM) and Eloxx Pharmaceuticals, Inc. (OTC ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases. ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.",2
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update,1
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update,1
"Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 12a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile -",0
"MediWound to Report Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast Scheduled for Thursday, March 21st at 830 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 830 am Eastern Time",2
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights,1
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501,1
"New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia REDWOOD CITY, Calif., March  15, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).",1
"Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. PALO ALTO, Calif., March  15, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it received Halal Certification of its commercial product ZTlido, indicating that ZTlido has undergone rigorous assessment to determine that it is permissible or acceptable in accordance with Islamic standards. The Halal certification was issued under the authority of Circle H International, Inc. (“Circle H”) and offers the Company the opportunity to provide ZTlido to Islamic markets globally. This announcement supports the global expansion strategy for Scilex, which Scilex anticipates will include a presence in the Middle East and North Africa (MENA) region with an initial priority focus on the UAE and Saudi Arabia.",1
"BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”)",1
"Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress ZUG, Switzerland and BOSTON, March  18, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced fourth quarter and full year financial results for the period ended December 31, 2023, and an overview of the Company’s progress.",1
"Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass., March  18, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of transthyretin (ATTR) amyloidosis. The MAGNITUDE trial is evaluating the efficacy and safety of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy.",1
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -,1
Mainz Biomed Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options Mainz Biomed Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options,0
"Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada PALO ALTO, Calif., March  18, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has responded to questions on the product composition in the ELYXYB patent from Health Canada’s Office of Patented Medicines and Liaison (OPML) during review of a New Drug Submission (“NDS”) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB® for acute treatment of migraine with or without aura in Canada.",1
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes,1
"QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers  Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB incidence countries, as part of U.S. immigrant visa medical exam  QIAGEN to host global, CPD-accredited event on March 21, just before World TB Day, focusing on TB infection screening, preventive therapy and challenges of high-risk groups Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers  Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB incidence countries, as part of U.S. immigrant visa medical exam  QIAGEN to host global, CPD-accredited event on March 21, just before World TB Day, focusing on TB infection screening, preventive therapy and challenges of high-risk groups",1
"QIAGEN und International Panel Physicians Association fördern gemeinsam Bewusstsein für Tuberkulose-Screenings Gemeinsame Bildungsinitiative konzentriert sich auf die Vorteile des Interferon-Gamma-Release-Assays (IGRA) für medizinisches Fachpersonal  Aktualisierte Richtlinien der US-amerikanischen CDC schreiben IGRA-Tests für Personen ab 2 Jahren aus Ländern mit hoher Tuberkulose-Inzidenz bei Gesundheitsprüfung für US-Visum vor  Globales, CPD-akkreditiertes QIAGEN-Event vor dem Welttuberkulosetag mit Fokus auf Tuberkulose-Screening, präventiver Therapie und Herausforderungen für Risikogruppen",1
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery,0
"Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID TORONTO, March  19, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company expects to submit the Type C meeting request by next week.",1
"Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials Dr. Nirmal Kumar, a globally recognized sericulture expert, will join Kraig Labs (OTCQBKBLB) Senior Management in Vietnam to supervise launch of the BAM-1",1
"Jasper Therapeutics Announces First Patient Dosed in Phase 1b2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria REDWOOD CITY, Calif., March  19, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU. The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD).",1
"Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem DALLAS, March  19, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”). The investment is structured as a note payable with a one-year maturity, an interest rate of 8%, and requiring earlier prepayment if Spectral IP is spun off to the Company's shareholders or sold.",0
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment,2
"Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation PALO ALTO, Calif., March  19, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the “Convertible Debentures”) previously issued and sold to YA II PN, Ltd. (“Yorkville”) in March 2023.   ",1
"Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates Data from first adult patient in REVEAL Phase 12 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in RSBQ at month six",2
"Longeveron Announces 1-for-10 Reverse Stock Split MIAMI, March  19, 2024  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the “common stock”) (the “Reverse Split”). The Reverse Split was previously approved by the Company’s stockholders at a special meeting held on February 21, 2024 The Reverse Split will legally take effect at 1159 p.m. Eastern Time, on March 26, 2024. The Company’s Class A common stock will open for trading under a new CUSIP number 54303L 203 on The Nasdaq Capital Market on March 27, 2024, on a split-adjusted basis under the current ticker symbol “LGVN.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.",0
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements -- Termination of the Forward Purchase Agreements simplifies AEON’s capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic partner following full funding of transaction --,2
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine – FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –,2
"BioNTech beruft Annemarie Hanekamp als Chief Commercial Officer in den Vorstand Mainz, Deutschland, 20. März 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Annemarie Hanekamp mit Wirkung zum 1. Juli 2024 als Chief Commercial Officer in den Vorstand beruft. Sie wechselt von der Novartis AG („Novartis“) zu BioNTech und tritt die Nachfolge von Sean Marett in der Funktion als Chief Commercial Officer an.",0
"BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis AG (“Novartis”) and succeed Sean Marett in this role.",0
BioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2023 sowie Informationen zur Geschäftsentwicklung Telefonkonferenz und Webcast sind für den 20. März 2024 um 13 Uhr MEZ (800 Uhr U.S. Eastern Time) geplant,0
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update   ,0
"Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q TUSTIN, Calif., March  20, 2024  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NasdaqCDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024 (the “Form 10-Q”) in a timely manner.",1
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024,2
"Annovis Bio Provides Data Announcement Update for the Phase IIIII Study of Buntanetap in Alzheimer’s Disease MALVERN, Pa., March  20, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase IIIII study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April.",2
"Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome JERUSALEM, March  20, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq “OPK”, or “OPKO”) with Entera’s proprietary N-Tab™ technology.",1
"Spectral AI Secures Access to $12.5 Million of New Equity Capital Issuance of Convertible Instrument Balances Certainty, Timing, and ExecutionCapital Supports Strategic Imperatives and Commercialization Initiatives",1
"MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society LA JOLLA, Calif., March  20, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that two abstracts entitled “STUDY PROTOCOL TO EVALUATE MN-001’S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)” and “MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX” have been accepted and selected for poster presentation at the 92nd European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.",1
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.,1
"X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024",2
"Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results Phase 12 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025",1
"NextCure Provides Business Update and Reports Full Year 2023 Financial Results BELTSVILLE, Md. – March 21, 2024, March  21, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer today provided a business update and reported full year 2023 financial results.",2
"Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients PALO ALTO, Calif., March  21, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the out-of-pocket costs for its product portfolio for commercially insured patients is expected to be capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company's postherpetic neuralgia pain product, ZTlido®, migraine product, ELYXYB®, and gout flare prophylaxis product, Gloperba®, which is expected to launch in the first half of 2024. Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company's commitment to provide non-opioid pain management products to patients.",1
"Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., March  21, 2024  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023.",1
"ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Preparing to submit response to the FDA’s CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review period",1
"IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 LAWRENCEVILLE, N.J., March  21, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 1000 a.m. ET on Thursday, March 28, 2024 to discuss financial results for the year ended December 31, 2023 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.",1
"HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights NEW YORK and VIENNA, Austria, March  22, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the fourth quarter and full year 2023.",1
"Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights WALTHAM, Mass., March  22, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.",1
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., March  22, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on March 22, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,700 shares of Iovance’s common stock to twenty new, non-executive employees.",1
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis,2
"Nkarta Announces Pricing of $240 Million Underwritten Offering SOUTH SAN FRANCISCO, Calif., March  25, 2024  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price.",2
"BioXcel Therapeutics Announces $25 Million Registered Direct Offering NEW HAVEN, Conn., March  25, 2024  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 3,054,609 shares of Common Stock at a combined offering price of $2.901 per Share and Accompanying Warrant and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 5,565,027 shares of Common Stock and Accompanying Warrants to purchase up to 5,565,027 shares of Common Stock at a combined offering price of $2.900 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant less the $0.001 exercise price per share of the Pre-Funded Warrants, for aggregate gross proceeds to the Company of approximately $25 million (excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Accompanying Warrants). The Pre-Funded Warrants have an exercise price of $0.001 per share of Common Stock and are exercisable at any time after the date of issuance, subject to certain ownership limitations. The Accompanying Warrants have an exercise price of $3.20 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance.",1
"Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros de todo el ejercicio 2023 – El Comité independiente para la monitorización de los datos (IDMC) ha recomendado la continuación de VIRAGE, ensayo clínico de fase 2b de VCN-01, en combinación con quimioterapia para el adenocarcinoma ductal pancreático (PDAC) metastásico, sin que se plantearan problemas de seguridad –",1
"Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results – The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised -",1
"Research Evaluating Benefits of VASCEPA®VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo -- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)Eicosapentaenoic Acid (EPA) Featured at the Meeting --    DUBLIN, Ireland and BRIDGEWATER, N.J., March  25, 2024  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQAMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.",1
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses Non-dilutive funding strengthens balance sheet and extends current operating runway,1
"QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care  QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management  Growing global presence Over 4,000 QIAstat-Dx instruments for reliable, fast and cost‑effective diagnosis of complex syndromes placed worldwide by the end of 2023 QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care  QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management  Growing global presence Over 4,000 QIAstat-Dx instruments for reliable, fast and cost‑effective diagnosis of complex syndromes placed worldwide by the end of 2023",1
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients.,1
"Bessere Zusammenarbeit im Gesundheitswesen QIAGEN stellt QIAstat-Dx Analyzer 2.0 mit Fernzugriff auf Testergebnisse vor QIAstat-Dx Analyzer 2.0 mit Software-Version 1.6 ermöglicht mobilen Zugriff auf Testergebnisse, optimiert diagnostische Prozesse und verbessert die Patientenversorgung  QIAstat-Dx Analyzer 2.0 bietet zudem verbesserte Epidemiologie-Dashboards und erweiterte Funktionen für das Systemmanagement aus der Ferne  Wachsende globale Präsenz Bis Ende 2023 wurden weltweit über 4.000 QIAstat-Dx Geräte für zuverlässige, schnelle und kosteneffektive Diagnose komplexer Syndrome platziert QIAstat-Dx Analyzer 2.0 mit Software-Version 1.6 ermöglicht mobilen Zugriff auf Testergebnisse, optimiert diagnostische Prozesse und verbessert die Patientenversorgung  QIAstat-Dx Analyzer 2.0 bietet zudem verbesserte Epidemiologie-Dashboards und erweiterte Funktionen für das Systemmanagement aus der Ferne  Wachsende globale Präsenz Bis Ende 2023 wurden weltweit über 4.000 QIAstat-Dx Geräte für zuverlässige, schnelle und kosteneffektive Diagnose komplexer Syndrome platziert",1
"Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers -",1
"InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 TEL AVIV, Israel and MIAMI, March  26, 2024  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.",1
"Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications JUPITER, Fla., March  26, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript ""Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models"" in Nature Communications (“Springer-Nature""), an international journal publishing peer-reviewed research in all fields of science and technology.",1
"Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months JERUSALEM, March  26, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months.",2
"BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress SAN DIEGO, March  26, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided highlights on its clinical programs. ",0
Aptose Reports Results for the Fourth Quarter and Full Year 2023 Aptose Reports Results for the Fourth Quarter and Full Year 2023,1
"INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 Management to host conference call and webcast at 430 pm ET on that day",1
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024,1
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 430 PM ET.,0
"MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan LA JOLLA, Calif., March  26, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.",1
"Evaxion Announces Business Update and Full Year 2023 Financial Results COPENHAGEN, Denmark, March  27, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.",0
Immuneering Announces First Patient Dosed in its Phase 12a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations Immuneering Announces First Patient Dosed in its Phase 12a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations,1
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis –PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin–,1
"Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend PALO ALTO, Calif., March  27, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”) has extended the expiration of the restrictions on transfer of the shares of common stock of Scilex that were previously distributed by Sorrento Therapeutics, Inc. (OTC SRNEQ, “Sorrento”), Scilex’s former controlling stockholder, to Sorrento’s stockholders as a dividend on January 19, 2023 (the “Dividend Stock”). Such lock-up period was previously set to expire on March 31, 2024. On March 26, 2024, the Court approved a motion to extend the lock-up period of the Dividend Stock to the earlier of (i) September 30, 2024 or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agree in writing or on the record in Sorrento’s chapter 11 cases certain claims that may be asserted in potential litigation to avoid Sorrento’s distribution of Dividend Stock and to recover such Dividend Stock (the “Stock Clawback Claims”) should not be pursued, or on such date that the Court deems just and proper. The Court did not make any determination regarding the merits of the Stock Clawback Claims.",1
"Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID TORONTO, March  27, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.",0
"BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results BioCardia®, Inc. today reported financial results for the year ended December 31, 2023",1
"Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat SAN MATEO, Calif., March  27, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",1
Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results 2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024,1
"Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spider Silk from Waste Plastics ANN ARBOR, Mich., March  28, 2024  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB KBLB) (""Kraig Labs"" or ""the Company""), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute (""RPI"").",1
IMUNON Reports 2023 Financial Results and Provides Business Update Conference Call Begins Today at 1000 a.m. Eastern Time,2
"Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., March  28, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.",1
"Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference IRVINE, Calif., March  28, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC. DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals.",1
"Dyadic Reports 2023 Full Year Results and Recent Company Progress JUPITER, Fla., March  28, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the year end 2023 and highlighted recent Company progress.",1
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023,1
"Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma NEEDHAM, Mass., March  28, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with rHGG that has recurred after standard of care (SoC) treatment. The data were presented today during the 5th Glioblastoma Drug Development Summit in Boston, Massachusetts.",1
"Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 -",1
"Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 Vincerx to also provide update on pipeline progress, including for VIP943 program Vincerx to also provide update on pipeline progress, including for VIP943 program",0
"Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Biora has entered into definitive agreements for the purchase and sale of 5,454,548 shares of common stock.",0
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans Further look at earlier Phase 1b study by ADCS unveils confirmatory data,1
"Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease MALVERN, Pa., April  01, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data Safety and Monitoring Board (DSMB) for the OCU410ST clinical trial recently convened and approved to proceed dosing with the medium dose of OCU410ST in the dose-escalation phase of the study.",1
"Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering SOUTH SAN FRANCISCO, Calif., April  02, 2024  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share. The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about April 4, 2024, subject to the satisfaction of customary closing conditions.",2
"Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection COPENHAGEN, Denmark, April  02, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus). In the animal studies, the EVX-B1 antigens significantly reduced disease burden. Currently, the two companies are engaged in discussions regarding the path forward.",2
"Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results MALVERN, Pa., April  02, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.",1
"Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder TORONTO, April  02, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-initiated IND at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy.",1
"Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC NORWOOD, Mass., April  02, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.",0
"Pliant Therapeutics to Participate in Upcoming Investor Events SOUTH SAN FRANCISCO, Calif., April  02, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following April investor events.",1
electroCore Expands Intellectual Property Portfolio electroCore Granted Two New U.S. Patents electroCore Granted Two New U.S. Patents,1
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, April  02, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 1, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 1,164,470 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue Announces CFO transition Announces CFO transition,1
"FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer SAN FRANCISCO, April  02, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors have progressed on at least one androgen receptor-signaling inhibitor (ARSI).",1
"MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) LA JOLLA, Calif., April  02, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago. The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.",1
"BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline    ",2
"Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston",1
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039,2
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -,1
"ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) SAN DIEGO, April  03, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that it has submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffy® (epinephrine nasal spray), for the treatment of Type I allergic reactions including anaphylaxis.",1
TransCode Therapeutics Reports 2023 Results; Provides Business Update TransCode Therapeutics Reports 2023 Results; Provides Business Update,1
"QIAGEN stärkt Portfolio für Krebsforschung und präsentiert Produktneuheiten auf dem Jahrestreffen der American Association for Cancer Research Neue QIAcuity dPCR PanCancer Kits können gleichzeitig seltene Mutationen von EGFR- und BRAF-Genen erkennen und dabei Probenmaterial, Zeit und Kosten einsparen  Neues QIAseq Targeted RNA-seq Panel for T-cell-Receptor ermöglicht zielgerichtetes Next-Generation-Sequencing von T-Zell-Rezeptoren mit höherer Genauigkeit und Sensitivität  PAXgene® Urine Liquid Biopsy Set wird nicht-invasive Probenentnahme sowie Stabilisierung zellfreier DNA und damit Fortschritte in urinbasierter Flüssigbiopsie ermöglichen Neue QIAcuity dPCR PanCancer Kits können gleichzeitig seltene Mutationen von EGFR- und BRAF-Genen erkennen und dabei Probenmaterial, Zeit und Kosten einsparen  Neues QIAseq Targeted RNA-seq Panel for T-cell-Receptor ermöglicht zielgerichtetes Next-Generation-Sequencing von T-Zell-Rezeptoren mit höherer Genauigkeit und Sensitivität  PAXgene® Urine Liquid Biopsy Set wird nicht-invasive Probenentnahme sowie Stabilisierung zellfreier DNA und damit Fortschritte in urinbasierter Flüssigbiopsie ermöglichen",1
"QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024 Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost  New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows targeted next-generation sequencing of T-cell receptors, increasing accuracy and sensitivity PAXgene® Urine Liquid Biopsy Set to enable non-invasive sample collection and cell-free DNA stabilization, thereby allowing researchers to make advances in urine liquid biopsy Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost  New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows targeted next-generation sequencing of T-cell receptors, increasing accuracy and sensitivity PAXgene® Urine Liquid Biopsy Set to enable non-invasive sample collection and cell-free DNA stabilization, thereby allowing researchers to make advances in urine liquid biopsy",1
"Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, April  03, 2024  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock and concurrent private placement of unregistered warrants to purchase up to 5,454,548 shares of common stock. The warrants have an exercise price of $1.10 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants, and will expire five years from the date of stockholder approval.",1
"BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure CAMBRIDGE, Mass. and NESS ZIONA, Israel, April  04, 2024  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission on April 4, 2024, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's 2023 audited financial statements or to its 2023 annual report on Form 10-K.",2
"Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed",1
"Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer NEEDHAM, Mass., April  04, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023.",2
"Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 12 ArMaDa Study for Geographic Atrophy Malvern, Pa., April  05, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the Phase 12 ArMaDa clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.",2
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, April  05, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale MARLBOROUGH, Mass., April  05, 2024  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode™ Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoya’s platforms.",1
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 - Multispecific CD73PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study,1
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., April  05, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 58,500 restricted stock units of Arcutis’ common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, April  05, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new employees (the “Inducement Grants”) on April 3, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  05, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2024 (the “Grant Date”), ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.",1
"Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting ZUG, Switzerland and BOSTON, April  08, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA.",1
"Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication MALVERN, Pa., April  08, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).",2
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74,0
"Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities NEW YORK, April  08, 2024  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ EYEN), a commercial-stage ophthalmic company, today announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to explore strategic alternatives to maximize shareholder value. As part of this process, the Company plans to consider a wide range of options, including potential sale of assets of the Company, a sale of the Company, a merger, or other strategic action. In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.",1
"ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors",1
"CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors SOUTH SAN FRANCISCO, Calif., April  08, 2024  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers. The cytotoxic payload utilized in CX-2051 is a derivative of camptothecin, a topoisomerase-1 inhibitor, a class of drug that has shown potent clinical anti-cancer activity and demonstrated significant clinical benefit as an approved ADC in multiple cancers. The CX-2051 Phase 1 dose escalation is designed to efficiently test the safety and preliminary anti-tumor activity of CX-2051, to provide initial clinical proof of concept to inform a potential decision to move into dose expansions in 2025.",1
"Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting ROCKVILLE, Md., April  08, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating the potential synergy between lead product candidate, VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft. Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.",1
"Theriva™ Biologics anuncia su presentación en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Génica ROCKVILLE, Maryland, April  08, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American TOVX), una empresa diversificada en fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy la presentación de datos preclínicos que demuestran la posible sinergia entre el principal candidato a producto, el VCN-01 y el irinotecán liposomal en un xenoinjerto pancreático humano en ratón. Los datos se presentarán en un póster en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Génica (ASGCT), que se celebrará tanto de forma virtual como presencial en Baltimore del 7 al 11 de mayo de 2024.",1
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer,1
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 Data Further Advance Understanding of VASCEPA®VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®VAZKEPA® Potential Mechanism of Action,1
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.,1
"electroCore Announces the Launch of Truvaga Plus® for General Wellness ROCKAWAY, N.J., April  08, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024.",1
"Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research JERUSALEM, April  08, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).",1
"Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting – In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy ––  First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 –",1
"Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.",0
"Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors",0
"Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing WARRINGTON, Pa., April  08, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. (“Varian”) to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor (aPKCi). The Company also completed a $1.5 million convertible note bridge financing.",2
"Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors NEEDHAM, Mass., April  09, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the presentation of a poster during the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5 through 10 in San Diego, which focused on a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures (TLS), being developed as a novel therapeutic strategy for solid tumors from Candel’s enLIGHTEN™ Discovery Platform.",0
Mainz Biomed Reports Full Year 2023 Financial Results Mainz Biomed Reports Full Year 2023 Financial Results,1
"Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool PALO ALTO, Calif., April  09, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced launching of co-pay programs for both ZTlido® and ELYXYB® with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company's postherpetic neuralgia pain product, ZTlido®, and migraine product, ELYXYB®. Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company's commitment to provide non-opioid pain management products to patients.",1
"QIAGEN N.V. to release results for Q1 2024 and hold webcast Venlo, The Netherlands, April  09, 2024  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE QGEN) (Frankfurt Stock Exchange QIA) announced plans to release results for the first quarter 2024.",1
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models,1
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients - Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status,1
"ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 PORTLAND, Maine, April  09, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.",2
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 – Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1L1 blockade –,1
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024,2
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions ,1
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia Company plans to initiate trial following recent meeting with FDA,1
"Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication MALVERN, Pa., April  10, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the pivotal OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and provided acceptability of the U.S.-based trial for submission of a Marketing Authorization Application (MAA).",2
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology,1
"IMUNON Reports Compliance with Nasdaq Listing Requirements LAWRENCEVILLE, N.J., April  11, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market. Accordingly, IMUNON complies with all applicable listing standards, and its common stock will maintain its listing on the Nasdaq Capital Market under the symbol “IMNN.”",1
"NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 12a trial initiation.",2
"Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer NEEDHAM, Mass., April  11, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.",2
"T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity LEXINGTON, Mass., April  11, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced results from the special meeting of stockholders on April 11, 2024. T2 Biosystems Stockholders voted for the approval of conversion of $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity.",1
"Longeveron Announces Closing of $5.2 Million Public Offering Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.",1
"Biomerica Reports Third Quarter 2024 Financial Results IRVINE, Calif., April  12, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2024 ended February 29, 2024.",1
"Kraig Biocraft Laboratories Announces Successful Launch of Spring Production Trials in Southeast Asia for Spider Silk Kraig Biocraft Labs (OTCQB KBLB) kicks off new BAM-1 hybrid spring production trials, on track to meet expectations and timeline",2
"TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April  15, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional presentations will be shared on Wednesday April 17, 2024.",1
"Biomerica provides update on inFoods® IBS expansion - Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas.",0
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 12 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors TransCode Therapeutics Announces FDA Clearance To Initiate Phase 12 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors,1
"ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations",1
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome,1
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.,1
"Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses PALO ALTO, Calif., April  16, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for gross and net sales for ZTlido® for the quarter ended March 31, 2024, and proposed plans to reduce research and development and other administrative expenses in 2024.",0
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy,1
"Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April  16, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering WALTHAM, Mass., April  16, 2024  (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock. All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",1
"HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) NEW YORK and VIENNA, Austria, April  16, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to Mark Winderlich, who was appointed Chief Development Officer of the Company effective April 1, 2024, to purchase an aggregate of 250,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. The award was granted as an inducement material to the employee’s acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $0.76 per share. The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal quarterly installments for three years thereafter, subject to the employee’s continued service with HOOKIPA on each such vesting date. The options are subject to the terms and conditions of HOOKIPA’s 2023 Inducement Plan approved by the Board of Directors in April 2023 and the terms and conditions of award agreements covering the grants.",1
"Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) REYKJAVIK, Iceland and PARSIPPANY, N.J., April  16, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.",1
"TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering WALTHAM, Mass., April  17, 2024  (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share,  which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024,  and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering are expected to be approximately $150.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan, assuming no exercise of the underwriters’ option to purchase additional shares of voting common stock. The offering is expected to close on or about April 19, 2024, subject to customary closing conditions.",1
"Evaxion Announces Phase 2 Clinical Trial Update First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 COPENHAGEN, Denmark, April  17, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).",2
"Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates WARRINGTON, Pa., April  17, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.",1
"Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA, April  17, 2024  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (""Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority regarding the Company’s upcoming TACTI-004 Phase III trial of eftilagimod alpha (“efti”) for first line treatment of metastatic non-small cell lung cancer (1L NSCLC).",2
"Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.",0
"Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product TORONTO, April  18, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions. The meeting date assigned by the FDA is June 7, 2024.",1
"TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis NEW YORK, April  18, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).",1
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans,2
"TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April  18, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below.",1
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 Media Release,2
"Windtree Therapeutics Announces Reverse Stock Split WARRINGTON, Pa., April  18, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 1159 p.m. Eastern Time on April 19, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a split-adjusted basis under the symbol “WINT” on April 22, 2024. At such time, the Company’s common stock will also commence trading under a new CUSIP number, 97382D 501.",0
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101 Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter,2
"Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostate Cancer SAN DIEGO, April  18, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 12 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fourth dosing cohort will receive ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 300 mg taken orally each day. The decision to proceed to this higher dose level was made by the study’s Safety Review Committee (SRC) after reviewing data from the patients treated to date, including the third dose level of 160 mg ONCT-534 daily.",1
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.,1
"NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit SANTA ANA, Calif., April  18, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson’s disease, and highlight clinical safety and efficacy data from the Company’s recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer’s disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit to be held in Boston, MA, from April 23–25, 2024.",2
"Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) REYKJAVIK, Iceland, April  19, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira.",2
"Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® - Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado -",2
"Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 12 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy MALVERN, Pa., April  19, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 12 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 1 million people in the United States alone.",1
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., April  19, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on April 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new, non-executive employees.",1
"BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritt MAINZ, Deutschland, 22. April 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 6. Mai 2024, die Ergebnisse für das erste Quartal 2024 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 1400 Uhr MESZ (800 Uhr Eastern Daylight Time) eine Telefonkonferenz samt Webcast für Investoren, Finanzanalysten sowie die allgemeine Öffentlichkeit durchführen, um die Finanzergebnisse sowie ein Unternehmensupdate zu präsentieren.",1
"BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 800 a.m. EDT (200 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.",1
"Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program NEW YORK, April  22, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients. The data demonstrate multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up. Fatigue is a debilitating symptom for many MS patients and is measured by the Modified Fatigue Impact Scale (MFIS).",2
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA,1
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials Kraig Labs (OTCQB KBLB) achieves major milestone; completes new BAM-1 1st gen parental strain rearing and cocoons at rates that exceeded expectations,2
"INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with  Officers, Employees and Directors Purchasing Approximately 20% of the Offering Boca Raton, Florida, April  22, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price  that include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzhzimer’s Disease program (as further described  below).  The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering. The offering was priced at the market based on the Friday, April 19th Nasdaq consolidated closing bid price of $8.32 per share. The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the “Termination Date”). The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 24, 2024, subject to the satisfaction of customary closing conditions. Members of management and the Company’s board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of $8.445 per share and warrant, and  in the case of officers and directors that participated in the offering, if the warrant termination date is on a blackout date then the officers and directors will have an additional 60 days from the termination of the blackout date to exercise the warrant. ",2
Amarin Announces Results of Annual General Meeting of Shareholders - Shareholders Approve Share Repurchase Program of up to $50 Million - - Shareholders Approve Share Repurchase Program of up to $50 Million -,0
"Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market ZUG, Switzerland, April  22, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market OCS) (“Oculis” or the “Company”) today announced that it closed its registered direct offering, successfully raising gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares, nominal value CHF 0.01 per share (the “Shares”) at a purchase price of $11.75 per Share to investors (the “Financing”). The Company also announced that trading in its ordinary shares on the Nasdaq Iceland Main Market (“Main Market”) under the ticker symbol “OCS” will begin on April 23, 2024. Oculis’ ordinary shares are currently listed on the Nasdaq Global Market in the U.S. under the ticker symbol “OCS” and began trading in the U.S. on March 3, 2023. The Company’s listing on the Main Market will make it the second company to dual-list its shares in the U.S. and in Iceland. To celebrate the listing on Main Market, Oculis will ring the opening bell at 930 GMT on April 23, 2024.",1
"Cidara Therapeutics Announces Reverse Stock Split SAN DIEGO, April  22, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The effective time of the reverse stock split will be 5 p.m. ET on April 23, 2024. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on April 24, 2024.",0
"CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting ZUG, Switzerland and BOSTON, April  22, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.",1
"Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April  22, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.  ",1
"Theriva™ Biologics presentará datos preclínicos que apoyan la sinergia potencial entre el VCN-01 y los regímenes de quimioterapia de primera línea contra el cáncer de páncreas en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Genética – El principal producto candidato, el VCN-01, en combinación con irinotecán liposomal, demostró mayores efectos antitumorales en un xenoinjerto pancreático humano en ratón –",2
"Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting – Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft–",2
"Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice SAN DIEGO, April  22, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K)  with the Securities and Exchange Commission (the SEC), in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.",1
"Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, April  22, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline.",1
"Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program NEW YORK, April  23, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed its intranasal foralumab non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients.",2
"Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID TORONTO, April  23, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The meeting date assigned by the FDA is June 9, 2024.",2
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma –Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children’s Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee–,0
Theriva™ Biologics anuncia datos de primera línea positivos del ensayo de fase 1 patrocinado por investigadores de VCN-01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario –El Comité de vigilancia del estudio ha determinado que el ensayo de fase 1 en colaboración con el Hospital Infantil Sant Joan de Déu Barcelona (SJD) tiene un resultado positivo–,0
"BiomX to Present Data from Phase 1b2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024 Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024",1
"INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay Boca Raton, Florida, April  23, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is delighted to announce the successful completion of the extended stability validation for XProTM continuous storage in solution at 2-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim of 24-month stability. The 24-month stability claim is consistent with other pegylated cytokines, such as alpha-interferon, and allows the Company to design a global supply chain using proven and established systems. With this data, the company can benefit from such existing systems that use temperature controlled and monitored shipment of liquid-formulation drugs at 2-8C, which is routine across the pharmaceutical industry. The 24-month stability data confirms that XProTM can mirror these established supply chain strategies. ",0
"Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) REYKJAVIK, Iceland, April  24, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confirmatory clinical study for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab). Alvotech is the first company to announce positive topline results of a clinical trial using a proposed biosimilar to Simponi and Simponi Aria and is one of only two companies known to have initiated such a patient study.",1
"HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers NEW YORK and VIENNA, Austria, April  24, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers.",2
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B Media Release,2
"Scilex Holding Company Announces $15 Million Registered Direct Offering PALO ALTO, Calif., April  24, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 15,000,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 15,000,000 shares of common stock, at a purchase price of $1.00 per share of common stock and accompanying warrant to purchase one share of common stock, in a registered direct offering. The warrants will have an exercise price of $1.10 per share, will become exercisable on the six month anniversary from the date of issuance and will expire on the date that is five years after the date of issuance.",0
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mgmL) Injection FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor,1
"RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership LOS ANGELES and AMSTERDAM, April  24, 2024  (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo.",0
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy -Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility-,2
Immunocore announces upcoming presentation and posters at ASCO 2024 Immunocore announces upcoming presentation and posters at ASCO 2024,1
"Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting REDWOOD CITY, Calif., April  24, 2024  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago.",1
"BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting Poster presentation scheduled for June 1, 2024, 130-430 PM CT 230-530 PM ET",1
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –,1
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients,1
"Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline SAN DIEGO, April  24, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has entered into an asset purchase agreement with its current partner, Mundipharma, for the divestiture of rezafungin. Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan. Mundipharma purchased the assets in consideration of its assumption of the ongoing obligation to conduct and fund the ReSPECT Phase 3 clinical trial, the costs of the rezafungin patent portfolio and CMC and regulatory obligations. Cidara estimates that it will achieve approximately $128 million in cost savings over the patent life of rezafungin comprised of approximately $67 million in clinical development expense, including the cost of the potential upsizing of the ReSPECT trial and CMC costs over the next three years, and an additional approximately $61 million in forecasted obligations through the expected patent life of rezafungin.",2
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma,1
"Kronos Bio to Present Clinical Update on Phase 12 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting SAN MATEO, Calif. and CAMBRIDGE, Mass., April  24, 2024  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 12 trial, KB-0742-1001 (NCT04718675), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.",2
"FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of  FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting SAN FRANCISCO, April  24, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.",2
"QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples  Panel significantly accelerates TB outbreak tracking and supports detection and management of antimicrobial resistance, critical needs in TB surveillance and control  Building upon success of leading diagnostics test QuantiFERON-TB Gold Plus as QIAGEN extends portfolio for TB management and control amid globally rising incidence rates Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples  Panel significantly accelerates TB outbreak tracking and supports detection and management of antimicrobial resistance, critical needs in TB surveillance and control  Building upon success of leading diagnostics test QuantiFERON-TB Gold Plus as QIAGEN extends portfolio for TB management and control amid globally rising incidence rates",1
"Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting NORWOOD, Mass., April  24, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4 with a third generation, site-specific cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Encouraging safety and efficacy data from this trial were presented at ASCO-GU 2024.",1
"TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting WALTHAM, Mass., April  24, 2024  (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually.",1
QIAGEN erweitert Tuberkulose-Portfolio Neues NGS-Panel unterstützt Echtzeit-Überwachung und Bekämpfung antimikrobieller Resistenzen QIAseq xHYB Mycobacterium tuberculosis Panel zu Forschungszwecken ermöglicht kulturfreies Whole Genome Sequencing komplexer Proben  Panel beschleunigt Nachverfolgung von TB-Ausbrüchen und unterstützt Erkennung und Management antimikrobieller Resistenzen – entscheidende Faktoren bei der TB-Überwachung und -Kontrolle  QIAGEN baut auf Erfolg des führenden diagnostischen Tests QuantiFERON-TB Gold Plus auf und erweitert Portfolio für TB-Management und -Kontrolle angesichts weltweit steigender Inzidenzraten QIAseq xHYB Mycobacterium tuberculosis Panel zu Forschungszwecken ermöglicht kulturfreies Whole Genome Sequencing komplexer Proben  Panel beschleunigt Nachverfolgung von TB-Ausbrüchen und unterstützt Erkennung und Management antimikrobieller Resistenzen – entscheidende Faktoren bei der TB-Überwachung und -Kontrolle  QIAGEN baut auf Erfolg des führenden diagnostischen Tests QuantiFERON-TB Gold Plus auf und erweitert Portfolio für TB-Management und -Kontrolle angesichts weltweit steigender Inzidenzraten,1
"BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting SAN DIEGO, April  24, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.",1
"Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 -- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million --",1
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye),0
"BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints CARSON CITY, Nev., April  25, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston, Massachusetts April 23-25.",0
"Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting NEEDHAM, Mass., April  25, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma. The presentation will focus on patients recruited in cohort C, treated with multiple injections of CAN-3110 (up to six), demonstrating that this approach is both feasible and well tolerated. The second presentation will show topline overall survival data from the phase 2 clinical trial of CAN-2409 plus valacyclovir, in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage IIIIV non-small cell lung cancer (NSCLC) who have an inadequate response to front line anti-PD(L)1 therapy.",0
"MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing",1
"Theriva™ Biologics hablará sobre el diseño del ensayo VIRAGE, un estudio clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia para el adenocarcinoma pancreático ductal, en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO) de 2024 ROCKVILLE, Maryland, April  25, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que, basándose en la solidez de la ciencia y su relevancia, VIRAGE —el ensayo clínico de fase 2b, aleatorizado, abierto, controlado con placebo y multicéntrico de VCN-01 administrado sistémicamente en combinación con quimioterapia de tratamiento estándar (gemcitabinanab-paclitaxel) como tratamiento de primera línea para pacientes con adenocarcinoma ductal pancreático (PDAC) metastásico de diagnóstico reciente— ha sido aceptado para su presentación como póster de ensayo en curso en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO) de 2024, que se celebrará en Chicago, Illinois, del 31 de mayo al 4 de junio.",1
"Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting ROCKVILLE, Md., April  25, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength of the science and its relevance, VIRAGE - the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabinenab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) - has been accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, from May 31-June 4.",1
"INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida, April  25, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock and accompanying warrant. The warrants include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzheimer’s Disease program (as further described  below).  The offering was priced at-the-market under Nasdaq rules based on the average of the previous 5-days’ closing prices, or $9.84 per share which includes $0.125 per warrant. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of positive top-line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the “Termination Date”). The gross proceeds of this offering are approximately $9.7 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 29, 2024, subject to the satisfaction of customary closing conditions. ",0
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial,1
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm,0
"Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab NEW YORK, April  25, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS). White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.",1
"Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering PALO ALTO, Calif., April  25, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering of an aggregate of 15,000,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 15,000,000 shares of common stock, at a purchase price of $1.00 per share of common stock and accompanying warrant to purchase one share of common stock. The warrants have an exercise price of $1.10 per share, will become exercisable on the six-month anniversary from the date of issuance and expire on the date that is five years after the date of issuance.",1
"Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants PALO ALTO, Calif., April  25, 2024  (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and common stock warrants in the proposed offering will be offered by Vincerx. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",0
"Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® CAMBRIDGE, Mass., April  25, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.",1
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating autoreactive T cells that contribute to neuroinflammation.,1
"Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants PALO ALTO, Calif., April  25, 2024  (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) to certain investors, pre-funded warrants to purchase up to an aggregate of 16,000,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 16,000,000 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.75, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.7499. Each pre-funded warrant will have an exercise price of $0.0001 per share and will be exercisable immediately after the original issue date until the pre-funded warrant is exercised in full. Each common stock warrant will have an exercise price of $1.00 per share, will be exercisable immediately after the original issue date and will expire 5 years from the date of issuance.",0
"Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 SAN DIEGO, April  26, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two poster presentations highlighting data on CD388 at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference, being held April 27-30, 2024 in Barcelona, Spain.",0
"X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome",0
"Ocugen Announces OCU400—Modifier Gene Therapy—Phase 12 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 MALVERN, Pa., April  29, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 12 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA.",2
Kraig Biocraft Laboratories Reports Signing Landmark Agreements in South East Asia Kraig Labs (OTCQB KBLB) signs key agreements with Lam Dong Agro-Forestry Research Experiment Center for spider silkworm rearing and breeding,2
"Intellia Therapeutics to Present Updated Data from Phase 12 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 CAMBRIDGE, Mass., April  29, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 12 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg).",2
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 12a SNK01 Clinical Trial in patients with Parkinson’s disease.,2
Immutep Quarterly Activities Report Q3 FY24 Media Release,1
"INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 12 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Boca Raton, Florida, April  29, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase III trial for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce the successful completion of the first cohort in the trial. Following review by the Safety Review Committee (SRC), approval has been granted to proceed with the second dose level (cohort 2). The first patient of the second cohort has been identified and will undergo screening to prepare for treatment. ",1
"BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID",1
"Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement IRVINE, Calif., April  29, 2024  (GLOBE NEWSWIRE) -- Biomerica Inc. (Nasdaq BMRA), is proud to announce a multi-year exclusive distribution agreement with one of the UAE's most substantial healthcare conglomerates. This strategic alliance is set to revolutionize the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region.",0
"Annovis Bio Announces Statistically Significant Phase IIIII Data in Patients With Early Alzheimer’s Disease MALVERN, Pa., April  29, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer’s (AD) and Parkinson’s disease (PD), today announced the data from its Phase IIIII Alzheimer study of buntanetap in mild to moderate AD patients. Based on these data, the Company plans to conduct a pivotal Phase III trial in biomarker-positive early AD patients.",1
"C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., April  29, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on April 29, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"QIAGEN übertrifft Prognosen für das erste Quartal 2024 und bleibt auf Kurs, die Jahresziele 2024 zu erreichen Q1 2024 Konzernumsatz von $459 Mio. (-5% bei tatsächlichen Kursen; -5% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,36; bereinigter verwässerter Gewinn je Aktie von $0,46  Konzernumsatz bei konstanten Wechselkursen (CER) von $462 Mio. übertrifft Prognose von mindestens $455 Mio. (CER); bereinigter verwässerter Gewinn je Aktie von $0,47 (CER) übertrifft Prognose von mindestens $0,44 CER  Ohne COVID-Produktgruppen sinkt Umsatz um 1% (CER)  Diagnostik-Umsätze steigen um 5% CER aufgrund zweistelliger CER-Zuwächse bei QuantiFERON und QIAstat-Dx  Bereinigte operative Marge steigt aufgrund von Effizienzsteigerungen von 25,6% (Q1 2023) auf 25,7%  Starker operativer Cashflow steigt im Vergleich zu Q1 2023 um 85% auf $133 Mio.  Prognose für 2024 bekräftigt Konzernumsatz von mindestens $2,0 Mrd. (CER); bereinigter verwässerter Gewinn je Aktie von mindestens $2,10 (CER)",0
"QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance Q1 2024 Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46  Net sales at CER of $462 million ahead of outlook for at least $455 million CER and  adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook  Excluding COVID-19 product groups, net sales decline 1% CER  Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx  25.7% adjusted operating income margin on efficiency gains vs. 25.6% in Q1 2023  Strong operating cash flow rises 85% to $133 million vs. Q1 2023  2024 outlook reaffirmed for at least $2.0 billion CER net sales and adj. diluted EPS of at least $2.10 CER Q1 2024 Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46  Net sales at CER of $462 million ahead of outlook for at least $455 million CER and  adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook  Excluding COVID-19 product groups, net sales decline 1% CER  Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx  25.7% adjusted operating income margin on efficiency gains vs. 25.6% in Q1 2023  Strong operating cash flow rises 85% to $133 million vs. Q1 2023  2024 outlook reaffirmed for at least $2.0 billion CER net sales and adj. diluted EPS of at least $2.10 CER",0
"U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) REYKJAVIK, Iceland and PARSIPPANY, N.J. and TEL AVIV, Israel, April  30, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE TEVA), disclosed today that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals, in alignment with its U.S. commercialization agreement with Teva. The interchangeable biosimilar will be distributed under Quallent’s private label.",2
"Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., April  30, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences",1
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma,1
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis,1
"Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial – Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment –",1
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600 Dosing of all patients in the trial has been successfully completed; final results are expected to be available in late Q2 2024.,1
"Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion ROCKAWAY, N.J., April  30, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, Truvaga Plus helped its users improve sleep, focus, stress, energy, and mood.",2
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers Antibody rise observed in lactating mothers and in their breast milk,2
"INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years Boca Raton, Florida, April  30, 2024  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer’s Disease (AD) for more than three years under the Australian compassionate use program known as the Special Access Scheme (SAS). ",2
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024,1
"Transforming Cancer Detection RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics LOS ANGELES and AMSTERDAM, April  30, 2024  (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.",2
"Spectral AI Awarded Quality Achievement Award from the Texas Manufacturer Assistance Center DALLAS, April  30, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the company received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for their UKCA Mark Attainment.",1
"BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes SUNNYVALE, Calif., May  01, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.",1
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed ,1
"Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum NORWOOD, Mass., May  01, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.",1
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation,2
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases,2
"Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May  01, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management.",1
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, May  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 605,349 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates – Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter –,0
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June –,1
"Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 REYKJAVIK, Iceland, May  02, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities Healthcare Conference 2024, which will be held on May 14-15, 2024 in Las Vegas, NV.",1
"Biogen Reports Progress on Corporate Responsibility Priorities CAMBRIDGE, Mass., May  02, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders.",1
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 12 trials (adolescentadult and pediatric),2
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma Media Release,1
"NextCure Provides Business Update and Reports First Quarter 2024 Financial Results BELTSVILLE, Md., May  02, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.",1
"QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data  New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence  Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inherited disease applications QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data  New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence  Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inherited disease applications",1
"QIAGEN verbessert Bioinformatik-Workflows mit neuer Sekundäranalyse-Lösung für Onkologie und Erbkrankheiten QCI Secondary Analysis ist eine direkt in QCI Interpret integrierte, Cloud-basierte Software und ermöglicht durchsatzstarke Sekundäranalyse von klinischen Next-Generation-Sequencing-Daten  Dank der neuen Software können kleinere und dezentralisierte Labore effizient, konsistent und zuverlässig mit NGS-Tests arbeiten – eine Weiterentwicklung der Präzisionsmedizin  Gemeinsam bieten QCI Secondary Analysis und QCI Interpret ein sicheres und konformes Umfeld für verlässliche und skalierbare Bioinformatik-Workflows in der Onkologie und bei Erbkrankheiten QCI Secondary Analysis ist eine direkt in QCI Interpret integrierte, Cloud-basierte Software und ermöglicht durchsatzstarke Sekundäranalyse von klinischen Next-Generation-Sequencing-Daten  Dank der neuen Software können kleinere und dezentralisierte Labore effizient, konsistent und zuverlässig mit NGS-Tests arbeiten – eine Weiterentwicklung der Präzisionsmedizin  Gemeinsam bieten QCI Secondary Analysis und QCI Interpret ein sicheres und konformes Umfeld für verlässliche und skalierbare Bioinformatik-Workflows in der Onkologie und bei Erbkrankheiten",1
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine – Trial did not meet primary endpoint – – Trial did not meet primary endpoint –,0
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., May  03, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of May 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., May  03, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Melnikoff’s commencement of employment and were granted as an employment inducement award pursuant to NASDAQ Listing Rule 5635(c)(4).",1
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, May  03, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 528,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO and SAN DIEGO, May  03, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2024 (the “Grant Date”), ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024.",1
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2024 sowie Informationen zur Geschäftsentwicklung Telefonkonferenz und Webcast sind für den 6. Mai 2024 um 1400 Uhr MESZ (800 Uhr U.S. Eastern Daylight Time) geplant,1
"BioNTech Announces First Quarter 2024 Financial Results and Corporate Update Conference call and webcast scheduled for May 6, 2024, at 800 a.m. EDT (200 p.m. CEST)",1
"Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders MALVERN, Pa., May  06, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase IIIII data from its Alzheimer’s study and sharing next steps.",1
"Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts MARLBOROUGH, Mass., May  06, 2024  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms.",1
"IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024 LAWRENCEVILLE, N.J., May  06, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 1100 a.m. ET on Monday, May 13, 2024 to discuss financial results for the first quarter ended March 31, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.",1
"FibroGen Reports First Quarter 2024 Financial Results SAN FRANCISCO, May  06, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today reported financial results for the first quarter 2024 and provided an update on the company’s recent developments.",2
"ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025",1
"Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results BEACON-IPF pivotal, adaptive Phase 2b3 trial design implementation significantly accelerates bexotegrast development in IPF",1
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity Strengthens balance sheet by reducing total debt by approximately 80% over the past year Strengthens balance sheet by reducing total debt by approximately 80% over the past year,2
Immuneering Recognizes Melanoma Awareness Month Immuneering Recognizes Melanoma Awareness Month,1
T2 Biosystems Announces First Quarter 2024 Financial Results Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period,2
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor Filed Pursuant to Rule 433,2
"MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) LA JOLLA, Calif., May  07, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to expire no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibudilast).",1
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome,0
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee-,0
"INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 Management to host conference call and webcast at 430 pm ET on that day",1
"Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™ SOUTH SAN FRANCISCO, Calif., May  07, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress™ taking place in Milan, Italy from June 5-8, 2024.",1
"Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update NORWOOD, Mass., May  07, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.",1
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update,1
"Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 SAN MATEO, Calif., May  07, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL) International Liver Congress 2024 held in Milan, Italy from June 5-8, 2024.",1
"Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.",2
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease Advances plan to launch T2Lyme Panel for detection of early Lyme disease Advances plan to launch T2Lyme Panel for detection of early Lyme disease,2
"Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings",1
"Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program -- Conference call today at 430 p.m. ET -- TAMPA, Fla., May  07, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024.",1
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates,1
"Adaptive Biotechnologies Reports First Quarter 2024 Financial Results SEATTLE, May  07, 2024  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024.",1
"QIAGEN und FBI entwickeln im Bereich Forensik gemeinsam neuen Test für digitale PCR-Plattform QIAcuity Neuer digitaler PCR-Assay soll Ergebnisse der DNA-Analyse menschlicher Proben für die Forensik und Personenidentifizierung verbessern  DNA-Quantifizierung ermöglicht Strafverfolgungsbehörden und Forensikern schnellere, exaktere und zuverlässigere Analyse von Beweismaterial  Kooperation stärkt Führungsposition von QIAGEN im Bereich Personenidentifizierung und Forensik Neuer digitaler PCR-Assay soll Ergebnisse der DNA-Analyse menschlicher Proben für die Forensik und Personenidentifizierung verbessern  DNA-Quantifizierung ermöglicht Strafverfolgungsbehörden und Forensikern schnellere, exaktere und zuverlässigere Analyse von Beweismaterial  Kooperation stärkt Führungsposition von QIAGEN im Bereich Personenidentifizierung und Forensik",1
"QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification  DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably  Collaboration strengthens QIAGEN’s leading position in human identification and forensics Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification  DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably  Collaboration strengthens QIAGEN’s leading position in human identification and forensics",1
Certara Reports First Quarter 2024 Financial Results Reiterates Full Year 2024 Financial Guidance Reiterates Full Year 2024 Financial Guidance,1
"CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) - CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -",1
Spectral AI Announces 2024 First Quarter Financial Results Q1 Overview,1
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024 - Se han presentado datos de primera línea del ensayo de fase 1 patrocinado por investigadores del VCN-01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario; el comité de vigilancia del estudio dictaminó que los resultados del ensayo son positivos -,0
Editas Medicine Announces First Quarter 2024 Results and Business Updates Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 123 RUBY clinical trial of reni-cel for severe sickle cell disease,0
Immunocore reports first quarter financial results and provides a business update Immunocore reports first quarter financial results and provides a business update,1
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach - ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma -,0
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned,1
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO Assumes leadership role as Company anticipates multiple near-term clinical milestones,1
"Dyadic to Attend Industry and Investor Events in May JUPITER, Fla., May  08, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry and investor events during the month of May 2024.",1
"Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer REDWOOD CITY, Calif., May  08, 2024  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.",1
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results -More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected-,1
"Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions New Seer Technology Access Center to open in Bonn, Germany",1
"Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis ZUG, Switzerland, May  08, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS; XICE OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the completion of enrollment in its multi-center, randomized, double-blind, placebo-controlled Phase 2 ACUITY trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON). Topline results are expected in Q4 2024.",1
"89bio to Participate in the BofA Securities 2024 Health Care Conference SAN FRANCISCO, May  08, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the BofA Securites 2024 Health Care Conference on Wednesday, May 15, 2024 at 220 PM PDT and participate in one-on-one investor meetings.",1
Seer Reports First Quarter 2024 Financial Results Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications,1
"Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 12 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 12 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program --",1
"Cytek Biosciences Reports First Quarter 2024 Financial Results FREMONT, Calif., May  08, 2024  (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024.",2
"electroCore Announces First Quarter 2024 Financial Results Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023Company to host a conference call and webcast today, May 8, 2024 at 430 PM EST",2
"Oculis Reports Q1 2024 Financial Results and Provides Company Updates ZUG, Switzerland, May  08, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS; XICE OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the three-month period ended March 31, 2024, and an overview of the Company’s progress.",1
"X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility $125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)",2
"Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.",1
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors Patient dosed with TSC-203-A0201 targeting cancer-associated antigen PRAME,1
BioXcel Therapeutics Reports First Quarter 2024 Financial Results      Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation,2
"HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights NEW YORK and VIENNA, May  09, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and recent business highlights for the first quarter of 2024.",1
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan – New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® – ,1
"Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., May  09, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the first quarter ended March 31, 2024.",1
"Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease MALVERN, Pa., May  09, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD). Topline efficacy data is expected in June.",2
"Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients.",1
RAPT Therapeutics Reports First Quarter 2024 Financial Results Company maintains solid cash position of $141.6 million Company maintains solid cash position of $141.6 million,0
AEON Biopharma Provides Update on Development Pipeline Includes two late-stage clinical programs and two early-stage clinical programs Includes two late-stage clinical programs and two early-stage clinical programs,1
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations Kraig Labs (OTCQBKBLB) BAM-1 spider silk spring production trials exceed expectations and Implementing Next Phase of Its Recombinant Spider Silk Plan,1
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting -Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)-,1
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights,1
"Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results SAN DIEGO, May  09, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2024 financial results.",1
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval,2
Kronos Bio Reports First-Quarter 2024 Financial Results — $152.0 million cash runway into the second half of 2026 —,1
"Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties SAN DIEGO, May  09, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli (dostarlimab) royalties. Anaptys intends to utilize the proceeds of the transaction to continue the broad development of its immune cell modulators (ICMs), including its best-in-class checkpoint agonists, in heterogeneous, systemic autoimmune and inflammatory diseases.",1
"INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, May 9, at 430pm ET Company to Host Conference Call Today, May 9, at 430pm ET",1
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results neffy® (epinephrine nasal spray) New Drug Application (NDA) and CRL response under review by FDA with anticipated review completion by early October 2024,1
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update –Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients–,1
"Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) SAN DIEGO, May  09, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.",1
"Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update SAN DIEGO, May  09, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.",1
"Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications",1
Humacyte First Quarter 2024 Financial Results and Business Update -Biologics License Application (BLA) for HAV™ Accepted by FDA-,1
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update -- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 --,1
"Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates WALTHAM, Mass., May  10, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates.",1
Immix Biopharma Announces Positive NXC-201 RelapsedRefractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation 92% (1213) overall response rate (ORR) for relapsedrefractory AL Amyloidosis patients enrolled in NEXICART-1,1
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May  10, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on May 6, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock MALVERN, Pa., May  10, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 500 p.m. Eastern Time on May 20, 2024. The shares of Series C Preferred Stock will be distributed to such recipients at 500 p.m. Eastern Time on May 22, 2024. The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to certain stockholder proposals, and will not be entitled to vote on any other matter, except to the extent required under the DGCL. Subject to certain limitations, each outstanding share of Series C Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series C Preferred Stock).",1
Longeveron Announces Board of Directors Planned Transitions Longeveron announces planned transitions on its Board of Directors.,1
"Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates JERUSALEM, May  10, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024.",1
QIAGEN erhält FDA-Zulassung für syndromischen QIAstat-Dx-Test zur schnellen und präzisen Diagnose von Atemwegserkrankungen QIAstat-Dx Respiratory Panel Plus ist für genaue Diagnose von Atemwegsinfektionen konzipiert und ermöglicht auch Erkennung von Ko-Infektionen  Panel liefert Ergebnisse in etwa einer Stunde bei weniger als einer Minute aktiver Arbeitszeit und bietet leicht ablesbare Cycle-Threshold (Ct)-Werte sowie Amplifikationskurven  QIAGEN arbeitet an der Erweiterung des QIAstat-Dx Testmenüs in den USA; die Zulassung eines Magen-Darm-Panels wird aktuell von der FDA geprüft QIAstat-Dx Respiratory Panel Plus ist für genaue Diagnose von Atemwegsinfektionen konzipiert und ermöglicht auch Erkennung von Ko-Infektionen  Panel liefert Ergebnisse in etwa einer Stunde bei weniger als einer Minute aktiver Arbeitszeit und bietet leicht ablesbare Cycle-Threshold (Ct)-Werte sowie Amplifikationskurven  QIAGEN arbeitet an der Erweiterung des QIAstat-Dx Testmenüs in den USA; die Zulassung eines Magen-Darm-Panels wird aktuell von der FDA geprüft,1
"QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections  Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves  QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA review QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections  Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves  QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA review",1
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update,1
"Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab NEW YORK, May  13, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has submitted an FDA request to obtain Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation. Our request is supported by clinical and non-clinical evidence of Foralumab’s effectiveness in na-SPMS. The prevalence estimates, in part, are supported from the Brigham & Women’s Hospital, Boston, Massachusetts, longitudinal study, the CLIMB data of which allowed the estimate of na-SPMS in the population.",0
"Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 JERUSALEM, May  13, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts.",1
"Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results MALVERN, Pa., May  13, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results.",2
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024,1
"Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology Arcutis today announced that the JCAD published an evaluation of formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%.",1
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024,2
"Jasper Therapeutics Announces Briquilimab Development Program in Asthma REDWOOD CITY, Calif., May  13, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024.",1
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Begins Today at 1100 a.m. Eastern Time,0
"Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 IRVINE, Calif., May  13, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, today announced the initiation of a pilot program for its inFoods® IBS product with a large 1,100-member physician group. This pilot launch will commence in June 2024.",1
TransCode Therapeutics Open Letter to Shareholders An Open Letter to Shareholders regarding a Reverse Stock Split,0
"Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock PALO ALTO, Calif., May  13, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provides information to its stockholders regarding short selling of Scilex common stocks traded on the Nasdaq Capital Market.",2
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment,0
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results      Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants,2
"Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 -",1
"MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome LA JOLLA, Calif., May  14, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome (ARDS).",1
"InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 -",1
"Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis 12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo",2
"Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., May  14, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.",1
"Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results NEW YORK, May  14, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the first quarter ended March 31, 2024.",1
"89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis —With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)—",2
"Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., May  14, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.",1
"Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV",1
"Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba® PALO ALTO, Calif., May  14, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the 45-day review period for the U.S. Federal Trade Commission and U.S. Department of Justice to comment on or object to the Settlement Agreement (the “Settlement Agreement”) entered into by the Company and its wholly owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex Pharma” and, together with the Company, the “Scilex Parties”) with Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceuticals Company LTD. (collectively “Takeda”) to resolve the Paragraph IV patent infringement lawsuit (the “Action”) that Takeda filed against the Scilex Parties in the federal district court in Delaware in November 2023 has expired and the U.S. District Court for the District of Delaware entered a Consent Judgment on May 3, 2024, approving the Settlement Agreement. The Action arose from Scilex’s filing of a revised label with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout. As part of the Settlement Agreement, the Scilex Parties entered into a License Agreement with Takeda granting the Company and its affiliates a non-exclusive license to certain patents owned by Takeda. The terms of those agreements are confidential.",1
"Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June CAMBRIDGE, Mass., May  14, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.",1
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress,1
"Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.",2
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Human Health Sector,1
"scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack",1
"Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 12 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x1015 total vg) with dosing scheduled for Q2 2024",0
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights – CONNECT1-EDO51 trial preliminary data from 5mgkg dose cohort expected mid-2024 –,1
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update Longeveron announces 2024 Q1 financial results and business update.  Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.,1
"QIAGEN erhält europäische IVDR-Zertifizierung für seine Medizinprodukte-Software zur Unterstützung der klinischen Entscheidungsfindung QIAGEN Clinical Insight Interpret Aktualisierte Version von QIAGEN Clinical Insight Interpret als erste NGS-Interpretationsplattform für Onkologie und Erbkrankheiten für den Einsatz in der Diagnostik zugelassen  Rechtsrahmen stellt besseren Patientenschutz, transparente Informationen und Nachverfolgbarkeit von Daten sicher  Weltweit über 4 Millionen NGS-Patiententests in den Bereichen Onkologie und Erbkrankheiten mit QIAGEN Clinical Insight Interpret durchgeführt Aktualisierte Version von QIAGEN Clinical Insight Interpret als erste NGS-Interpretationsplattform für Onkologie und Erbkrankheiten für den Einsatz in der Diagnostik zugelassen  Rechtsrahmen stellt besseren Patientenschutz, transparente Informationen und Nachverfolgbarkeit von Daten sicher  Weltweit über 4 Millionen NGS-Patiententests in den Bereichen Onkologie und Erbkrankheiten mit QIAGEN Clinical Insight Interpret durchgeführt",1
"QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use  Regulatory framework ensures greater patient protection, transparency of information, and traceability of data  Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight Interpret As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use  Regulatory framework ensures greater patient protection, transparency of information, and traceability of data  Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight Interpret",1
"BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress SAN DIEGO, May  14, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and provided highlights on its clinical programs. ",2
"AEON Biopharma Reports First Quarter 2024 Financial Results – Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints –",1
"Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress – Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation –",1
"Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC)",1
"T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock LEXINGTON, Mass., May  14, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that entities affiliated with CRG Servicing LLC (“CRG”) have converted Series A and Series B Convertible Preferred Stock to Common Stock.",2
"Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May  14, 2024  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters Tokyo, CEO Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq BIIB, Corporate headquarters Cambridge, Massachusetts, CEO Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).",1
"Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 12 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy MALVERN, Pa., May  15, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 12 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life.",2
"T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules LEXINGTON, Mass., May  15, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $3.70 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 17, 2024, subject to the satisfaction of customary closing conditions.",2
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 Media Release,2
"Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024",2
"Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting LAWRENCEVILLE, N.J., May  15, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago from May 31st to June 4th.",1
Mdxhealth to Present at Upcoming Investor Conferences        ,1
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants,0
"Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules SAN DIEGO, May  15, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff (the Staff) of the Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance with Nasdaq’s requirements for continued listing. In addition, the Nasdaq Hearing Panel (the Panel) imposed a discretionary Panel monitor until May 14, 2025, such that if the Company fails to maintain compliance with any continued listing requirement during such period, the Staff will issue a delist determination letter and the Company will promptly schedule a new hearing before the Panel to address such noncompliance.",0
"Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine",0
"Galapagos en Blood Centers of America kondigen een strategische samenwerking aan om Galapagos' gedecentraliseerde CAR-T productienetwerk in de VS versneld op te schalen Mechelen, België; 15 mei 2024, 2201 CET; Galapagos NV (Euronext & NASDAQ GLPG) en Blood Centers of America (BCA) hebben vandaag aangekondigd dat zij een strategische samenwerking zijn aangegaan voor de gedecentraliseerde productie van Galapagos' CAR-T celtherapieën via het netwerk van BCA in de VS. ",1
"Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. Mechelen, Belgium; 15 May 2024, 2201 CET; Galapagos NV (Euronext & NASDAQ GLPG) and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the U.S. ",1
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025,1
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update — Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on related matter— Site optimization projects near completion— Conference call begins today at 430 pm ET,0
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025,1
"Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results SAN DIEGO, May  15, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate activities and product pipeline.",0
"Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors DALLAS, May  15, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the “AGM”). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company.",2
"Biogen and Ionis Announce Topline Phase 12 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis CAMBRIDGE, Mass. and CARLSBAD, Calif., May  16, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 12 ALSpire study. BIIB105 was designed to reduce expression of ataxin-2 (ATXN2) protein and demonstrated statistically significant cerebrospinal fluid (CSF) ATXN2 protein reductions in the study. However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage. Additionally, BIIB105 did not demonstrate an impact on clinical outcome measures of function, breathing, and strength.",1
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa ,1
"Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH",2
"NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition SANTA ANA, Calif., May  16, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.",1
"Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., May  16, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"CytomX Therapeutics Announces New Employment Inducement Grants SOUTH SAN FRANCISCO, Calif., May  16, 2024  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.",1
"Spectral AI Announces Purchases of Over 100,000 Shares by Insiders DALLAS, May  17, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company’s officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions on May 10, 2024 and May 15, 2024.",1
"Aktionärinnen und Aktionäre stimmen auf der ordentlichen Hauptversammlung 2024 der BioNTech SE allen Tagesordnungspunkten zu MAINZ, Deutschland, 17. Mai 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) hat heute, am 17. Mai 2024, die diesjährige ordentliche Hauptversammlung abgehalten. Insgesamt waren 87,51 Prozent des Grundkapitals bei der virtuellen Versammlung vertreten. Es standen 14 Punkte auf der Tagesordnung der Hauptversammlung. Die Aktionärinnen und Aktionäre stimmten allen Beschlussvorschlägen der Verwaltung zu den zur Abstimmung stehenden Tagesordnungspunkten mit breiter Mehrheit zu.",1
"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders.",1
"T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules LEXINGTON, Mass., May  17, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $3.70 per share and are exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance.",0
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., May  17, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 16, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance’s common stock to thirty new, non-executive employees.",1
"MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer LA JOLLA, Calif., May  20, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis of eye cancer.",1
"Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 MALVERN, Pa., May  20, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada.",1
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024 Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.,2
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade,1
"Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial",0
"NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial  in Alzheimer’s Disease SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events.",2
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems Cytek has announced its Enhanced Small Particle Detection Option for its Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.,1
"BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025",1
"BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 31. Mai bis 4. Juni 2024 in Chicago, Illinois, stattfindet, klinische Studiendaten für ausgewählte Programme aus der innovativen Immuno-Onkologie-Pipeline des Unternehmens präsentieren. Darüber hinaus wird BioNTech auch epidemiologische Daten sowie Erkenntnisse aus der Praxis aus zwei Beobachtungsstudien vorstellen. Diese Studien sollen die laufenden Programme zu CAR-T-Zell- und individualisierten mRNA-Kandidaten des Unternehmens unterstützen und wurden in entsprechenden Patientenpopulationen durchgeführt.",1
"BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024 MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studies in patient populations for which product candidates are being developed in the Company’s respective clinical programs.",1
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160,1
"Annovis Announces New Publication in a Peer-Reviewed Journal MALVERN, Pa., May  21, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue Role of Amyloid Protein in Neurological Diseases.",1
Certara Appoints New Chief Human Resources Officer & General Counsel Certara has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.,1
"BioCardia Announces Reverse Stock Split SUNNYVALE, Calif., May  21, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock split will become effective at 1201 a.m. Eastern Daylight Time on Thursday, May 30, 2024. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on Thursday, May 30, 2024. The Company’s common stock and warrants will continue to be traded on The Nasdaq Capital Market under the ticker symbols “BCDA” and “BCDAW,” respectively. The reverse stock split is intended to increase the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company, however, cannot assure that the price of its common stock after the reverse stock split will reflect the corresponding split ratio, that the price per share following the effective time will be maintained for any period of time, or that the price will remain above the pre-split trading price.",1
"Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update REYKJAVIK, Iceland, May  21, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of 2024 and provided a summary of recent corporate highlights.",1
"Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference SOUTH SAN FRANCISCO, Calif., May  21, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2024 International Conference, held from May 17-22, 2024.",1
"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May  22, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.",1
BioVie’s Bezisterim Demonstrates Potential Improvements in SleepFatigue and Restless Leg Symptoms for Parkinson’s Disease Patients Full Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened,1
"T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements LEXINGTON, Mass., May  22, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.",1
"89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-",1
"Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance TUSTIN, Calif., May  23, 2024  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has achieved a Committed Badge from EcoVadis, one of the world’s most trusted providers of business sustainability ratings. Avid earned a score of 56 from EcoVadis, placing the company in the 62nd percentile globally.",1
"Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer ROCKVILLE, Md., May  23, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma. In VIRAGE, the ongoing multinational Phase 2b clinical study, intravenous VCN-01 is being evaluated in combination with standard-of-care (SoC) chemotherapy (gemcitabinenab-paclitaxel) as a first line therapy for patients with pancreatic ductal adenocarcinoma (PDAC). Previously, the FDA granted orphan drug designation to VCN-01 for treatment of PDAC.",2
Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label - EPA approved an amendment to the label of INTERLINE herbicideto include Camelina,1
"Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May  23, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq VXRT) (the “Company” or “Vaxart”) today announced that on May 17, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common stock to one new non-executive employee to induce him to accept employment with Vaxart.",1
"Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting NEEDHAM, Mass., May  23, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced topline overall survival data from its phase 2 clinical trial of CAN-2409, a multimodal biological immunotherapy candidate, plus valacyclovir (prodrug), together with standard of care (SoC) immune checkpoint inhibitor (ICI) therapy in patients with Stage IIIIV non-small cell lung cancer (NSCLC) inadequately responding to ICI (anti-PD-(L)1) therapy.  The data will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, May 31 to June 4, 2024, by Charu Aggarwal, MD, MPH, FASCO, Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the Perelman School of Medicine, University of Pennsylvania and Co-Principal Investigator of the clinical trial.",2
"Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study",1
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting,1
"Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024 COPENHAGEN, Denmark, May  23, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study. The study assesses the personalized cancer vaccine EVX-01 in combination with anti-PD1 therapy in patients with advanced melanoma. The conference will take place in Chicago, IL, from May 31 – June 4, 2024. ",1
"HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting NEW YORK and VIENNA, May  23, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive updated results from its Phase 12 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive (HPV16+) head and neck cancers. The data were published in the Company’s abstract for the ASCO 2024 Annual Meeting and support the Company’s pivotal Phase 23 trial design for HB-200 in combination with pembrolizumab in the first line setting.",1
"NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors.",1
"Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting NORWOOD, Mass., May  23, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 900 AM -1200 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.",1
"FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting SAN FRANCISCO, May  23, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b2 study conducted by the University of California San Francisco of FG-3246 (FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with a MMAE-containing payload, in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.",1
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug,2
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation – ,1
Kronos Bio to Present Clinical Update on Phase 12 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting — KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 34 neutropenia observed —,1
"Theriva™ Biologics anuncia la designación de vía rápida concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas metastásico ROCKVILLE, Maryland, May  24, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha concedido la designación de vía rápida (FTD, por sus siglas en inglés) al candidato clínico principal VCN-01 en combinación con gemcitabina y nab-paclitaxel para mejorar la supervivencia libre de progresión y la supervivencia global en pacientes con adenocarcinoma pancreático metastásico. En VIRAGE, el estudio clínico multinacional de fase 2b en curso, se está evaluando el VCN-01 intravenoso en combinación con quimioterapia de tratamiento estándar (gemcitabinanab-paclitaxel) como tratamiento de primera línea para pacientes con adenocarcinoma pancreático ductal (PDAC). Anteriormente, la FDA concedió la designación de fármaco huérfano al VCN-01 para el tratamiento del PDAC.",1
"Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company PALO ALTO, Calif., May  24, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to the U.S. House of Representatives on illegal market manipulation of the common stock of Scilex.",2
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy,0
"TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May  28, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee. Abstracts are now available online and can be accessed on the CMSC meeting website at www.mscare.org2024 or by clicking on the following link httpsmeridian.allenpress.comijmscarticle26s11500896Abstracts-from-the-38th-Annual-Meeting-of-the. Details for the upcoming BRIUMVI presentations are outlined below.",1
"Longeveron® to Attend BIO International Convention 2024 Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.",2
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. -- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mgml [≥ 1.7 mmoll) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe --,1
"Evaxion Announces Business Update and First Quarter 2024 Financial Results COPENHAGEN, Denmark, May  28, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (""Evaxion"" or the ""Company""), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results.",1
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial,1
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China Cytek announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China NMPA approval for for clinical diagnostic use.,1
Immunocore converts Phase 23 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Immunocore converts Phase 23 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma,1
"TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning",1
"MediWound Reports First Quarter 2024 Financial Results and Provides Company Update  NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year",1
"Ocugen to Present at BIO International Convention 2024 MALVERN, Pa., May  29, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.",0
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline,2
"BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem MAINZ, GermanyOSLO, Norway, May 29, 2024 – BioNTech SE (Nasdaq BNTX, “BioNTech”, “the Company”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem. CEPI is committing up to US $145 million1 to support BioNTech to establish mRNA vaccine R&D, clinical and commercial-scale manufacturing capabilities at the Company’s facility in Kigali, Rwanda. These capabilities will contribute to efforts to better prepare for potential future epidemic and pandemic threats in Africa. ",1
BioNTech und CEPI erweitern Partnerschaft zur Stärkung des afrikanischen mRNA-Impfstoff-Ökosystems    ,1
"BioAtla to Participate in the Jefferies Global Healthcare Conference SAN DIEGO, May  29, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.",0
"Spectral AI Set to Join Russell Microcap® Index DALLAS, May  29, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024.",1
"TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138",0
"Neues Bibliotheksvorbereitungskit von QIAGEN vereinfacht multiomische Studien und treibt Präzisionsmedizin voran QIAseq Multimodal DNARNA Lib Kit ermöglicht DNA- und RNA-Bibliotheksvorbereitung für Next-Generation-Sequencing aus einer einzigen Probe  Neues Kit verbessert Präzisionsmedizin und Verständnis komplexer Krankheiten wie Krebs durch multiomische Studien und Comprehensive Genomic Profiling  Erstes multimodales Sequencing-Kit für mehrere Probenarten bietet hohe Flexibilität und Sensitivität, was Probenmaterial und Zeit einspart QIAseq Multimodal DNARNA Lib Kit ermöglicht DNA- und RNA-Bibliotheksvorbereitung für Next-Generation-Sequencing aus einer einzigen Probe  Neues Kit verbessert Präzisionsmedizin und Verständnis komplexer Krankheiten wie Krebs durch multiomische Studien und Comprehensive Genomic Profiling  Erstes multimodales Sequencing-Kit für mehrere Probenarten bietet hohe Flexibilität und Sensitivität, was Probenmaterial und Zeit einspart",1
"QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine QIAseq Multimodal DNARNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample  New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer  Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time QIAseq Multimodal DNARNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample  New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer  Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time",1
"Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research NEW YORK, May  30, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious “Giants of MS” award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.",0
"BiomX to Present Phase 1b2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024 GAITHERSBURG, Md. and NESS ZIONA, Israel, May  30, 2024  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present at two upcoming conferences data from BiomX’s Phase 1b2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in an oral presentation and an ePoster at the 47th European Cystic Fibrosis Conference, which is taking place June 5-8, 2024, in Glasgow, United Kingdom, and in a Rapid Fire oral presentation and a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-17, 2024, in Atlanta, Georgia.",1
Monte Rosa Therapeutics Announces Leadership Team Promotions Monte Rosa Therapeutics Announces Leadership Team Promotions,1
"INmune Bio Inc. to Join Russell 3000® Index Boca Raton, Florida, May  30, 2024  (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.",2
"FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma NEEDHAM, Mass., May  30, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110, a next generation oncolytic viral immunotherapy, for the treatment of recurrent high-grade glioma (rHGG). Glioblastoma (GBM) is the most common and aggressive form of high-grade glioma.",1
"Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference SAN DIEGO, May  30, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the American Society for Microbiology (ASM) Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia.",1
"NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 BELTSVILLE, Md., May  30, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.",1
"Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostate Cancer SAN DIEGO, May  30, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phase 12 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fifth cohort are receiving ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day. The decision to proceed to this higher dose level was made by the study’s Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily. An initial update on ONCT-534 safety and efficacy based on prostate-specific antigen (PSA) levels from this study is expected in the third quarter of 2024 and will include data from this 600 mg dose cohort.",1
"QIAGEN und Myriad Genetics entwickeln vermarktbaren HRD-Test für weltweite Forschung und Begleitdiagnostik Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD) basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungen und proprietären, von der FDA zugelassenen MyChoice-CDx®-Biomarkern von Myriad  Weltweite Vermarktung des HRD-Testkits durch QIAGEN, um Forschung und die Entwicklung von Begleitdiagnostika zusammen mit pharmazeutischen Partnern zu unterstützen, um einen breiteren Einsatz von MyChoice CDx und potenzielle Erweiterung seiner klinischen Indikationen zu ermöglichen  Projekt baut auf der vor kurzem bekannt gegebenen Rahmenkooperationsvereinbarung zwischen beiden Unternehmen auf",1
"QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digitial Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers  QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx  Project builds on recently announced master collaboration agreement between the two companies Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digitial Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers  QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx  Project builds on recently announced master collaboration agreement between the two companies",1
"Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS CAMBRIDGE, Mass., May  30, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). QALSODY is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).",1
"TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May  31, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links.",1
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,0
"Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy MALVERN, Pa., May  31, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and Safety Monitoring Board (DSMB) Review for its Phase 12 ArMaDa clinical trial for OCU410 (AAV5-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 2-3 million people in the U.S. and Europe combined.",1
"Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024",1
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response,1
"QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings  New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens  Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings  New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens  Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves",1
"QIAGEN erweitert QIAstat-Dx-Menü in den USA mit syndromischem Test für bessere Versorgung bei Magen-Darm-Erkrankungen QIAstat-Dx Gastrointestinal Panel 2 von der FDA in den USA zur klinischen Anwendung zugelassen  Neues Panel erkennt bis zu 16 gängige Erreger von Magen-Darm-Erkrankungen schnell und genau  Generiert Ergebnisse innerhalb rund einer Stunde, basierend auf Echtzeit-PCR-Technologie; ermöglicht einfachen Zugang zu Ct-Werten und Amplifikationskurven QIAstat-Dx Gastrointestinal Panel 2 von der FDA in den USA zur klinischen Anwendung zugelassen  Neues Panel erkennt bis zu 16 gängige Erreger von Magen-Darm-Erkrankungen schnell und genau  Generiert Ergebnisse innerhalb rund einer Stunde, basierend auf Echtzeit-PCR-Technologie; ermöglicht einfachen Zugang zu Ct-Werten und Amplifikationskurven",1
"MediciNova Announces Data from Phase 1b2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 LA JOLLA, Calif., June  03, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that MediciNova’s collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented new data and results of a Phase 1b2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma (GBM) at the American Society of Clinical Oncology (ASCO) Annual meeting 2024 held May 31- June 4th in Chicago, IL.",1
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting,0
"Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in Production Kraig Labs (OTCQB KBLB) is now in production with its BAM-1 spider silk hybrids, following the resounding successes of its spring production trials",2
"TG Therapeutics to Participate in the Jefferies Global Healthcare Conference Fireside chat scheduled for Wednesday, June 5, 2024, at 130 PM ET Fireside chat scheduled for Wednesday, June 5, 2024, at 130 PM ET",1
"Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024 COPENHAGEN, Denmark, June  03, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the Company’s AI-Immunology™ designed personalized cancer vaccine, EVX-01, in combination with an anti-PD1 inhibitor. The EVX-01 vaccine targets neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells.",1
"Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 JERUSALEM, June  03, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, as presented on June 1st at the Endocrine Society ENDO 2024 Annual Meeting.",1
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024,1
"NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 SANTA ANA, Calif., June  03, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.",0
"electroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules ROCKAWAY, N.J., June  03, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to an institutional accredited investor an aggregate of 225,000 registered pre-funded warrants to purchase shares of common stock and unregistered warrants to purchase up to an aggregate of 112,500 shares of common stock. The pre-funded warrants were sold at a purchase price of $6.43 minus $0.001 per pre-funded warrant, and are exercisable immediately at an exercise price of $0.001 per share. Each share of common stock is being sold together with one-half of one warrant at a combined effective offering price of $6.4925 per share and related warrant. The warrants will be immediately exercisable after the date of issuance at a price of $6.43 per share and will expire five years after issuance.",2
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare,2
"FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors SAN FRANCISCO, June  03, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.",2
"FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials SAN FRANCISCO, June  03, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.",2
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June  03, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 166,353 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market 
Under Nasdaq Rules",1
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an award from U.S. Department of Defense Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an award from U.S. Department of Defense,1
"Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab NEW YORK, June  04, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced it has been honored with an invitation to apply for a prestigious grant from the ALS Association head by James Berry, MD, MPH and Suma Babu, MBBS, MS, the Director and Co-Director of the Neurological Clinical Research Institute (NCRI) at Mass General Hospital, a founding member of Mass General Brigham. The grant is offered as part of the Hoffman ALS Clinical Trial Awards Program, which is specifically designated to support a groundbreaking clinical trial.",1
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy --Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p 0.001)-- --Stabilization in Left Ventricular Ejection Fraction (LVEF) Suggests Preservation of Cardiac Function--,2
"Annexon Announces Proposed Public Offering of Common Stock BRISBANE, Calif., June  04, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock. All of the shares are being offered by Annexon. In addition, Annexon expects to grant the underwriters a 30-day option to purchase up to an additional $18.750 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.",1
"Immutep successfully completes institutional placement and institutional component of entitlement offer Sydney, Australia, June  05, 2024  (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX IMM, NASDAQ IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares).",1
"MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer LA JOLLA, Calif., June  05, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.",1
"Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference Arcutis today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago June 8-10.",1
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform,2
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., June  05, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 57,500 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 3, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers’ customization needs, complementing QIAGEN’s existing pre-designed assays  GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively  Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applications New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers’ customization needs, complementing QIAGEN’s existing pre-designed assays  GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively  Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applications",1
"ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® PORTLAND, Maine , June  05, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain®.",1
"QIAGEN führt Assay-Design-Tool für digitale PCR Plattform QIAcuity ein und erweitert Anpassungsmöglichkeiten in Forschungsplattform GeneGlobe Neues Custom Assay Design Tool für digitale PCR-Plattform QIAcuity zur Anylayse von Kopienzahlvariationen unterstützt individuelle Bedürfnisse von Forschern und ergänzt QIAGENs bestehende vorgefertigte Assays  GeneGlobe Design- und Analyse-Hub erhält weitere Funktionen zur Verbesserung der Benutzerfreundlichkeit und gemeinsamen Erstellung von Panels  Neuerungen stärken QIAGEN als vertrauenswürdigen Partner für Forscherinnen und Forscher, die die Arzneimittelentdeckung und weitere Anwendungen forcieren Neues Custom Assay Design Tool für digitale PCR-Plattform QIAcuity zur Anylayse von Kopienzahlvariationen unterstützt individuelle Bedürfnisse von Forschern und ergänzt QIAGENs bestehende vorgefertigte Assays  GeneGlobe Design- und Analyse-Hub erhält weitere Funktionen zur Verbesserung der Benutzerfreundlichkeit und gemeinsamen Erstellung von Panels  Neuerungen stärken QIAGEN als vertrauenswürdigen Partner für Forscherinnen und Forscher, die die Arzneimittelentdeckung und weitere Anwendungen forcieren",1
"Annexon Announces Pricing of $125 Million Underwritten Public Offering BRISBANE, Calif., June  05, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.",1
"Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated approval in MASH",1
"Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients - Conference call and webcast to be held June 14, 2024 at 730 a.m. ET featuring lead investigator -",1
"electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules ROCKAWAY, N.J., June  06, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced the closing of its previously announced registered direct offering of 225,000 registered pre-funded warrants to purchase shares of common stock (the “registered pre-funded warrants”) to an institutional accredited investor; the concurrent private placement of unregistered common stock warrants to purchase up to 112,500 shares of common stock to the investor; and the separate private placement of an aggregate of 1,208,310 shares of common stock (or pre-funded warrants to purchase common stock) and common stock warrants to purchase up to an aggregate of 604,150 shares of common stock, to certain institutional and accredited investors and directors and officers of the Company.",1
"Cytek Biosciences Announces $50 Million Stock Repurchase Program FREMONT, Calif., June  06, 2024  (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program will continue until December 31, 2024 unless extended or shortened by the Board of Directors.",2
"Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ SOUTH SAN FRANCISCO, Calif., June  06, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, were presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ being held June 5-8, 2024.",1
"Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab NEW YORK, June  06, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the qualitative results for all 10 non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients enrolled in the intermediate-size patient population Expanded Access (EA) Program receiving foralumab for at least six months.",1
Spectral AI Reaches 50% Enrollment at Burn Centers for U.S. Pivotal Burn Study Total Patient Enrollment of 90 Towards Overall Target of 240 Total Patient Enrollment of 90 Towards Overall Target of 240 ,0
"Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024 PALO ALTO, Calif., June  06, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has the FDA approval of commercial manufacturing of Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June 2024. Scilex will stock Gloperba® in all major wholesalers and pharmacies starting June 10, 2024.",2
"QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends  Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales  Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024 NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends  Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales  Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024",1
"QIAGEN stellt sein integriertes PCR-Testsystem NeuMoDx ein und unterstützt Kunden in der Übergangsphase Entscheidung über molekulare Systeme NeuMoDx 96 und NeuMoDx 288 beruht auf der schwierigen Marktentwicklung im Anschluss an die Covid-Pandemie  QIAGEN bestätigt Prognose für zweites Quartal 2024 und erhöht für das Gesamtjahr 2024 aufgrund der NeuMoDx-Entscheidung Prognose für den bereinigten verwässerten Gewinn je Aktie auf $2,14 (CER); Gespräche mit NeuMoDx-Kunden aufgenommen, um Auswirkungen auf Umsätze in 2024 zu bewerten  Umstrukturierungskosten in Höhe von ca. $400 Mio., davon ca. $300 Mio. nicht zahlungswirksam, entstehen überwiegend in 2024",1
"Alvotech Announces Strategic Refinancing Agreement REYKJAVIK, Iceland, June  07, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. The financing, led by GoldenTree Asset Management, with participation from other institutional investors (collectively, the “Lenders”), will enable Alvotech (the “Company”) to improve cost of capital, address upcoming debt maturities in 2025 and enhance its financial flexibility by adding incremental cash to the balance sheet.",1
"BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach BioCardia announces that the USPTO has granted Patent No 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.",2
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, June  07, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 3, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 360,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June  07, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 3, 2024 (the “Grant Date”), ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.",1
"Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 SOUTH SAN FRANCISCO, Calif., June  08, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic disorders marked by high unmet medical need, today announced two presentations featuring its lead product candidate efruxifermin (EFX) at the European Association for the Study of the Liver (EASL) Congress 2024, in Milan, Italy. The presentations will also be available on Akero’s website following the meeting.",1
"PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial PETACH TIKVA, Israel, June  10, 2024  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, June 17, 2024, at 1000 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company’s ongoing D-PLEX100 Phase 3 trial. To register, click here.",1
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience,0
"Inotiv, Inc. Provides Business Updates WEST LAFAYETTE, Ind., June  10, 2024  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates",1
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis,1
"Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S. PALO ALTO, Calif., June  10, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S. GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is launching today.",1
"Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference Arcutis today announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15%.",1
"Alvotech and STADA add to strategic alliance through denosumab partnership REYKJAVIK, Iceland and BAD VILBEL, Germany, June  11, 2024  (GLOBE NEWSWIRE) -- Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.",1
"Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH SOUTH SAN FRANCISCO, Calif., June  11, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin (EFX) in patients with compensated cirrhosis, fibrosis stage 4 (F4) due to metabolic dysfunction-associated steatohepatitis (MASH).",1
"Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids Kraig Labs’ (OTCQB KBLB) BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness.",1
"FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis NEW YORK, June  11, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received acceptance of its submission for intranasal foralumab to receive Fast Track Designation approval for the treatment of non-active, secondary-progressive multiple sclerosis (na-SPMS) to the U.S. Food and Drug Administration (FDA).",1
"electroCore to Join Russell Microcap® Index ROCKAWAY, N.J., June  11, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024.",1
"Candel Therapeutics to Join Russell 3000® Index NEEDHAM, Mass., June  11, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.",1
"Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024 Biora will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the conference on June 19, 2024.",1
"Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA® PALO ALTO, Calif., June  11, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that many national pharmacy chains and independent pharmacy stores have begun stocking GLOPERBA®. Scilex launched GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., on June 10, 2024.",1
"Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.",2
"Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway --FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June  11, 2024  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA) on next steps for the Biologics License Application (BLA) submission with its lead asset, CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). Additionally, Deramiocel has been selected as the proposed International Nonproprietary Name (INN) for CAP-1002 by the World Health Organization.",1
"Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation",1
"QIAGEN führt neue QIAcuity digitale PCR-Assays für mikrobielle Anwendungen zur Erforschung und Überwachung von Infektionskrankheiten ein 35 neue laborvalidierte dPCR Microbial DNA Detection Assays auf Forschungsplattform GeneGlobe verfügbar, die eine Vielzahl an Erregern von tropischen Krankheiten, sexuell übertragbaren Infektionen und Harnweginfektionen nachweisen  Die QIAcuity digitale PCR-Technologie ermöglicht eine präzise und sensitive Pathogenerkennung und unterstützt damit die Erforschung von Infektionskrankheiten sowie Initiativen im Bereich der öffentlichen Gesundheit  Neue Assays ergänzen QIAGENs umfassendes Portfolio für die mikrobielle Forschung, das vom 13. bis 17. Juni auf der ASM Microbe-Konferenz vorgestellt wird 35 neue laborvalidierte dPCR Microbial DNA Detection Assays auf Forschungsplattform GeneGlobe verfügbar, die eine Vielzahl an Erregern von tropischen Krankheiten, sexuell übertragbaren Infektionen und Harnweginfektionen nachweisen  Die QIAcuity digitale PCR-Technologie ermöglicht eine präzise und sensitive Pathogenerkennung und unterstützt damit die Erforschung von Infektionskrankheiten sowie Initiativen im Bereich der öffentlichen Gesundheit  Neue Assays ergänzen QIAGENs umfassendes Portfolio für die mikrobielle Forschung, das vom 13. bis 17. Juni auf der ASM Microbe-Konferenz vorgestellt wird",1
"QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections  QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts  New assays add to QIAGEN’s comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections  QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts  New assays add to QIAGEN’s comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17",1
"Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies PALO ALTO, Calif., June  11, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a commitment letter (the “Commitment Letter”) with Perigrove LLC and Graf Holdings (collectively the “Lender”) for a $100 million 5-year term financing with royalty-based payments (“Commitment”). The Company intends to use the funds to repay the outstanding amount of its existing senior secured loan provided by Oramed Pharmaceuticals Inc., which is approximately $85 million. The Company intends to use the rest of the funds raised, which is estimated to be $15 million, for general corporate purposes.",1
"Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 12 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting Company to host webcast on Tuesday, June 18, 2024, at 800 AM Eastern Time",1
"Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID TORONTO, June  12, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID (the “Study”).",1
"Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., June  12, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Chohee Yun, M.D., the Company’s newly appointed Senior Vice President of Clinical Development as a material inducement to her employment.",0
"QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees  Environment 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage  Social  Leveraging partnerships, QIAGEN broadens diagnostic access worldwide  Commits to goal of at least 40% women in leadership by 2027  Governance New Supplier Code of Conduct and Human Rights Committee, upholding high ethical standards across supply chain ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees  Environment 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage  Social  Leveraging partnerships, QIAGEN broadens diagnostic access worldwide  Commits to goal of at least 40% women in leadership by 2027  Governance New Supplier Code of Conduct and Human Rights Committee, upholding high ethical standards across supply chain",1
"Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024 PALO ALTO, Calif., June  13, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced it will be presenting a poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be held in San Diego, CA on June 13-16, 2024.",2
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100,1
"Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants NEW YORK, June  13, 2024  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock plus the shares of common stock underlying pre-funded warrants sold in connection with the public offering. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed or as to the actual size or terms of the public offering. All of the shares in the public offering are being offered by the Company.",0
"QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results  New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows  Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalability Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results  New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows  Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalability",1
"Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate — 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —",2
"Vaxart Announces $40 Million Underwritten Offering of Common Stock SOUTH SAN FRANCISCO, Calif., June  13, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 17, 2024, subject to customary closing conditions.",2
"Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants NEW YORK, June  13, 2024  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $60 million.",0
"Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion",1
"Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion",1
"Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached –",1
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress,1
"Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress REDWOOD CITY, Calif., June  14, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematology Association (EHA) Hybrid Congress, being held June 13 – 16, 2024 in Madrid, Spain.",1
"Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024",1
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis,1
"Renovaro, Inc. Announces $10 million in Equity Committed Renovaro Announces $10m in Equity Committed",1
"Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica) PALO ALTO, Calif., June  14, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the publication of results of the pivotal registration trial of SP-102 (SEMDEXA™) in PAIN, the official journal of the International Association for the Study of Pain, which features original research on the nature, mechanisms and treatment of pain.",1
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, June  14, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 25,500 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on June 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat NEW YORK, June  17, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, reports that Takeda Pharmaceutical Company Limited (Takeda) has announced topline data from its Phase 3 SKYLINE and SKYWAY studies evaluating soticlestat for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). ",0
Kraig Biocraft Laboratories Successfully Completes Cocooning in First Commercial Production Run of BAM-1 Spider Silk Hybrids Kraig Labs (OTCQB KBLB) successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids,1
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 - Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate - Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate,1
"QIAGEN announces 2028 strategy for solid profitable growth Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028   Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization  Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $1 billion to shareholders Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028   Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization  Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $1 billion to shareholders",1
"QIAGEN kündigt Strategie für solides profitables Wachstum bis 2028 an Erläuterung der Strategie auf dem Kapitalmarkttag in New York durchschnittliche jährliche Wachstumsrate von ca. 7% (CER) durch verstärkte Fokussierung auf Wachstumsträger  Straffung des Portfolios (einschließlich der NeuMoDx-Entscheidung), operative Effizienzsteigerungen und Digitalisierung sollen zu einer bereinigten operativen Gewinnmarge von mindestens 31% im Jahr 2028 führen  Disziplinierte Kapitalallokation soll durch Investitionen in F&E und Digitalisierung, Fokus auf Mehrwert schaffende Übernahmemöglichkeiten sowie Pläne zur Rückführung von mind. $1 Mrd. an Aktionärinnen und Aktionäre sichergestellt werden Erläuterung der Strategie auf dem Kapitalmarkttag in New York durchschnittliche jährliche Wachstumsrate von ca. 7% (CER) durch verstärkte Fokussierung auf Wachstumsträger  Straffung des Portfolios (einschließlich der NeuMoDx-Entscheidung), operative Effizienzsteigerungen und Digitalisierung sollen zu einer bereinigten operativen Gewinnmarge von mindestens 31% im Jahr 2028 führen  Disziplinierte Kapitalallokation soll durch Investitionen in F&E und Digitalisierung, Fokus auf Mehrwert schaffende Übernahmemöglichkeiten sowie Pläne zur Rückführung von mind. $1 Mrd. an Aktionärinnen und Aktionäre sichergestellt werden",1
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.,1
"Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™) – Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV –",0
"Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutrition Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutrition",1
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds,0
"Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal COPENHAGEN, Denmark, June  17, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces publication of data from its Phase 1 dose escalation study of its lead personalized cancer vaccine candidate, EVX-01, for metastatic melanoma. The study results, published in the Journal for ImmunoTherapy of Cancer, demonstrated that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses. Further, EVX-01 immunization did not induce vaccine-related serious adverse events in patients co-administered with anti-PD1 therapy.",0
Vaxart Provides Business Update — Cash runway extended into 2026 —,2
"Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., June  17, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 14, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer SOUTH SAN FRANCISCO, Calif., June  17, 2024  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.",1
"Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LDHD in Europe REYKJAVIK, Iceland and LONDON, June  18, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of Alvotech’s proposed biosimilar to Eylea® (aflibercept). Alvotech is currently developing AVT06, a proposed biosimilar to Eylea® low dose (2 mg) and AVT29, a biosimilar candidate for Eylea® high dose (8 mg).",1
"Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma",1
"Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 12 Trials Evaluating TSHA-102 in Rett Syndrome Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communicationsocialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity",0
"FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024 SAN FRANCISCO, June  18, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 1000 AM ET. To register, click here.",1
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients,1
XBiotech Results from Randomized Double-Blinded Phase 12 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE5-FU Combination and Targeted anti-IL-1alpha Therapy,2
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B,1
"Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors REDWOOD CITY, Calif., June  19, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper’s Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024.",1
"MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations Company to rededicate efforts toward updating stakeholders oncorporate vision, strategy, and ongoing activities",1
"Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication MALVERN, Pa., June  20, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).",1
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson’s disease Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson’s disease,1
"Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. PALO ALTO, Calif., June  20, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly respected distributor with over 10 years of sales excellence, Endeavor Distribution LLC. (“Endeavor”). Endeavor has logistics expertise to sell and distribute our currently marketed non-opioid products nationally.",1
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease •  Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial•  DSMB Determination to Proceed with High Dose Cohort Dosing,1
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., June  21, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 187,650 shares of Iovance’s common stock to forty-three new, non-executive employees.",1
"BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324DB-1311 bei Prostatakrebs MAINZ, Deutschland, und SHANGHAI, China, 24. Juni 2024 – BioNTech SE (Nasdaq BNTX, „BioNTech“) und Duality Biologics (Suzhou) Co., Ltd. („DualityBio“) gaben heute bekannt, dass die amerikanische Arzneimittelbehörde (U.S. Food and Drug Administration, „FDA“) BNT324DB-1311 den Fast-Track-Status für die Behandlung von Patienten mit fortgeschritteneminoperablem oder metastasiertem kastrationsresistentem Prostatakrebs (castration resistant prostate cancer, „CRPC“) erteilt hat, bei denen die Erkrankung während oder nach einer systemischen Standardtherapie weiter fortgeschritten ist. BNT324DB-1311 ist ein innovativer Antikörper-Wirkstoff-Konjugat (antibody-drug-conjugate, „ADC“)-Kandidat, der sich gegen das transmembrane Glykoprotein B7-H3 richtet. B7-H3 ist ein Immun-Checkpoint-Protein, das in einer Reihe von Tumorarten überexprimiert wird und mit dem Fortschreiten von Tumorerkrankungen und einer schlechten Prognose in Verbindung gebracht wurde. Der Kandidat wird derzeit in einer klinischen Phase-12-Studie (NCT05914116) bei Patientinnen und Patienten mit fortgeschrittenen soliden Tumoren untersucht.",1
"BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324DB-1311 in Prostate Cancer MAINZ, Germany and SHANGHAI, China, June 24, 2024 – BioNTech SE (Nasdaq BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT324DB-1311 for the treatment of patients with advancedunresectable, or metastatic castration-resistant prostate cancer (“CRPC”) who have progressed on or after standard systemic regimens. BNT324DB-1311 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the transmembrane glycoprotein B7-H3, an immune checkpoint protein which is overexpressed in a range of tumor types and has been associated with disease progression and poor prognosis for patients. The candidate is currently being evaluated in an ongoing Phase 12 study (NCT05914116) in patients with advanced solid tumors.",1
"Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission WALTHAM, Mass., June  24, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.",2
"TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union Cambridge, Mass., June  24, 2024  (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq BIIB) announced that the European Commission (EC) has granted approval for TOFIDENCETM, a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been granted marketing authorization by the EC for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.",1
"Spectral AI Supports Naked Short Selling Inquiry DALLAS, June  24, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has provided support to Nasdaq and the state securities authorities in Florida, Louisiana and Texas to bring to their attention potential market manipulation of the Company’s common stock, primarily in the form of naked short selling.",2
"Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds NEW YORK, June  24, 2024  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its underwritten public offering of 11,250,000 shares of its common stock at a price to the public of $4.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,750,000 shares of its common stock at a price to the public of $3.999 per pre-funded warrant, in each case, before underwriting discounts and commissions. All of the shares and warrants in the public offering were sold by the Company.",1
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment,0
"BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose)",2
Kraig Biocraft Laboratories Increases Spider Silk Production with Next Generation of Hybrid Eggs Completed Kraig Labs (OTCQB KBLB) expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid,1
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024 SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopalevodopa,0
"electroCore Announces the Commercial Launch of TAC-STIM™ Upgraded TAC-STIM enhances Energy, Focus and Readiness Upgraded TAC-STIM enhances Energy, Focus and Readiness",1
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program – BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes –,1
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer Media Release,1
"Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy SAN DIEGO, June  25, 2024  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre-BLA (Biologics License Application) meeting with the Company in the third quarter of 2024 for deramiocel (CAP-1002), for the treatment of Duchenne Muscular Dystrophy (DMD). Capricor’s goal for this meeting will be to finalize its BLA filing plans based on all currently available data as well as to work with the FDA to outline the rolling BLA submission timeline.",1
"T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor LEXINGTON, Mass., June  25, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.",1
"CORRECTION Capricor Therapeutics SAN DIEGO, June  25, 2024  (GLOBE NEWSWIRE) -- In a release issued under the headline ""Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy"" on Tuesday, June 25th by Capricor Therapeutics, please note that the words ""Pre-BLA Meeting with FDA for Deramiocel"" were omitted from the headline. The corrected release follows.",1
"Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform CAMBRIDGE, Mass., June  25, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPRCas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting, taking place June 22–25 in Montreal, Canada.",1
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints,1
"Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants DALLAS, June  25, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.",1
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab,0
"Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method COPENHAGEN, Denmark, June  26, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.",2
"Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants DALLAS, June  26, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering at the public offering price, less the underwriting discount. The gross proceeds from the offering to Taysha are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriter’s option to purchase additional shares. The offering is expected to close on or about June 27, 2024, subject to customary closing conditions.",0
"Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis",1
"X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial 100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +- stable-dose G-CSF as of the interim analysis data cut-off date",0
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160,1
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds,1
"Spectral AI Surpasses 90% of Pediatric Enrollment Target in Burn Centers for Pivotal U.S. Burn Study DALLAS, June  27, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has surpassed 90% of the enrollment target for pediatric patients at burn centers for its 2024 pivotal study designed to validate the AI-driven algorithm used by its DeepView™ System for its burn indication.",1
"INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint.",2
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction – Transaction aligns with Coherus’ strategic focus on oncology – – Transaction aligns with Coherus’ strategic focus on oncology –,2
"Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. (NYSE PFE, “Pfizer”) and BioNTech SE (Nasdaq BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY® JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition and the European Medicines Agency's Emergency Task Force (ETF) to update COVID-19 vaccines to target the SARS-CoV-2 variant JN.1 for the 2024-2025 vaccination campaign. ETF stated that “evidence indicates that targeting JN.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.” 1, 2",1
"Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union NEW YORK und MAINZ, Deutschland, 27. Juni 2024 — Pfizer Inc. (NYSE PFE, „Pfizer“) und BioNTech SE (Nasdaq BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“) eine positive Beurteilung für die Marktzulassung (Marketing Authorization) des an Omikron JN.1 angepassten monovalenten COVID-19-Impfstoffs (COMIRNATY® JN.1) der Unternehmen für die aktive Immunisierung zur Vorbeugung von COVID-19 verursacht durch SARS-CoV-2 bei Personen ab 6 Monaten ausgesprochen hat. Die Anpassung basiert auf der Empfehlung der technischen Beratungsgruppe für die Zusammensetzung von COVID-19-Impfstoffen (Technical Advisory Group on COVID-19 Vaccine Composition) der Weltgesundheitsorganisation (World Health Organization, „WHO“) und der Notfall-Taskforce (Emergency Task Force, „ETF“) der EMA, die vorschlagen, COVID-19-Impfstoffe zu aktualisieren, um die SARS-CoV-2-Variante JN.1 für die Impfkampagne 2024-2025 abzudecken. Die Notfall-Taskforce erklärte „Es gibt Hinweise darauf, dass eine Anpassung an JN.1 ausreichend ist, um die Wirksamkeit der Impfstoffe gegen das sich fortlaufend weiterentwickelnde SARS-CoV-2 aufrechtzuerhalten.“ 1, 2",1
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma,0
QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages  New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages  New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection,1
"Elicio Therapeutics Announces Proposed Public Offering BOSTON, June  27, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying common warrants. All of the common stock, pre-funded warrants and accompanying common warrants are being offered by Elicio. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",0
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China China is the Third Country to Launch LEQEMBI Following the United States and Japan China is the Third Country to Launch LEQEMBI Following the United States and Japan,1
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) EURneffy positioned to be the first and only needle-free adrenaline option authorized for emergency treatment of allergic reactions (anaphylaxis) in Europe,1
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025,1
"Eyenovia Announces Pricing of $5M Registered Direct Offering NEW YORK, June  28, 2024  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder, providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock (the ""Offering""). The combined offering price for each share of common stock and accompanying warrant is $0.66.",0
"Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership JUPITER, Fla., June  28, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.",1
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy -Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients-,1
"Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering BOSTON, June  28, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the pricing of an approximately $11.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and accompanying common warrants to purchase common stock, before deducting underwriting discounts and commissions and estimated offering expenses payable by Elicio.",0
"Tiziana Receives $3.4 Million in Non-Dilutive Funding NEW YORK, June  28, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.  ",2
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025,2
"QIAGEN delivers solid performance and exceeds outlook for Q2 2024 Q2 2024 Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER); net loss per share of $0.83 but adjusted diluted EPS of $0.55  Net sales at CER of $502 million ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.55 CER ahead of $0.52 CER outlook  28.4% adj. operating income margin up 1 percentage point from 27.4% in Q2 2023  Q2 2024 free cash flow up 56% to $129 million vs. Q2 2023  FY 2024 outlook updated after solid H1 2024 results ahead of outlook  Updated net sales outlook of at least $1.985 billion CER reflects solid core business trends and NeuMoDx decision  Adj. diluted EPS outlook increased to at least $2.16 CER Q2 2024 Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER); net loss per share of $0.83 but adjusted diluted EPS of $0.55  Net sales at CER of $502 million ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.55 CER ahead of $0.52 CER outlook  28.4% adj. operating income margin up 1 percentage point from 27.4% in Q2 2023  Q2 2024 free cash flow up 56% to $129 million vs. Q2 2023  FY 2024 outlook updated after solid H1 2024 results ahead of outlook  Updated net sales outlook of at least $1.985 billion CER reflects solid core business trends and NeuMoDx decision  Adj. diluted EPS outlook increased to at least $2.16 CER",1
"QIAGEN zeigt solide Entwicklung und übertrifft Prognose für das zweite Quartal 2024 Q2 2024 Konzernumsatz von $496 Mio. (+0% bei tatsächlichen Kursen; +1% bei konstanten Wechselkursen, CER); Nettoverlust je Aktie von $0,83, bereinigter verwässerter Gewinn je Aktie von $0,55  Konzernumsatz bei konstanten Wechselkursen (CER) von $502 Mio. übertrifft Prognose von mindestens $495 Mio. (CER); bereinigter verwässerter Gewinn je Aktie von $0,55 (CER) übertrifft Prognose von mindestens $0,52 CER  Bereinigte operative Marge steigt um einen Prozentpunkt auf 28,4% im Vergleich zu 27,4% im Vorjahresquartal  Free Cashflow steigt um 56% im Vergleich zu Q2 2023 auf $129 Mio.  Prognose für 2024 nach solidem ersten Halbjahr mit über der Prognose liegenden Ergebnissen aktualisiert  Aktualisierte Prognose für Konzernumsatz von $1,985 Mrd. (CER); dies berücksichtigt die solide Entwicklung des Kerngeschäfts sowie die NeuMoDx-Entscheidung  Prognose für bereinigten verwässerten Gewinn je Aktie auf mindestens $2,16 (CER) erhöht",1
"QIAGEN to enhance the identification of human remains of Indigenous people and African Americans Partnership with University of Montana drives the implementation of next-generation sequencing and forensic investigative genetic genealogy in identifying human remains  QIAGEN provides instruments, kits and training for building the first Indigenous-owned DNA database and identifying African American human remains  Collaboration underlines QIAGEN’s leading position in the use of next-generation sequencing for forensic applications and human identification Partnership with University of Montana drives the implementation of next-generation sequencing and forensic investigative genetic genealogy in identifying human remains  QIAGEN provides instruments, kits and training for building the first Indigenous-owned DNA database and identifying African American human remains  Collaboration underlines QIAGEN’s leading position in the use of next-generation sequencing for forensic applications and human identification",1
"QIAGEN verbessert die Identifizierung menschlicher Überreste von Indigenen und Afroamerikanern Partnerschaft mit der University of Montana treibt Anwendung von Next-Generation-Sequencing und forensischer genetischer Genealogie zur Identifizierung menschlicher Überreste voran  QIAGEN unterstützt den Aufbau der ersten von Indigenen geführten DNA-Datenbank und die Identifizierung menschlicher Überreste von Afroamerikanern mit Instrumenten, Kits und Schulungen  Zusammenarbeit unterstreicht QIAGENs führende Position bei der Nutzung von Next-Generation-Sequencing für forensische Anwendungen und die Personenidentifizierung",1
"QIAGEN N.V. to release results for Q2 2024 and hold webcast Venlo, The Netherlands, July  02, 2024  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE QGEN) (Frankfurt Stock Exchange QIA) announced plans to release results for the second quarter 2024.",1
"electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., Aug.  02, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on August 1, 2024, Stephen Smith joined electroCore as the Company’s VP, Quality, Regulatory, and Compliance, and the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Smith in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Smith’s commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Smith’s continued employment by the Company on the applicable vesting date.",1
Non-invasive Vagus Nerve Stimulation (nVNS) is effective at accelerating foreign language learning Clinical Trial demonstrates that nVNS is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants Clinical Trial demonstrates that nVNS is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants,1
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations ,1
"MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients",1
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue,1
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs),1
"MediWound Announces $25 Million Strategic Private Placement Financing Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment",1
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources,1
"Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease Collaboration to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet® dispensing technology, following consultation with FDA",1
"PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds Funding Extends Company’s Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised",1
"Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024 PALO ALTO, Calif., Aug.  01, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for the month ended July 31, 2024. Scilex generates continuous sales growth in ZTlido® going into third quarter of 2024 with preliminary net sales for ZTlido® in the range of $4.0 million to $5.0 million.",0
"Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region PALO ALTO, Calif., July  17, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that that it has entered into a Memorandum of Understanding (MOU) for collaboration agreement with ACEA, a China-based company focused on the development of innovative treatments for high unmet needs. Under the terms of the MOU, ACEA may receive exclusive rights to develop and commercialize of ZTlido® in mainland China, Taiwan, Hong Kong, Macau, including the current formulation and a right of first negotiation for a future next generation formulation of a 3X version of ZTlido, SP-103. The MOU provides Scilex with the opportunity to expand collaboration with ACEA across other products in Scilex’s non-opioid pain management portfolio in the Greater China region.",1
"Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq DECA) Enter into a Letter of Intent for a Proposed Business Combination PALO ALTO, Calif., July  02, 2024  (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, and Denali Capital Acquisition Corp., a Cayman Islands corporation and special purpose acquisition company (Nasdaq DECA, “SPAC”), today announced the signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug.  02, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2024 (the “Grant Date”), ORIC® granted a total of 33,000 non-qualified stock options and 5,600 restricted stock units to two new non-executive employees who began their employment with ORIC® in July 2024.",1
"ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC",2
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July  05, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2024 (the “Grant Date”), ORIC granted a total of 34,000 non-qualified stock options and 5,600 restricted stock units to three new non-executive employees who began their employment with ORIC in June 2024.",1
"T2 Biosystems Announces Second Quarter 2024 Financial Results Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods",2
"T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor LEXINGTON, Mass., July  29, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.",2
"IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules LAWRENCEVILLE, N.J., July  31, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at-the-market under Nasdaq rules. In a concurrent private placement and also pursuant to the securities purchase agreements, the Company has agreed to issue to the investors unregistered warrants to purchase shares of common stock. Upon the closing of the offering, which is anticipated to occur on or about August 1, 2024, the Company expects to receive gross proceeds of $10 million, before deducting placement agent fees and other offering expenses payable by the Company. The closing of the offering is subject to customary closing conditions.",0
"IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 Conference call begins today at 830 a.m. Eastern time",2
"IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow Results to be announced at 800 a.m. Eastern time, conference call to begin at 830 a.m. Eastern time",2
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Aug.  02, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 38,000 restricted stock units of Arcutis’ common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. Arcutis today announced the signing of a co-promotion agreement with Kowa Pharmaceuticals America, Inc.",1
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.,1
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over Arcutis today announced the submission of an sNDA in scalp and body psoriasis.,1
"FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis",1
"Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis WESTLAKE VILLAGE, Calif., July  09, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) for adults and children down to the age of 6. The FDA has indicated that they are working to finalize the action letter and have not indicated they would extend the Prescription Drug User Fee Act (PDUFA) goal date of July 7, 2024.",1
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., July  03, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 325,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 55,000 shares of Arcutis’ common stock to 43 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 Immunocore to report second quarter 2024 financial results and host call on August 8, 2024",1
"Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostate Cancer SAN DIEGO, July  15, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Phase 12 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the sixth cohort are receiving ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 1200 mg taken orally once each day. The decision to proceed to this higher dose level was made by the study’s Safety Review Committee (SRC) after reviewing data from the fifth dose level of 600 mg ONCT-534 daily. An initial update on ONCT-534 safety and efficacy based on prostate–specific antigen (PSA) levels from this study is expected in the third quarter of 2024 and will include data from this 1200 mg dose cohort.",1
"STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe",1
"Alvotech Announces Closing of Private Debt Financing REYKJAVIK, Iceland, July  11, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvotech to refinance outstanding debt obligations, reduce the cost of capital and improve its overall debt maturity profile.",1
"Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® REYKJAVIK, Iceland, July  02, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confirmatory patient study for AVT03, a proposed biosimilar to Prolia® (denosumab) and Xgeva® (denosumab). The study met its primary endpoints. The objective of the study is to demonstrate clinical similarity of AVT03 to Prolia in terms of efficacy, safety, immunogenicity, and pharmacokinetics (PK) in postmenopausal women with osteoporosis. The results will be used to support additional indications for AVT03 as a proposed biosimilar to Xgeva, based on extrapolation.",1
"Alvotech Issues New Shares to Holders of Convertible Bonds REYKJAVIK, Iceland, July  01, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, with maturity on December 20, 2025 (the “Convertible Bonds”).",1
"Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 REYKJAVIK, Iceland, July  01, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows",1
"Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference COPENHAGEN, Denmark, July  16, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today showcases improved performance of its key building block, EvaxMHC, within its AI-Immunology™ platform, at the 32nd Intelligent Systems for Molecular Biology (ISMB) conference taking place in Montreal, Canada, from July 12-16, 2024.",1
"Evaxion Reinforces Milestone Timeline and Provides Shareholder Update COPENHAGEN, Denmark, July  03, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.",1
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience,1
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test,0
"Mainz Biomed Provides Half Year 2024 Corporate Update Mainz Biomed Provides Half Year 2024 Corporate Update -
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study",2
"scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025 FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025",1
Spectral AI Announces Continuing Progress in Development of Handheld DeepView SnapShot M® for Military Field Use Poster Presentation at 2024 Military Health System Research Symposium Poster Presentation at 2024 Military Health System Research Symposium,1
"Spectral AI Announces Total U.S. and International Patent Portfolio Now Stands at 26 Granted Patents and 38 Pending Applications in Support of its AI-Driven DeepView System DALLAS, July  24, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a 30% increase in its patent portfolio that strengthens and protects its proprietary, AI-driven DeepView System wound assessment platform.",1
"Spectral AI Adds Three New Clinical Trial Sites To Expedite Emergency Department Patient Enrollment DALLAS, July  23, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study University Medical Center (UMC) Burn Center at Texas Tech University Health Sciences Center led by principal investigator Alan Pang, M.D., Tampa General Hospital Burn Center led by principal investigator Jared Troy, M.D., and University of South Alabama (USA) Health Emergency Department led by Andrew Bright, D.O.",1
"Spectral AI Announces Collaboration with Global Wound Care Company PolyNovo to Introduce DeepView System for Burn Indication to Australian Market DALLAS, July  08, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has signed a Memorandum of Understanding (“MOU”) with global medical device company and burn wound therapy leader PolyNovo Limited (“PolyNovo”) under which the companies will collaborate to assist Spectral AI in a potential limited deployment of its DeepView System for burn indication in Australia.",2
"Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study DALLAS, July  03, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added two new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study the University of California San Diego and the University of Utah.",1
"Spectral AI Achieves 100% Pediatric Enrollment in Burn Centers for Pivotal U.S. Burn Study DALLAS, July  02, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 100% pediatric patient enrollment at burn centers for its 2024 pivotal study designed to validate the AI-driven algorithm used by its DeepView™ System for its burn indication.",0
"Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired.",1
"Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024 Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.",1
"Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon",1
"Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron announces closing of previously announced registered direct offering, raising $9 million in gross proceeds.",1
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron announces $9.0 million registered direct offering.,0
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.,2
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease,2
"Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers IRVINE, Calif., July  01, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.",0
"Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer — KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation —",1
"Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July  03, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Corrina Pavetto, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 10,275 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 28, 2024. The stock option has an exercise price of $11.94 per share, which is equal to the closing price of Cidara’s common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 14 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of Cidara’s 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.",1
"Intellia Therapeutics Receives Authorization to Initiate Phase 12 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency CAMBRIDGE, Mass., July  30, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 12 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. AATD is a rare, genetic disease that most commonly manifests in lung dysfunction due to insufficient levels of alpha-1 antitrypsin (AAT) protein. NTLA-3001 is a systemically administered in vivo CRISPRCas9-based targeted gene insertion candidate. It is designed to precisely insert a healthy copy of the SERPINA1 gene, which encodes the AAT protein, with the potential to restore permanent expression of functional AAT protein to therapeutic levels after a single dose. This approach seeks to improve patient outcomes, including eliminating the need for weekly intravenous infusions of AAT augmentation therapy or lung transplant in severe cases.",1
"Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July  24, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice President and Chief Financial Officer, Edward Dulac, under Intellia’s 2024 Inducement Plan as a material inducement to employment.",1
"Tiziana Life Sciences Granted FDA Fast Track Designation NEW YORK, July  24, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its intranasal formulation of foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).",2
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer,2
"Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) to unleash potential efficacy, while maintaining safety comparable to pembrolizumab alone -",1
"Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025 -- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment –",1
"BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day SAN DIEGO, July  25, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase AXL, and its antibody targeting CTLA-4, evalstotug. The R&D Day also featured renowned key opinion leaders, Dr. Edwin Yau, Dr. Omid Hamid and Dr. Ankit Mangla. ",1
"BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in treatment-refractory patients with squamous cell carcinoma of the head and neck (SCCHN) in its Phase 2 clinical trial",1
"Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data",1
Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock $12.9 Million Transaction Includes Approximately $3.4 Million of New Fundingand a $9.5 Million Full Cancellation of Outstanding Senior Notesand Extinguishment of Series B Preferred Shares,1
"Kraig Biocraft Laboratories Prepares for Second BAM-1 Hybrid Spider Silk Production Harvest Renowned sericulture expert, Dr. Nirmal Kumar, rejoins Kraig Labs’ (OTCQBKBLB) team in Asia to complete second BAM-1 spider silk hybrids production cycle",1
Kraig Biocraft Laboratories Enter Rapid Growth Rearing Phase for Third Spider Silk Production Cycle Kraig Labs (OTCQB KBLB) entered the exponential specialized silkworm growth rearing phase for its third spider silk production cycle of the season.,2
Kraig Biocraft Laboratories Further Expands Spider Silk Production Levels with Launch of Third Production Cycle Kraig Labs (OTCQB KBLB) launched its third and largest production cycle of the 2024 spider silk production season.,1
Kraig Biocraft Laboratories Completes Phase One of its Spider Silk Production Facility Expansion Kraig Labs (OTCQB KBLB) completed the first phase of construction for its production facility expansion to support the Company's third production wave,1
Kraig Biocraft Laboratories Expands Facilities to Support Spider Silk Production Growth Kraig Labs (OTCQB KBLB) achieved full capacity at its current production location and will open additional production facilities,1
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials,1
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial.,1
"Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio Certara has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.",1
"Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure TORONTO, July  02, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. Control studies have been initiated and the DRDC expects to evaluate the data this month. Treatment studies will follow after the conclusion of the control group evaluation. The research study is expected to be completed in August 2024.",1
"Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - Nufarm to pay up to USD $5 million in consideration for the license-The parties will negotiate the sale of essentially all of Yield10’s assets to Nufarm",2
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism Second rare disease program with RZ358 in Phase 3 development,0
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer,2
"C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 WATERTOWN, Mass., July  16, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 12 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.",1
"BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family BioCardia, Inc., today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath with the FDA.",1
"Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure SUNNYVALE, Calif., July  25, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction (HFrEF) has commenced enrollment in the United States.",1
"BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application SUNNYVALE, Calif., July  17, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No 12,036,371 titled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035.",1
"CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction CellProthera, and BioCardia [Nasdaq BCDA], today announce success from a collaborative Phase II trial of ProtheraCytes for the treatment of AMI.",0
"Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes SAN DIEGO, July  01, 2024  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024.",1
"eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures NEW YORK, July  10, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, announced that eNeuro, a peer-reviewed, open-access journal from the Society for Neuroscience published several preclinical studies validating OV329’s mechanism of action and anti-convulsant properties.",1
"Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations NEW YORK, July  01, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, and Graviton Bioscience Corporation, a privately held clinical-stage biotechnology company focused on developing Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitors and other innovative therapeutic compounds, today announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK) profile of multiple ascending doses of OV888GV101 capsule. Ovid and Graviton plan to progress to a Phase 2 clinical study in cerebral cavernous malformations (CCM) later this year.",1
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Aug.  02, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2024, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 356,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",0
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, July  05, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 3, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 484,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch",1
"Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa MALVERN, Pa., Aug.  05, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from FDA to begin its expanded access program (EAP) for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candidate.",0
"Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 12 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy • Initiated Phase 2 clinical trial",1
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026,0
"Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., July  16, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on July 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation,1
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance            ,1
"INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, August 1, at 430pm ET",1
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways,0
"INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 Management to host conference call and webcast at 430 pm ET on that day",1
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics,1
"Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis – ATEV demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis –",1
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD) – Third RMAT designation by FDA for ATEV –,2
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., July  19, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 106,010 shares of Iovance’s common stock to nineteen new, non-executive employees.",1
"Theriva™ Biologics obtiene la designación de fármaco pediátrico poco frecuente por la FDA estadounidense para el VCN-01 para el tratamiento del retinoblastoma ROCKVILLE, Maryland, July  31, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la Administración de Alimentos y Medicamentos (FDA, por sus siglas en inglés) de EE. UU. ha concedido la designación de fármaco pediátrico poco frecuente (RPDD, por sus siglas en inglés) al VCN-01 para el tratamiento del retinoblastoma. El VCN-01, candidato a producto principal de Theriva, es un adenovirus oncolítico sistémico, selectivo y degradador del estroma. Anteriormente, la FDA concedió la designación de fármaco huérfano al VCN-01 para el tratamiento del retinoblastoma.",2
"Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma ROCKVILLE, Md., July  31, 2024  (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, Theriva’s lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma.",0
"TransCode Therapeutics, Inc. Announces Closing of Public Offering Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to",1
"TransCode Therapeutics, Inc. Announces Pricing of Public Offering Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t",0
"TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t",0
Immutep Quarterly Activities Report Q4 FY24 Media Release,1
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer Media Release,1
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases Media Release,1
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression Media Release,1
"Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July)",2
"Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected JERUSALEM, Aug.  01, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting which will be held on September 27-30, 2024 in Toronto, ON, Canada.",1
"Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder ADELAIDE, Australia and CAMBRIDGE, Mass., July  31, 2024  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the favorable outcomes of an EoP2 meeting with the FDA, supporting the advancement of its lead asset BNC210 for the treatment of PTSD into Phase 3 based on the positive results of the recently completed Phase 2b ATTUNE study.",0
"Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder ADELAIDE, Australia and CAMBRIDGE, Mass., July  18, 2024  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 for the acute, as-needed treatment of social anxiety disorder (SAD).",2
"BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update Conference call and webcast scheduled for August 5, 2024, at 800 a.m. EDT (200 p.m. CEST)",1
BioNTech veröffentlicht Ergebnisse für das zweite Quartal 2024 sowie Informationen zur Geschäftsentwicklung Telefonkonferenz und Webcast sind für den 5. August 2024 um 1400 Uhr MESZ  (800 Uhr U.S. Eastern Daylight Time) geplant,1
"BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma MAINZ, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) today announced positive topline data from the ongoing Phase 2 clinical trial (EudraCT No. 2020-002195-12; NCT04526899) in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. The randomized trial evaluates the clinical activity and safety of the investigational mRNA cancer immunotherapy BNT111 in combination with Libtayo® (cemiplimab), an anti-PD-1 monoclonal antibody being developed by Regeneron, and assesses the two single agents alone. ",1
"BioNTech gibt erste positive Ergebnisse aus laufender Phase-2-Studie mit mRNA-basiertem Immuntherapiekandidaten BNT111 bei fortgeschrittenem Hautkrebs bekannt MAINZ, Deutschland, 30. Juli 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) gab heute erste positive Daten aus der laufenden klinischen Phase-2-Studie (EudraCT-Nr. 2020-002195-12; NCT04526899) bei Patientinnen und Patienten mit inoperablem Melanom im Stadium III oder IV bekannt, deren Erkrankung nach einer anti-PD-(L)1-Behandlung weiter fortschritt. Die randomisierte Studie untersucht die klinische Aktivität und Sicherheit des mRNA-basierten Krebsimmuntherapiekandidaten BNT111 in Kombination mit Libtayo® (Cemiplimab), einem monoklonalen anti-PD-1-Antikörper, der von Regeneron entwickelt wird, sowie der beiden einzelnen Komponenten als Monotherapie.",1
"BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024 MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 800 a.m. EDT (200 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.",1
"BioNTech veröffentlicht am 5. August 2024 Ergebnisse für das  zweite Quartal 2024 und informiert über operativen Fortschritt MAINZ, Deutschland, 22. Juli 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. August 2024, die Ergebnisse für das zweite Quartal 2024 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 1400 Uhr MESZ (800 Uhr Eastern Daylight Time) eine Telefonkonferenz samt Webcast für Investoren, Finanzanalysten sowie die allgemeine Öffentlichkeit durchführen, um die Finanzergebnisse sowie ein Unternehmensupdate zu präsentieren.",1
"Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma PDUFA goal date of December 28, 2024 set by FDA PDUFA goal date of December 28, 2024 set by FDA",1
"GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research YONGIN, South Korea and WALTHAM, Mass., July  15, 2024  (GLOBE NEWSWIRE) -- GC Cell (KRX 144510.KS) and Checkpoint Therapeutics (""Checkpoint"") (Nasdaq CKPT) have announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint’s anti-PD-L1 antibody with dual mechanism of action, with GC Cell’s Immuncell-LC, an innovative autologous Cytokine Induced Killer (“CIK”) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells.",0
"Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WALTHAM, Mass., July  02, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 5,853,659 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.05 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 5,853,659 shares of common stock. The warrants will have an exercise price of $2.05 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrant and will expire five years following the issuance date.",1
"Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab WALTHAM, Mass., July  02, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.",1
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug.  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on July 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 708,236 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock GAITHERSBURG, Md., July  10, 2024  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company’s stockholders have voted to approve a proposal to convert BiomX’s outstanding Series X Non-Voting Convertible Preferred Stock (“Series X Preferred Stock”) into shares of BiomX’s common stock. The result of the vote was previously disclosed in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 9, 2024.",1
"HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split NEW YORK and VIENNA, July  08, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock will be effective as of 500 p.m. Eastern Time on July 9, 2024.",0
"HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV NEW YORK and VIENNA, July  01, 2024  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead.",1
"NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results BELTSVILLE, Md., Aug.  01, 2024  (GLOBE NEWSWIRE) -- – NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported second-quarter 2024 financial results.",1
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, July  12, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 125,000 shares of the Company’s common stock to six new employees (the “Inducement Grants”) on July 9, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus SOUTH SAN FRANCISCO, Calif., July  24, 2024  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sponsored trial (“IST”) of NKX019, Nkarta’s allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy in patients with systemic lupus erythematosus (SLE). The IST broadens the clinical evaluation of NKX019 in lupus. In June 2024, Nkarta announced the initiation of Ntrust-1, its Phase 1 clinical trial of NKX019 in patients with lupus nephritis (LN).",1
"Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President SOUTH SAN FRANCISCO, Calif., July  16, 2024  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings.",2
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024,1
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease ,1
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024,2
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events,1
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450 – Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –,1
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.,1
"GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024",1
"Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update -- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPAVAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO --  DUBLIN and BRIDGEWATER, N.J., July  31, 2024  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQAMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update.",0
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal -- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD)1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe --,1
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) -- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mgdL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China --,1
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024 51% of No Tau  Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau  Low Tau Patient Group,1
"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease CAMBRIDGE, Mass. and BREA, Calif. and TOKYO, July  30, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer’s disease (AD). The development of tau-specific blood-based biomarkers that can measure a patient’s tau burden could provide critical insights into the underlying pathological processes of AD and may help advance the development of a new generation of therapies impacting tau pathology.",1
"Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., July  26, 2024  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters Tokyo, CEO Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq BIIB, Corporate headquarters Cambridge, Massachusetts, CEO Christopher A. Viehbacher, “Biogen”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD).1",0
"Biogen Completes Acquisition of Human Immunology Biosciences CAMBRIDGE, Mass., July  02, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).",1
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients at the European Society of Hematology (EHA) 2024 Annual Meeting –,1
"Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes AUSTIN, TX & DURHAM, NC, July  01, 2024  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck’s addition will be effective today when the U.S. equity markets open.",0
"Aptose Announces Receipt of Deficiency Notice from Nasdaq SAN DIEGO and TORONTO, July  19, 2024  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ APTO, TSX APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has received a deficiency letter (the ""Deficiency Letter"") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (""Nasdaq"") notifying the Company that, for the last thirty (30) consecutive business days, the closing bid price for the Company's common shares have been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the ""Minimum Bid Price Requirement"").",0
"FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update SAN FRANCISCO, July  30, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and a corporate update.",0
"Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results SEATTLE, Aug.  01, 2024  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024.",1
"SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN STAMFORD, Conn., July  01, 2024  (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, for the treatment of pediatric and adult patients with neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN).",1
"Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements MIAMI, Sept.  20, 2024  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that on September 19, 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3,939,394 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering at a purchase price of $1.65 per share. In a concurrent private placement, the Company also agreed to issue to the same investors warrants to purchase up to 3,939,394 shares of common stock. The private placement warrants have an exercise price of $1.84 per share, will be exercisable commencing six months from the date of issuance, and will expire five and one-half years following the date of issuance.",0
"Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults",2
"QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU  Provides absolute quantitation, essential for precise monitoring of low-abundance targets in clinical diagnostics  Enhances lab efficiency and reduces costs with all-in-one instrument for either IVD assays or tests designed and used by laboratories, user-friendly software and flexible scheduling features Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU  Provides absolute quantitation, essential for precise monitoring of low-abundance targets in clinical diagnostics  Enhances lab efficiency and reduces costs with all-in-one instrument for either IVD assays or tests designed and used by laboratories, user-friendly software and flexible scheduling features",1
"QIAGEN führt digitales PCR-System QIAcuityDx für klinische Tests in der Onkologie ein Erweitert das Anwendungsspektrum für die erfolgreiche digitale PCR-Plattform QIAcuity durch Einführung in den klinischen Bereich in Nordamerika und der EU  Bietet absolute Quantifizierung, die für die präzise Überwachung seltener Targets in der klinischen Diagnostik unerlässlich ist  Steigert Laboreffizienz und reduziert Kosten mit einem All-in-One-Gerät für IVD-Assays sowie Tests, die von Laboren entwickelt und verwendet werden, benutzerfreundlicher Software und flexiblen Planungsfunktionen",1
"QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections  Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe  QIAGEN on track to transition over 180 products to new IVDR regulatory framework Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections  Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe  QIAGEN on track to transition over 180 products to new IVDR regulatory framework",1
"QIAGEN erhält europäische IVDR-Zertifizierung für syndromisches Testsystem QIAstat-Dx und zugehörige Assays Produktlinie erhält CE-Kennzeichnung gemäß neuer EU-IVDR-Verordnung – darunter QIAstat-Dx Analyzer, QIAstat-Dx Rise sowie Panels zum Nachweis von Magen-Darm- und Atemwegsinfektionen  Zertifizierung bestätigt, dass QIAGENs Geräte die strengen Sicherheits-, Qualitäts- und Leistungsstandards für In-vitro-Diagnostika in Europa erfüllen  QIAGEN ist auf dem besten Weg, über 180 Produkte auf den neuen IVDR-Rechtsrahmen umzustellen Produktlinie erhält CE-Kennzeichnung gemäß neuer EU-IVDR-Verordnung – darunter QIAstat-Dx Analyzer, QIAstat-Dx Rise sowie Panels zum Nachweis von Magen-Darm- und Atemwegsinfektionen  Zertifizierung bestätigt, dass QIAGENs Geräte die strengen Sicherheits-, Qualitäts- und Leistungsstandards für In-vitro-Diagnostika in Europa erfüllen  QIAGEN ist auf dem besten Weg, über 180 Produkte auf den neuen IVDR-Rechtsrahmen umzustellen",1
"PreAnalytiX, ein Joint Venture von QIAGEN und BD, bringt neuartige Lösung für urinbasierte Flüssigbiopsie auf den Markt Das PAXgene Urine Liquid Biopsy Set mit Sammelbehälter und Nukleinsäure-Stabilisierungsröhrchen ermöglicht eine nicht-invasive Probenentnahme und direkte Stabilisierung zellfreier DNA aus Urin  QIAGEN vermarktetet das Set mit dem ersten verifizierten, standardisierten und vollständigen präanalytischen Workflow von der Urinsammlung über die Stabilisierung bis zur Isolierung zellfreier DNA  Zellfreie DNA im Urin kann wichtige Informationen liefern, die in Blutproben nicht zu finden sind Das PAXgene Urine Liquid Biopsy Set mit Sammelbehälter und Nukleinsäure-Stabilisierungsröhrchen ermöglicht eine nicht-invasive Probenentnahme und direkte Stabilisierung zellfreier DNA aus Urin  QIAGEN vermarktetet das Set mit dem ersten verifizierten, standardisierten und vollständigen präanalytischen Workflow von der Urinsammlung über die Stabilisierung bis zur Isolierung zellfreier DNA  Zellfreie DNA im Urin kann wichtige Informationen liefern, die in Blutproben nicht zu finden sind",1
"PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine  QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA  Cell-free DNA in urine can provide important information to data not found in blood samples PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine  QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA  Cell-free DNA in urine can provide important information to data not found in blood samples",1
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains  Collaboration ensures GEDmatch PRO development remains focused on the needs of forensic genealogists and investigators in the U.S. and other countries worldwide  Partnership builds on QIAGEN’s leading global position in providing extensive portfolio for use in human identification and forensics QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains  Collaboration ensures GEDmatch PRO development remains focused on the needs of forensic genealogists and investigators in the U.S. and other countries worldwide  Partnership builds on QIAGEN’s leading global position in providing extensive portfolio for use in human identification and forensics,1
"QIAGEN und Bode Technology treiben Nutzung der GEDmatch PRO Datenbank für forensische genetische Genealogie voran QIAGEN wählt Bode Technology als exklusiven globalen Vertriebspartner, um den Einsatz der Genealogie-Datenbank GEDmatch PRO in der Strafverfolgung und bei der Identifizierung menschlicher Überreste zu beschleunigen  Zusammenarbeit stellt sicher, dass das Hauptaugenmerk bei der Weiterentwicklung von GEDmatch PRO auf den Bedürfnissen forensischer Genealogen und Ermittlern in den USA und anderen Ländern weltweit liegt  Partnerschaft baut auf QIAGENs globaler Führungsposition mit einem umfangreichen Portfolio für Personenidentifizierung und Forensik auf QIAGEN wählt Bode Technology als exklusiven globalen Vertriebspartner, um den Einsatz der Genealogie-Datenbank GEDmatch PRO in der Strafverfolgung und bei der Identifizierung menschlicher Überreste zu beschleunigen  Zusammenarbeit stellt sicher, dass das Hauptaugenmerk bei der Weiterentwicklung von GEDmatch PRO auf den Bedürfnissen forensischer Genealogen und Ermittlern in den USA und anderen Ländern weltweit liegt  Partnerschaft baut auf QIAGENs globaler Führungsposition mit einem umfangreichen Portfolio für Personenidentifizierung und Forensik auf",1
"QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications  QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations  Portfolio expansion and partnerships support increased adoption of QIAcuity across multiple application areas QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications  QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations  Portfolio expansion and partnerships support increased adoption of QIAcuity across multiple application areas",1
"QIAGEN erweitert Portfolio für digitales PCR-System QIAcuity um über 100 neue Assays auf seiner GeneGlobe‑Plattform QIAGEN führt über 100 neue, laborvalidierte QIAcuity digitale PCR Assays für Krebsforschung, vererbte genetische Störungen, Überwachung von Infektionskrankheiten und weitere Anwendungen ein  QIAcuitys digitale PCR ermöglicht den präzisen und sensitiven Nachweis gering verbreiteter Pathogene, erkennt Kopienzahl-Variationen und identifiziert seltene Mutationen  Portfolioerweiterung und Partnerschaften unterstützen den zunehmende Einsatz von QIAcuity in zahlreichen Anwendungsbereichen QIAGEN führt über 100 neue, laborvalidierte QIAcuity digitale PCR Assays für Krebsforschung, vererbte genetische Störungen, Überwachung von Infektionskrankheiten und weitere Anwendungen ein  QIAcuitys digitale PCR ermöglicht den präzisen und sensitiven Nachweis gering verbreiteter Pathogene, erkennt Kopienzahl-Variationen und identifiziert seltene Mutationen  Portfolioerweiterung und Partnerschaften unterstützen den zunehmende Einsatz von QIAcuity in zahlreichen Anwendungsbereichen",1
"QIAGEN und Bio-ManguinhosFiocruz verbessern Nachweis von Malaria und Dengue-Fieber in Brasiliens nationalem Screening-Programm Moderne PCR-basierte Screening-Plattform kommt landesweit in 30 Laboren zum Einsatz und bietet neue Möglichkeiten zum Nachweis von Malaria, HIV, HCV und HBV in Blutspenden  Modernste Funktionen unterstützen epidemiologische Überwachung des anhaltenden Dengue-Ausbruchs in Brasilien mit einzigartigen von QIAGEN und Bio-ManguinhosFiocruz entwickelten Reagenzien  Partnerschaft unterstreicht QIAGENs Engagement für kundenspezifische und OEM-Lösungen sowie für Technologietransfer und langfristigen Support",1
"QIAGEN and Bio-ManguinhosFiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations  Advanced capabilities support epidemiological surveillance of ongoing dengue outbreak in Brazil with unique chemistry developed by QIAGEN and Bio-ManguinhosFiocruz  Partnership highlights QIAGEN’s commitment to custom and OEM solutions, technology transfer and long-term support Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations  Advanced capabilities support epidemiological surveillance of ongoing dengue outbreak in Brazil with unique chemistry developed by QIAGEN and Bio-ManguinhosFiocruz  Partnership highlights QIAGEN’s commitment to custom and OEM solutions, technology transfer and long-term support",1
"QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications  New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s Disease  Collaboration set to launch the first commercially available IVD Kit for APOE genotyping QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications  New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s Disease  Collaboration set to launch the first commercially available IVD Kit for APOE genotyping",1
"QIAGEN und Lilly kooperieren bei der Entwicklung eines QIAstat-Dx IVD-Panels zur Identifizierung von Patienten mit erhöhtem Risiko für Alzheimererkrankungen QIAGEN entwickelt erstes QIAstat-Dx IVD-Panel für neurodegenerative Anwendungen  Neues QIAstat-Dx-Panel identifiziert APOE-Genotypen, die als einer von vielen Faktoren eine Rolle bei der Einschätzung des Risikos einer Alzheimererkrankung spielen können  Kooperation sieht Markteinführung des ersten kommerziell erhältlichen IVD-Kits für die APOE-Genotypisierung vor QIAGEN entwickelt erstes QIAstat-Dx IVD-Panel für neurodegenerative Anwendungen  Neues QIAstat-Dx-Panel identifiziert APOE-Genotypen, die als einer von vielen Faktoren eine Rolle bei der Einschätzung des Risikos einer Alzheimererkrankung spielen können  Kooperation sieht Markteinführung des ersten kommerziell erhältlichen IVD-Kits für die APOE-Genotypisierung vor",1
"QIAGEN N.V. announces conversion price of new net share settled convertible bonds NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. ",1
"QIAGEN N.V. announces successful placement of new net share settled convertible bonds NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE.",1
"QIAGEN N.V. launches non-US offering of net share settled convertible bonds NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE.",1
"QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases  QIAGEN’s syndromic testing platform QIAstat-Dx enables specialty care providers to make fast decisions about patients’ eligibility for investigational precision medicines New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases  QIAGEN’s syndromic testing platform QIAstat-Dx enables specialty care providers to make fast decisions about patients’ eligibility for investigational precision medicines",1
"Partnerschaft für Begleitdiagnostika für chronische Krankheiten QIAGEN weitet Anwendung von QIAstat-Dx auf die Präzisionsmedizin aus Neue Vereinbarung erweitert die Zusammenarbeit mit AstraZeneca über die Onkologie hinaus - einschließlich komplexer chronischer Erkrankungen  QIAGENs syndromische Testplattform QIAstat-Dx ermöglicht Fachärzten schnell zu entscheiden, welche Patienten für Präzisionsmedikamente in der klinischen Phase geeignet sind",1
"Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference JUPITER, Fla., Sept.  23, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ DYAI), a biotechnology company focused on the efficient, large-scale manufacture of proteins for use in non-pharmaceutical applications including food, nutrition and wellness, as well as animal and human health therapeutics and vaccines, today provided an update on business progress and announced its attendance at the Bioprocess International Conference in Boston, September 23-26, 2024. ",1
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress Alternative Proteins,1
"Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b2a Study of Briquilimab in Asthma REDWOOD CITY, Calif., Sept.  10, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company’s Clinical Trial Application (CTA) for a Phase 1b2a asthma challenge study evaluating briquilimab in asthma.",0
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing,1
"Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi",2
"Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update SAN DIEGO, Aug.  05, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.",1
"electroCore Engages FNK IR to Execute Expanded Investor Relations Program ROCKAWAY, N.J., Sept.  24, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has engaged FNK IR, an institutionally focused investor relations consulting firm, to develop and deploy an expanded outreach and communications program.",1
Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training,1
"electroCore Announces Second Quarter 2024 Financial Results Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023",1
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages,1
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update Completed Construction of New NexoBrid® Manufacturing Facility,1
"Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041",2
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol’s prescribing information New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol’s prescribing information,2
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024 Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024,1
"Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product",0
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted During the Current Quarter,1
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results Approximately 320 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections,1
"Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 PALO ALTO, Calif., Sept.  26, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”) has extended the expiration of the restrictions on transfer of the shares of common stock of Scilex that were previously distributed by Sorrento Therapeutics, Inc. (OTC SRNEQ, “Sorrento”), Scilex’s former controlling stockholder, to Sorrento’s stockholders as a dividend on January 19, 2023 (the “Dividend Stock”). Such lock-up period was previously set to expire on the earlier of (i) September 30, 2024 or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agreed in writing or on the record in Sorrento’s chapter 11 cases certain claims that may be asserted in potential litigation to avoid Sorrento’s distribution of Dividend Stock and to recover such Dividend Stock, should not be pursued, or on such date that the Court deems just and proper. On September 25, 2024, the Court approved a motion to extend the lock-up period on the Dividend Stock to January 31, 2025.",1
"Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan PALO ALTO, Calif., Sept.  18, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the continuing support from Endeavor Distribution LLC (“Endeavor”) on Scilex’s commercial products and the satisfaction of the FSF 33433 LLC $10 million loan under the Commitment Side Letter dated June 11, 2024 (the “Commitment Side Letter”).",1
"Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®) PALO ALTO, Calif., Sept.  12, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®). Scilex has satisfied all the drug distributor criteria set in place by the NABP.         ",1
"Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion PALO ALTO, Calif., Sept.  03, 2024  (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, and Denali Capital Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company (Nasdaq DECA, the “SPAC”), today announced the signing of an agreement and plan of merger for a proposed business combination, by and among Semnur, the SPAC and Denali Merger Sub Inc., a Delaware Corporation and wholly owned subsidiary of the SPAC, which provides for a pre-transaction equity value of Semnur at $2.5 billion.   Prior to the closing of the transaction, the SPAC will be redomesticated as a Delaware corporation. Upon closing of the transaction, the combined company (the “Combined Company”) will be renamed Semnur Pharmaceuticals, Inc., and its common stock and warrants are expected to be listed on Nasdaq under the ticker symbols “SMNR” and “SMNRW”, respectively. The boards of directors of each of the SPAC, Semnur and Scilex have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur by the first quarter of 2025, is subject to the approval of the SPAC’s shareholders, any applicable regulatory approval, and the satisfaction or waiver of certain other closing conditions.",2
"Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label PALO ALTO, Calif., Aug.  29, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced FDA approval of a Supplemental New Drug Application for Label Updates to GLOPERBA®.",1
"Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain PALO ALTO, Calif., Aug.  21, 2024  (GLOBE NEWSWIRE) --  Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Patent and Trademark Office has allowed numerous claims from U.S. patent application no. 17562,229 and will issue a new patent containing those claims related to the treatment of acute pain (the “Patent”), to Scilex in late 2024, further strengthening the Company’s intellectual property position and coverage for its acute migraine treatment drug product, ELYXYB®, a liquid, micro-encapsulation formulation of celecoxib. The Patent, titled “Methods of Treating Pain,” covers methods of treating acute pain.",1
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.  06, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024.",1
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer,1
"T2 Biosystems Highlights New Article Published in The Lancet Changing the Culture of Blood Culture LEXINGTON, Mass., Sept.  23, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted a recently published article in The Lancet, a world-leading medical journal. The article titled “Changing the Culture of Blood Culture” was authored by Sally Davies, Richard A Marfuggi, Rick A Bright, Steve Brozak, and Michael Osterholm on September 20, 2024.",1
"T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union LEXINGTON, Mass., Sept.  20, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQTTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.",1
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients Expands available market to include over 200 children’s hospitals in the United States Expands available market to include over 200 children’s hospitals in the United States,1
"T2 Biosystems Provides Updates on its New Product Development Pipeline Progress Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris",1
"ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect",1
"ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children",2
"ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a prescription for neffy ahead of product availability expected by late September",1
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) EURneffy offers adults and children (≥30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the EU,1
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results neffy® (epinephrine nasal spray) New Drug Application (NDA) under review by FDA; discussions are ongoing to finalize labeling with FDA; PDUFA date in early October 2024,1
"UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline",1
IMUNON to Host R&D Day on September 18th R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer ,1
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference Call Begins Today at 1100 a.m. Eastern Time,1
"IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024 LAWRENCEVILLE, N.J., Aug.  07, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 1100 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.",1
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.,1
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.,1
"Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology WESTLAKE VILLAGE, Calif., Sept.  19, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of American Medical Association Dermatology (JAMA Dermatology) published the positive results from two pivotal Phase 3 studies (INTEGUMENT-1 and INTEGUMENT-2) evaluating the efficacy and safety of ZORYVE® (roflumilast) cream 0.15% as a once-daily, steroid-free treatment for mild to moderate AD. ZORYVE cream, 0.15%, was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the topical treatment of mild to moderate AD in adult and pediatric patients 6 years of age and older and is available in pharmacies nationwide.",1
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Sept.  05, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 37,000 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 3, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.,1
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.,1
"CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.",1
"Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.",1
"Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer",1
Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth,1
"ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 PORTLAND, Maine, Aug.  13, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024.",0
"Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives SAN DIEGO, Sept.  12, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT) (the “Company”) today announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer, and ONCT-808, its ROR1-targeting autologous CAR T program for the treatment of patients with aggressive B-cell lymphoma, and to explore strategic alternatives.",1
"Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results SAN DIEGO, Aug.  08, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2024 financial results.",1
"Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® REYKJAVIK, Iceland, Sept.  25, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio® (vedolizumab). The objective of the study is to demonstrate comparative efficacy, safety, and immunogenicity of AVT16 and Entyvio, in male and female participants 18-80 years old with moderate to severe active Ulcerative Colitis. Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio.",1
"Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 REYKJAVIK, Iceland, Aug.  15, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.",2
"European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) REYKJAVIK, Iceland and LONDON, Aug.  15, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025.",1
"Evaxion significantly expands vaccine development collaboration with MSD COPENHAGEN, Denmark, Sept.  26, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) for two preclinical vaccine candidates. The agreement expands the companies’ current collaboration and carries significant value for Evaxion.",2
"Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, Sept.  16, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces positive one-year data from the ongoing phase 2 trial with its lead asset EVX-01, an AI-designed personalized cancer vaccine.",1
"Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 COPENHAGEN, Denmark, Sept.  09, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new pre-clinical data demonstrating the ability of its novel EVX-B2 mRNA Gonorrhea vaccine candidate in eliminating gonorrhea bacteria by triggering a targeted immune response.",1
"Evaxion Announces Business Update and Second Quarter 2024 Financial Results COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (""Evaxion""), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2024 financial results.",2
"Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September COPENHAGEN, Denmark, Aug.  08, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024. The EVX-01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma (skin cancer).",1
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025,1
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador,0
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of AI for the Expansion and Optimization of Biomarker Selection for PancAlert,1
"scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million",1
"scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class",1
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg1 mL) Autoinjector SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints,1
"scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants BURLINGTON, Mass., Aug.  12, 2024  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock or, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Shares (the “Offering”). scPharmaceuticals also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of Shares offered in the Offering. All Shares and Pre-Funded Warrants to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.",1
"Spectral AI Achieves 25% Patient Enrollment at Emergency Departments for U.S. Burn Pivotal Study and Adds Two New Clinical Trial Sites DALLAS, Sept.  24, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 25% patient enrollment at Emergency Departments (“ED”) for its U.S. Burn Pivotal Study and added two new ED Clinical Trial Sites for this study MedStar Washington Hospital Center in Washington, DC led by Principal Investigator Shawn Tejiram, MD and the University of Utah led by Principal Investigator Giavonni Lewis, MD, FACS. The addition of these two clinical research sites expands participating EDs to 11 facilities.",1
"Spectral AI Outlines U.S. Regulatory Pathway for DeepView® System for Burn Indication DALLAS, Sept.  17, 2024  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided an outline of its regulatory pathway strategy to enter the U.S. market with its flagship DeepView® System for burn indication (“DeepView AI®-Burn”). ",1
American Burn Association Study Highlights Inequities in Access to Specialized Burn Care Spectral AI’s DeepView® System Designed to Provide Equity in Burn Care Access While Optimizing Healthcare Resources Spectral AI’s DeepView® System Designed to Provide Equity in Burn Care Access While Optimizing Healthcare Resources,1
Spectral AI Awarded Additional Funding from Medical Technology Enterprise Consortium to Support Ongoing Development of DeepView SnapShot M® Project Funding Exceeds $7.0 Million Project Funding Exceeds $7.0 Million,1
Spectral AI Completes Burn Center Enrollment for U.S. Burn Pivotal Study Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn Indication Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn Indication,2
Spectral AI Announces 2024 Second Quarter Financial Results Second Quarter Revenue Totals $7.5 Million,1
Biora Therapeutics Achieves ISO 13485 Certification ISO certification underscores the company’s commitment to quality and excellence,0
Biora Therapeutics Announces Positive Nasdaq Listing Decision Company granted extension to regain compliance with Nasdaq listing requirements Company granted extension to regain compliance with Nasdaq listing requirements,1
"Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan",2
Biora Therapeutics Announces Funding Agreement with Existing Investors $16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership,2
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension – On track to announce topline data in Q1 2025 –,1
"Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 RADNOR, Pa., Aug.  05, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August 13, 2024.",1
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.,1
"Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS) Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.",2
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update Longeveron reports Q2 2024 financial results and provides business update.  Phase 2b clinical trial in HLHS achieves 70% enrollment.,0
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer - 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer,2
"Biomerica Reports Fiscal 2024 Year End Results IRVINE, Calif., Aug.  29, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales to $5.4 million, compared to $5.3 million in the prior year. This growth was primarily driven by strong demand for EZ Detect™ colorectal screening tests and Aware® breast self-exam products in the Middle East including the United Arab Emirates.",2
"Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy – Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –",1
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer – New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –,1
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update — First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 —,1
"Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference SAN DIEGO, Sept.  25, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara’s influenza drug-Fc conjugate (DFC) candidate.",2
"Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK",1
"Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts SAN DIEGO, Sept.  19, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB).",1
"Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 SAN DIEGO, Sept.  12, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company’s novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce.",0
"Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference SAN DIEGO, Sept.  05, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference.",1
"Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara’s management team Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara’s management team",1
"Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results SAN DIEGO, Aug.  13, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline.",1
"Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions CAMBRIDGE, Mass., Oct.  01, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z, also known as NTLA-2001) will be presented in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18 in Chicago, Illinois. Nex-z is an investigational in vivo CRISPR-based gene editing therapy designed to be a single-dose treatment for transthyretin (ATTR) amyloidosis. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron. The presentation will include safety, reduction in serum TTR and biomarkers of disease progression, and functional capacity data in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).",1
"Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting CAMBRIDGE, Mass., Sept.  12, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.",1
"Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Sept.  03, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants to five new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.",1
"Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., Aug.  08, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the second quarter ended June 30, 2024.",1
"Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease NEW YORK, Sept.  19, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the National Institutes of Health (NIH), National Institute on Aging have awarded a $4 Million grant to Dr. Howard Weiner as principal investigator at Brigham and Women’s Hospital to be the key research site, to study nasal anti-CD3 for the treatment of Alzheimer’s disease (AD). This significant grant will fund a key research study over the next several years, advancing preclinical and ultimately, clinical studies of intranasal anti-CD3 as a potential treatment for this devastating neurodegenerative condition.",2
"Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule NEW YORK, Aug.  14, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.",1
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line,2
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates,1
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely,1
"New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment ",1
IN8bio Announces Pricing of $12.4 Million Private Placement IN8bio Announces Pricing of $12.4 Million Private Placement,1
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia,2
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights,1
"Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee -- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept.  26, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentation of new data in support of its gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data will be presented at the American College of Rheumatology’s annual ACR Convergence meeting, being held in Washington, D.C. November 14–19.",1
"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) TAMPA, Fla., Sept.  09, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the granting of inducement awards on September 4, 2024 to 17 new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors.",1
"Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey TAMPA, Fla., Aug.  09, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid.",1
"BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody Context to obtain exclusive development and commercialization rights to BA3362",0
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens,0
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias,1
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments,0
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock Topline data anticipated in late September 2024 Topline data anticipated in late September 2024,2
"Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates WARRINGTON, Pa., Aug.  20, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024 and provided key business updates.",1
Kraig Biocraft Laboratories Leverages New Production Center for Largest Ever Batch of Spider Silk Parental Lines Kraig Labs (OTCQB KBLB) leverages new production center’s expanded capacity to launch its largest BAM-1 cycle for finished silk reeling and future product,1
Kraig Biocraft Laboratories Launches Spider Silk Production at Recently Completed Higher Capacity Facility Kraig Labs (OTCQBKBLB) begins first BAM-1 parental strains production at its new production center with capacity to support 25 tons of spider silk,1
"Kraig Biocraft Laboratories Completes New Production Center, Expands Capacity more than Eightfold Kraig Labs (OTCQB KBLB) completes second expansion wave and transitioning spider silk manufacturing operations to its new, larger production center",1
"Kraig Biocraft Laboratories Significantly Increases Spider Silk Reeling Efficiency, Boosting Per Cocoon Yield Kraig Labs (OTCQB KBLB) further boosts spider silk production with the introduction of new silk cocoon reeling protocols resulting in higher silk yields",1
"Kraig Biocraft Laboratories Successfully Completes Third Commercial Spider Silk Production Cycle Kraig Labs (OTCQB KBLB) completed third commercial spider silk production cycle, primarily focused on producing BAM-1 recombinant spider silk hybrids",1
Kraig Biocraft Laboratories Confirms Strength and Toughness of Its Commercially Produced Recombinant Spider Silk Kraig Labs (OTCQB KBLB) confirmed the exceptional strength and toughness of its commercially produced recombinant spider silk,2
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May,1
"InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update - Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –",1
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.,1
"Certara Launches Phoenix™ Version 8.5 Drug Development Software Certara today announced the launch of Phoenix™ version 8.5 software, the pharmaceutical industry's gold standard in PKPD modeling and simulation.",1
Certara Reports Second Quarter 2024 Financial Results Reiterates Full Year 2024 Financial Guidance Reiterates Full Year 2024 Financial Guidance,0
"Akoya Biosciences Reports Second Quarter 2024 Financial Results MARLBOROUGH, Mass., Aug.  05, 2024  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024.",1
"MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11",1
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11,1
"PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes",2
"RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress AMSTERDAM, Sept.  13, 2024  (GLOBE NEWSWIRE) -- (NASDAQ RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.",1
"RenovaroCube Announces Strategic Offering of Up to 20% Ownership AMSTERDAM, Sept.  11, 2024  (GLOBE NEWSWIRE) -- (NASDAQ RENB) The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of RenovaroCube (Cube), currently a wholly owned subsidiary.",1
"Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures TORONTO, Sept.  18, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today its strategic focus on dedicating its resources to advancing the clinical development of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties. The Company has decided not to pursue the development of the Long COVID diagnostic product.",0
"Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections TORONTO, Aug.  28, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. The research study is progressing and is expected to be now completed in October 2024.",0
"Yield10 Bioscience Announces Second Quarter 2024 Financial Results WOBURN, Mass., Aug.  14, 2024  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NasdaqYTEN) (""Yield10"" or the ""Company""), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024.",1
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.,2
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025,1
"Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates • AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death• AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T cells• Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings• AMPLIFY-7P Phase 2 randomized clinical trial anticipated to complete 135-patient enrollment in the fourth quarter of 2024• $43 million raised in 2024 funds Elicio into the second quarter of 2025",1
"Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note BOSTON, Aug.  12, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it entered into a securities purchase agreement dated August 12, 2024, pursuant to which Elicio has sold and issued a principal amount of $20.0 million in the form of a 3.0% Senior Secured Convertible Promissory Note due February 15, 2026 (the “Convertible Note”) in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The purchaser of the Convertible Note was GKCC, LLC, an entity controlled by a member of Elicio’s Board of Directors (the “Purchaser”).",1
"NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report SANTA ANA, Calif., Aug.  22, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq NKGN) (“NKGen” or the “Company”), today announced it received a standard notice (the “Notice”) on August 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because it had not timely filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”) on or before August 19, 2024, the extended period provided for the filing under Rule 12b-25(b) of the Securities Exchange Act of 1934, as amended. The delay is in part due to the recent change in the Company’s independent registered public accounting firm and its valuation firm. The Notice indicated that the Company has 60 calendar days, or until October 21, 2024, to submit a plan to regain compliance and that Nasdaq can grant an exception of up to 180 calendar days from the Form 10-Q due date, or until February 18, 2025, to regain compliance. The Notice from Nasdaq has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market.",1
"C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Sept.  30, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on September 30, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).",1
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities,1
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen Milestone Results in $8 Million Payment to C4 Therapeutics,1
"BioCardia Regains Full Compliance with Nasdaq Listing Requirements SUNNYVALE, Calif., Sept.  18, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s (the “Panel”) decision on May 13, 2024.",1
"BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules SUNNYVALE, Calif., Sept.  09, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the closing of its upsized public offering with participation from management and directors, institutional investors, and certain existing investors of the Company for the purchase and sale of 2,400,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,400,000 shares of common stock at a combined offering price of $3.00 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The company received aggregate gross proceeds of $7.2 million, before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $3.00 per share, will be exercisable immediately and will expire five years from the issuance date.",1
"BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules SUNNYVALE, Calif., Aug.  30, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of its upsized public offering with participation from management and directors, institutional investors, and certain existing investors of the Company for the purchase and sale of 2,400,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,400,000 shares of common stock at a combined offering price of $3.00 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The company expects to receive aggregate gross proceeds of $7.2 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $3.00 per share, will be exercisable immediately and will expire five years from the issuance date.",0
"BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family SUNNYVALE, Calif., Aug.  29, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Food and Drug Administration (FDA) has cleared BioCardia to market the Morph DNA Steerable Introducer product family, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act.",2
"FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial",0
"BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results SUNNYVALE, Calif., Aug.  13, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 430 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.",2
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) Academic group to receive a total of $22 million for the trial Academic group to receive a total of $22 million for the trial,2
"MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting LA JOLLA, Calif., Sept.  03, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b 3 study at the 2024 Annual NEALS Meeting to be held October 21-24, 2024 (a hybrid meeting in Clearwater, Florida and Online). The presentation will be in poster format and be presented by lead Principal Investigator of the clinical trial, Björn Oskarsson, MD, FAAN, Associate Professor of Neurology at Jacksonville, FL and Director, ALS Center of Excellence.",1
"MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition LA JOLLA, Calif., Aug.  29, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.",1
"Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy -Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue-",2
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update -Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy-,2
"Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin NEW YORK, Sept.  26, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions presented the results of a head-to-head animal study evaluating whether OV329 could be found to accumulate in mouse retinas and brains, as has been previously shown to occur with vigabatrin (VGB) the only FDA-approved GABA-aminotransferase (GABA-AT) inhibitor.",1
"Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results NEW YORK, Aug.  13, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024.",1
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Sept.  06, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 3, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 311,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",1
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia,1
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia Estimated 23 million annual agitation episodes in the at-home setting 1-3 ,1
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program,1
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH,1
"Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference MALVERN, Pa., Sept.  24, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan’s 8th Annual Genetic Medicines Conference being held September 30-October 1, 2024 in New York, New York.",0
"Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 12 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy MALVERN, Pa., Aug.  28, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 12 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the United States (U.S.) and Europe.",1
"Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication MALVERN, Pa., Aug.  26, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT (pronounced “limelight”) clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).",1
Ocugen Provides Business Update with Second Quarter 2024 Financial Results Conference Call and Webcast Today at 830 a.m. ET,1
"Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award ZUG, Switzerland, Sept.  19, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collaboration with EURETINA, today announced the winner of the Inaugural Ramin Tadayoni Award.",1
"Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update ZUG, Switzerland, Aug.  27, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS; XICE OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the quarter ended June 30, 2024, and provided an overview of the Company’s progress.",1
"Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Sept.  16, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 13, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Aug.  16, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phase 3 Trial; Potential to be First Targeted Therapy for GBS; Topline Real-World Evidence (RWE) Comparability Data Now Expected by Year-End 2024",1
"Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements VANCOUVER, British Columbia, Oct.  31, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSEMYCO) (AQSEMYIG) (OTCMYCOF) (FSE0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with (i) its previously announced Common Share Subscription Agreement (the “Opensky Subscription Agreement”) with OpenSky Opportunities Fund Ltd. (“Opensky”) dated 10 March 2023; and (ii) a Common Share Subscription Agreement dated 25 October 2023 (the “Standalone Subscription Agreement”, and collectively with the Opensky Subscription Agreement, the “Subscription Agreements”) between the Company and an arms-length investor (the “Standalone Investor” and collectively with Opensky, the “Investors”), the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated 28 January 2022 (together, the “Shelf Prospectus”).",1
"Mydecine Reports its Special Meeting Results VANCOUVER, British Columbia, July  05, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (""Mydecine"" or the ""Company"") (NEOMYCO) (OTCMYCOF) (FSE0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce the results of voting at its special meeting of shareholders which was held on Tuesday, July 4, 2023, by conference call (the “Meeting”). There were 15 shareholders represented in person or by proxy at the Meeting, holding 3,670,377 common shares, representing 14.72% of the Company’s total issued and outstanding common shares as of the record date for the Meeting. The voting results for the Meeting are set out below",1
MDxHealth Announces Pricing of Offering of Ordinary Shares MDxHealth Announces Pricing of Offering of Ordinary Shares,0
MDxHealth Announces Launch of Offering of Ordinary Shares MDxHealth Announces Launch of Offering of Ordinary Shares,0
MDxHealth Reports Q2 and Half Year 2024 Results MDxHealth Reports Q2 and Half Year 2024 Results,0
"Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate — 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator —",1
"Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug.  30, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.",2
"Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia - Data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis -",1
Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results         BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart’s oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats,1
"INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease Boca Raton, Florida, Sept.  30, 2024  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), announced today that it closed enrollment for its Phase 2 trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the “AD02 trial”) is focused on patients with Early AD and biomarkers of elevated neuroinflammation. ",2
"INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort BOCA RATON, Fla., Sept.  26, 2024  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ INMB) (the ""Company""), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase III trial (the “CaRe PC” trial) for men with metastatic Castration-Resistant Prostate Cancer (mCRPC). The Company is pleased to announce initial results from the first patient cohort in the trial.",2
"INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints BOCA RATON, Fla., Sept.  17, 2024  (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ INMB) (the ""Company""), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated  exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials.",1
"INmune Bio Announces $13.0 Million Registered Direct Offering Boca Raton, Florida, Sept.  13, 2024  (GLOBE NEWSWIRE) --  INmune Bio Inc. (Nasdaq INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as the “Insiders”), for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The warrants will be exercisable commencing six months from the date of issuance at a price of $6.40 per share and will expire five years from the initial exercise date. The warrant term may be subject to acceleration following the satisfaction of certain conditions. In the case of Insiders that participated in the offering, if the warrant termination date is on a blackout date, then the Insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant.",0
"INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference Boca Raton, Florida, Sept.  03, 2024  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that management will participate in the following investor conferences in September and October, 2024. ",1
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™) - New U.S. patent covers the design and composition of the BVP -,2
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program - Results presented at the Department of Defense’s Military Health System Research Symposium (MHSRS) -,1
Humacyte Second Quarter 2024 Financial Results and Business Update -FDA requires additional time to complete its review of ATEV™ (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma-,1
"Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma – 2nd quarter conference call to be held Tuesday, August 13th, at 830 a.m. ET –",0
"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Aug.  16, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 289,710 shares of Iovance’s common stock to twenty-four new, non-executive employees.",1
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue,2
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July-,1
"Theriva Biologics Announces Pricing of $2.5 Million Public Offering ROCKVILLE, Md., Sept.  26, 2024  (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 1,428,600 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,428,600 shares of common stock at a combined offering price of $1.75 per share and accompanying warrant (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $2.00 per share, will be exercisable immediately and will expire five years from the issuance date.",0
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabinenab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months –,2
"Theriva™ Biologics logra el objetivo de inscripción de pacientes en VIRAGE, el ensayo de Fase 2b de VCN-01 con gemcitabinanab-paclitaxel para el tratamiento del cáncer de páncreas metastásico - Objetivo de 92 pacientes evaluables (46 en la rama de control y 46 en la rama de tratamiento con VCN-01) inscritos en 15 centros de España y EE. UU. en un plazo de 21 meses –",2
"Theriva™ Biologics obtiene financiación para la fabricación del plan nacional de transferencia de conocimiento del Gobierno español Theriva Biologics y la Universidad Autónoma de Barcelona recibirán un total de 2,28 millones de euros en apoyo del proyecto THERICEL, una plataforma de células en suspensión para la producción de terapias basadas en virus Theriva Biologics y la Universidad Autónoma de Barcelona recibirán un total de 2,28 millones de euros en apoyo del proyecto THERICEL, una plataforma de células en suspensión para la producción de terapias basadas en virus",0
"Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies",0
"Theriva Biologics Announces Reverse Stock Split ROCKVILLE, Md., Aug.  16, 2024  (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 1201 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The reverse stock split was authorized by the Company’s Board of Directors on August 15, 2024. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U 508.",0
"Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2024 - Se espera que la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico (PDAC), finalice en el tercer trimestre de 2024 -",1
"Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results - VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024-",1
Editas Medicine Announces Second Quarter 2024 Results and Business Updates On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end,1
"Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN CARLOS, Calif., Sept.  06, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.",1
"Vaxcyte Announces Pricing of $1.3 Billion Public Offering SAN CARLOS, Calif., Sept.  04, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.",1
"Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants SAN CARLOS, Calif., Sept.  03, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of $1.0 billion of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $150.0 million of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",1
"Vaxcyte Reports Positive Topline Data from Phase 12 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older -- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes --",2
"Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 12 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Adult Phase 12 Study Results, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program --",1
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate,2
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against,1
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate,1
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation,2
"Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity WEST LAFAYETTE, Ind., Sept.  16, 2024  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering.",1
Inotiv Reports Third Quarter Financial Results for Fiscal 2024 and Provides Business Update — Third quarter fiscal 2024 revenue down 32.8% to $105.8 million — Year-to-date fiscal 2024 revenue down 16.5% to $360.3 million — Conclusion of certain government investigations — Site optimization projects complete — Conference call begins today at 430 pm ET,0
"Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update NORWOOD, Mass., Aug.  06, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.",1
Immutep Receives A$3.6 million R&D Tax Incentive from French Government Media Release,1
"New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma SYDNEY, AUSTRALIA, Sept.  18, 2024  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) for patients with  soft tissue  sarcoma (STS), will be presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting taking place 13-16 November 2024, in San Diego, California. ",2
"Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer SYDNEY, AUSTRALIA, Sept.  16, 2024  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L HNSCC).",0
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024 Media Release,1
"Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody Media Release",2
"Immutep to Participate in Upcoming Investor Conferences SYDNEY, AUSTRALIA, Aug.  07, 2024  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (""Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences",2
"Entera Bio and OPKO Health Provide Update on PKPD Results of Oral Oxyntomodulin (GLP-1Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders JERUSALEM and MIAMI, Sept.  25, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ OPK) (OPKO) announced today topline pharmacokineticpharmacodynamic (PKPD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera’s proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss.",0
"Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates JERUSALEM , Aug.  09, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.",1
"Bionomics Limited announces intention to re-domicile to the United States ADELAIDE, Australia and CAMBRIDGE, Mass., Oct.  01, 2024  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, today announced its intention to re-domicile from Australia to the United States via a proposed scheme of arrangement between Bionomics and its shareholders (the “Scheme”) that will be governed by Australian law. Implementation of the Scheme is subject to approval of Bionomics’ shareholders as well as regulatory and court approvals.",1
"BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd. (“InstaDeep”), today presents an overview of its AI approach during an edition of the Company’s Innovation Series, AI Day.",1
"BioNTech stellt auf dem ersten „AI Day” ihre Fähigkeiten im Bereich Künstliche Intelligenz und deren Anwendung in der Forschung und Entwicklung vor LONDON, Vereinigtes Königreich, 1. Oktober 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen”) gibt heute zusammen mit ihrem Tochterunternehmen für Künstliche Intelligenz (artificial intelligence, „AI“), InstaDeep Ltd. („InstaDeep“), einen Einblick in die Anwendung von AI. Dies findet im Rahmen des „AI Day“ statt, der Teil der „Innovation Series“ des Unternehmens ist.",1
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union  ,1
"Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron KP.2 angepassten COVID-19-Impfstoff in der Europäischen Union NEW YORK und MAINZ, Deutschland, 20. September 2024 — Pfizer Inc. (NYSE PFE, „Pfizer“) und BioNTech SE (Nasdaq BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“) eine positive Beurteilung für die Marktzulassung (Marketing Authorization) des an Omikron KP.2 angepassten monovalenten COVID-19-Impfstoffs (COMIRNATY® KP.2) der Unternehmen für die aktive Immunisierung zur Vorbeugung von COVID-19 verursacht durch SARS-CoV-2 bei Personen ab 6 Monaten ausgesprochen hat. Die Europäische Kommission („EK“) wird die Empfehlung des CHMP prüfen. Eine endgültige Entscheidung wird in Kürze erwartet. Im Anschluss an die Entscheidung der EK werden Pfizer und BioNTech den an Omikron KP.2 angepassten COVID-19-Impfstoff den Mitgliedstaaten der Europäischen Union („EU“) ausliefern, die genau diese Formulierung bestellt haben. ",1
"BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024 MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech’s “Innovation Series”, at 0900 a.m. EDT (300 p.m. CEST) on Tuesday, October 1st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech’s and InstaDeep’s AI strategy and capabilities, and the application of AI in BioNTech’s pipeline and internal processes.",2
"BioNTech veranstaltet am 1. Oktober 2024 „AI Day“ als eine Ausgabe der „Innovation Series“ MAINZ, Deutschland, 17. September 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech“) veranstaltet zusammen mit ihrem Tochterunternehmen für künstliche Intelligenz (artificial intelligence, „AI“), InstaDeep Ltd. („InstaDeep“), am Dienstag, den 1. Oktober 2024 um 1500 Uhr MESZ (0900 Uhr EDT) den „AI Day“, eine Ausgabe von BioNTechs „Innovation Series“ in London, Vereinigtes Königreich. Die Veranstaltung gibt einen Überblick über die Strategie und die Fähigkeiten von BioNTech und InstaDeep im Bereich AI und informiert über die Anwendung von AI in der Pipeline und den internen Prozessen von BioNTech.",2
"BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech’s clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches.",1
"BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio MAINZ, Deutschland, 05. September 2024 – BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) wird auf dem diesjährigen Kongress der European Society for Molecular Oncology („ESMO“), der vom 13. bis 17. September 2024 in Barcelona, Spanien, stattfindet, klinische Studiendaten für ausgewählte, sich in der Entwicklung befindende Produkte aus der Multi-Plattform-Onkologie-Pipeline präsentieren. Die Daten-Updates werden in Vorträgen und Poster-Präsentationen zu verschiedenen Prüfpräparaten aus BioNTechs klinischer Pipeline vorgestellt, darunter mRNA-basierte Krebsimpfstoffe, innovative Immunmodulatoren und zielgerichtete Therapieansätze.",1
"Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine NEW YORK and MAINZ, GERMANY, August 22, 2024 — Pfizer Inc. (NYSE PFE, “Pfizer”) and BioNTech SE (Nasdaq BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season’s vaccine is for use as a single dose for most individuals 5 years of age and older. Individuals 5 years of age and older with certain kinds of immunocompromise previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under the age of 5 who have not already completed a three-dose series with previous formulas of a COVID-19 vaccine may be eligible to receive additional doses. ",1
"Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age NEW YORK and MAINZ, Germany, August 16, 2024 — Pfizer Inc. (NYSE PFE, “Pfizer”) and BioNTech SE (Nasdaq BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one was met. In a separate Phase 2 trial, Pfizer evaluated trivalent (“tIRV”) influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.  ",1
"Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19  bei Personen im Alter von 18 bis 64 Jahren bekannt NEW YORK und MAINZ, Deutschland, 16. August 2024 — Pfizer Inc. (NYSE PFE, „Pfizer“) und BioNTech SE (Nasdaq BNTX, „BioNTech“) gaben heute erste Ergebnisse aus der klinischen Phase-3-Studie der Unternehmen mit ihrem mRNA-basierten Kombinationsimpfstoffkandidaten gegen Grippe und COVID-19 bei gesunden Erwachsenen im Alter von 18 bis 64 Jahren bekannt. Der Kombinationsimpfstoffkandidat besteht aus Pfizers mRNA-basiertem Grippeimpfstoffkandidaten und dem zugelassenen COVID-19-Impfstoff der beiden Unternehmen. In der Phase-3-Studie wurden zwei primäre Ziele zur Immunogenität gemessen (Immunogenität gegen SARS-CoV-2 sowie Immunogenität gegen Influenza A und B), von denen eines erreicht wurde. In einer separaten Phase-2-Studie untersuchte Pfizer trivalente mRNA-basierte Einzelimpfstoffkandidaten gegen Grippe, die bei Personen im Alter von 18 bis 64 Jahren eine robuste Immunogenität zeigten. Die Unternehmen prüfen Anpassungen des Kombinationsimpfstoffkandidaten mit dem Ziel, die Immunantwort gegen Influenza B zu verbessern, und werden nächste Schritte mit den Gesundheitsbehörden besprechen.   ",1
"Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Aug.  13, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.",1
"RAPT Therapeutics Reports Second Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Aug.  08, 2024  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the second quarter and six months ended June 30, 2024.",1
"Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024",1
"Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates WALTHAM, Mass., Aug.  12, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates.",1
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct.  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on September 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 744,468 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept.  03, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 230,588 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences BOSTON, Aug.  28, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in three upcoming investor conferences in September 2024",1
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval,2
"BiomX to Provide Latest Update on Positive Phase 1b2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference GAITHERSBURG, Md., Sept.  18, 2024  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX’s Phase 1b2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections.",1
"BiomX to Present Positive Phase 1b2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024 GAITHERSBURG, Md., Sept.  03, 2024  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present data from BiomX’s Phase 1b2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented as a poster at the European Respiratory Society (ERS) Congress in Vienna, Austria taking place September 7-11, 2024. The poster will be presented on Monday, September 9, 2024, 800AM – 930AM local time, at Poster Session 234 “Navigating the journey of adult cystic fibrosis past and future perspectives” (Room PS-21; Board Number 2, Poster ID 2341).",0
"UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split In a release issued under the same headline yesterday by BiomX (NYSE American PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split",1
"BiomX Inc. Announces 1-for-10 Reverse Stock Split GAITHERSBURG, Md., Aug.  15, 2024  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it intends to effect a one-for-ten reverse split (the ""Reverse Stock Split"") of the Company’s common stock (the ""Common Stock""). The Common Stock will continue to trade on the NYSE American under the existing symbol “PHGE” and will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 09090D 301.",0
"HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024",2
"HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 23 “AVALON-1” study with eseba-vec in Q4 2024",1
"Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million --",1
"NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 BELTSVILLE, Md., Sept.  16, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was presented at ESMO 2024. The trial, which is evaluating the combination in ovarian cancer and immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)microsatellite instability-low (MSI-L) colorectal cancer (CRC), demonstrated clinical activity in these hard-to-treat cancers. The data were presented by clinical trial investigators Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center (ovarian) and Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (CRC). The presentations are available on the NextCure website (www.nextcure.com).",0
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Sept.  19, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on September 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Aug.  09, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 19,800 shares of the Company’s common stock to two new employees and 350,000 shares of the Company’s common stock to the newly-hired Chief Operating Officer, Francis Sarena (the “Inducement Grants”) on August 5, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates –The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients–,1
"Correction Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.",1
"Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., Aug.  13, 2024  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024.",1
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study,1
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update,2
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease,2
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions,1
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update,2
"Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept.  30, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Gary Palmer, M.D., the Company’s newly appointed Senior Vice President of Medical Affairs as a material inducement to his employment.",1
"Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024 SOUTH SAN FRANCISCO, Calif., Sept.  10, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced its presentations at the European Respiratory Society (ERS) International Congress 2024 taking place in Vienna, Austria September 7 - 11, 2024.",1
"Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 SOUTH SAN FRANCISCO, Calif., Aug.  26, 2024  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced four upcoming presentations at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024.",1
"Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast",1
"Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept.  20, 2024  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs), today announced that on September 16, 2024, the Compensation Committee of Sutro’s Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee. The grant was made as an inducement material to the employee’s acceptance of employment with Sutro and was approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).",1
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - 4.3 mgkg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mgkg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) -,1
"Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer SOUTH SAN FRANCISCO, Calif., Aug.  22, 2024  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025.",1
"Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 -",1
"Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference REDWOOD CITY, Calif., Aug.  22, 2024  (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.",1
Seer Reports Second Quarter 2024 Financial Results Launched STAC in Europe and additional customer papers published in leading journals Launched STAC in Europe and additional customer papers published in leading journals,0
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting – Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –,2
"AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 IRVINE, Calif., Aug.  19, 2024  (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON’s President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 130 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.",1
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –,2
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility Cytek announced that its San Diego reagent manufacturing facility has been awarded EN ISO 134852016 Quality Management System (QMS) certification.,1
"Cytek Biosciences Reports Second Quarter 2024 Financial Results FREMONT, Calif., Aug.  06, 2024  (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024.",0
"Research Highlighting the Clinical Impact of VASCEPA®VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting DUBLIN, Ireland and BRIDGEWATER, N.J., Sept.  09, 2024  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQAMRN) today announced that new supported andor funded research on the clinical impact of VASCEPA®VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Spain.",1
"Latest Research Highlighting VASCEPA®VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress DUBLIN, Ireland and BRIDGEWATER, N.J., Aug.  22, 2024  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQAMRN) today announced new supported andor funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.",1
"UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 BRUSSELS and CAMBRIDGE, Mass., Sept.  24, 2024  (GLOBE NEWSWIRE) -- UCB (Euronext Brussels UCB) and Biogen Inc. (NASDAQ BIIB) today announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe systemic lupus erythematosus (SLE). Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks versus placebo in addition to SOC. Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.",1
"Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA CAMBRIDGE, Mass., Sept.  04, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 23 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA). The investigational higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA). The study met its primary endpoint at six months, achieving a statistically significant improvement in motor function in infants who received the higher dose regimen as compared to a prespecified matched sham (untreated) control group from the ENDEAR study.",1
"BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin Patents covering BioVie’s terlipressin liquid formulation now secured in the United States, India and Chile, and are pending in nine additional markets",1
"BioVie Inc. Announces Closing of Public Offering CARSON CITY, Nev., Sept.  25, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of a previously announced best efforts public offering of 1,360,800 shares of its common stock, pre-funded warrants to purchase 600,000 shares of its common stock (“Pre-funded Warrants”) and warrants to purchase up to 1,960,800 shares of common stock (the ""Common Warrants"") at a combined public offering price of $1.53 per share (or Pre-funded Warrant) and associated Common Warrant. The Common Warrants have an exercise price of $1.53 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.",1
"BioVie Inc. Announces Pricing of Public Offering CARSON CITY, Nev., Sept.  23, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions.",0
"BioVie Inc. Announces Proposed Public Offering CARSON CITY, Nev., Sept.  23, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (andor pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying common stock purchase warrants in a best efforts public offering. All of the shares of common stock (andor Pre-Funded Warrants) and accompanying common stock purchase warrants are to be sold by the Company.",0
"BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to receivebulk of $13.1 million grant funding",2
"BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim’s impact on neurological symptoms associated with long COVID",0
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging,1
"BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting Presentation to showcase potential impact of bezisterim on biological age, gene expression and measures of aging-related diseases from growing body of clinical evidence Presentation to showcase potential impact of bezisterim on biological age, gene expression and measures of aging-related diseases from growing body of clinical evidence",2
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopalevodopa,1
"BioVie Inc. Announces Reverse Stock Split Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024 Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024",1
"CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors SOUTH SAN FRANCISCO, Calif., Sept.  09, 2024  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors.",1
"CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -",1
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH,2
"Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN MATEO, Calif., Oct.  01, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference at 230 PM ET on Monday, October 7, 2024.",2
"Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit SAN MATEO, Calif., Sept.  12, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting denifanstat’s anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the 8th Annual MASH Drug Development Summit being held in Boston on September 24-26, 2024.",1
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress,2
"Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1ADR3 Signaling Pathway – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –  ",0
"Vincerx Pharma Reports Second Quarter 2024 Financial Results Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024",1
Aptose Announces Results from Special Meeting of Shareholders Aptose Announces Results from Special Meeting of Shareholders,1
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib Aptose Receives $10 Million Through a Facility Agreement with Hanmi Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib,2
Aptose Reports Results for the Second Quarter 2024 Aptose Reports Results for the Second Quarter 2024,1
"FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update SAN FRANCISCO, Aug.  06, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ FGEN) today reported financial results for the second quarter 2024 and provided an update on the company’s recent developments.",2
"TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning",1
Adaptive Announces IVDR Certification for clonoSEQ® in European Union clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies,1
"FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN – PDUFA target action date of February 28, 2025 –",1
"QIAGEN übertrifft Prognose für drittes Quartal 2024 mit solidem Wachstum und erhöht Jahresprognose für bereinigten Gewinn je Aktie Q3 2024 Konzernumsatz von $502 Mio. (+5% bei tatsächlichen Kursen, +6% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,44 und bereinigter verwässerter Gewinn je Aktie von $0,57  Konzernumsatz bei konstanten Wechselkursen (CER) von $502 Mio. übertrifft Prognose von mindestens $495 Mio. (CER); bereinigter verwässerter Gewinn je Aktie von $0,58 (CER) übertrifft Prognose von mindestens $0,55 (CER)  Diagnostiklösungen sind mit 10% CER-Wachstum die stärkste Produktgruppe  Bereinigte operative Marge steigt um 3 Prozentpunkte auf 29,6% im Vergleich zu 26,6% in Q3 2023  Free Cashflow steigt in den ersten neun Monaten 2024 im Vergleich zum Vorjahres-zeitraum um 73% auf $364 Mio.  Umsatzprognose für das Geschäftsjahr 2024 von mindestens $1,985 Mrd. (CER) aufgrund solider Trends im Kerngeschäft bestätigt; Prognose für bereinigten verwässerten Gewinn je Aktie auf mindestens $2,19 (CER) erhöht",1
"QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook Q3 2024 Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57  Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER  +10% CER growth in Diagnostic solutions leads results among product groups  29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023  Free cash flow up 73% to $364 million in first nine months of 2024 vs. same 2023 period  FY 2024 net sales outlook reaffirmed for at least $1.985 billion CER on solid core business  trends; adj. diluted EPS outlook increased to at least $2.19 CER Q3 2024 Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57  Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER  +10% CER growth in Diagnostic solutions leads results among product groups  29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023  Free cash flow up 73% to $364 million in first nine months of 2024 vs. same 2023 period  FY 2024 net sales outlook reaffirmed for at least $1.985 billion CER on solid core business  trends; adj. diluted EPS outlook increased to at least $2.19 CER",1
"QIAGEN erhält FDA-Zulassung für QIAstat-Dx Meningitis Enzephalitis-Panel zur Unterstützung der Notfalldiagnostik QIAstat-Dx MeningitisEnzephalitis-Panel in den USA für den klinischen Einsatz zugelassen, um Diagnosen von Infektionen des zentralen Nervensystems zu unterstützen  Vierte FDA-Zulassung in 2024 markiert Meilenstein bei der erfolgreichen Erweiterung von speziell für die USA entwickelten QIAstat-Dx-Tests  QIAGEN bietet breites Portfolio von FDA-zugelassenen Tests für Infektionen der Atemwege, des Magen-Darm-Trakts und des zentralen Nervensystems – weitere Erweiterungen geplant  Dank Echtzeit-PCR liefert QIAstat-Dx Ergebnisse in etwa einer Stunde und gewährleistet so schnelle und genaue Ergebnisse zur Unterstützung der klinischen Entscheidungsfindung QIAstat-Dx MeningitisEnzephalitis-Panel in den USA für den klinischen Einsatz zugelassen, um Diagnosen von Infektionen des zentralen Nervensystems zu unterstützen  Vierte FDA-Zulassung in 2024 markiert Meilenstein bei der erfolgreichen Erweiterung von speziell für die USA entwickelten QIAstat-Dx-Tests  QIAGEN bietet breites Portfolio von FDA-zugelassenen Tests für Infektionen der Atemwege, des Magen-Darm-Trakts und des zentralen Nervensystems – weitere Erweiterungen geplant  Dank Echtzeit-PCR liefert QIAstat-Dx Ergebnisse in etwa einer Stunde und gewährleistet so schnelle und genaue Ergebnisse zur Unterstützung der klinischen Entscheidungsfindung",1
"QIAGEN receives FDA clearance of QIAstat-Dx meningitisencephalitis panel to support emergency diagnostics QIAstat-Dx MeningitisEncephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections  Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S.  QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion  QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making QIAstat-Dx MeningitisEncephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections  Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S.  QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion  QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making",1
"QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions  With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship  FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024 QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions  With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship  FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024",1
"QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen  Mithilfe des neuen Tests und des QIAstat-Dx Respiratory Panel Plus für 21 Erreger können Ärzte ihren diagnostischen Ansatz individuell auf jeden Patienten abstimmen und diese somit besser betreuen  FDA-Entscheidung ist für QIAstat-Dx das dritte positive Ergebnis bei US-Zulassungsbehörden im Jahr 2024 QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen  Mithilfe des neuen Tests und des QIAstat-Dx Respiratory Panel Plus für 21 Erreger können Ärzte ihren diagnostischen Ansatz individuell auf jeden Patienten abstimmen und diese somit besser betreuen  FDA-Entscheidung ist für QIAstat-Dx das dritte positive Ergebnis bei US-Zulassungsbehörden im Jahr 2024",1
"QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows  New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance liquid biopsy workflows for cancer research  New QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for use in downstream applications Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows  New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance liquid biopsy workflows for cancer research  New QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for use in downstream applications",1
"QIAGEN erweitert Automationsportfolio für Flüssigbiopsien zur Anwendung in Onkologie, Pränatalmedizin und Organtransplantation Portfolioerweiterung stärkt QIAGENs Marktführerschaft bei automatisierten Lösungen für nicht-invasive Flüssigbiopsie in Kombination mit kompletten Workflows  Aktualisiertes ccfDNA-Kit mit urinbasiertem Protokoll für die Verwendung auf EZ1- und EZ2-Instrumenten verbessert Flüssigbiopsie-Workflows in der Krebsforschung  Neue QIAsymphony DSP-Circulating-DNA- und Maxi-Kits liefern hochwertige cfDNA für Downstream-Anwendungen Portfolioerweiterung stärkt QIAGENs Marktführerschaft bei automatisierten Lösungen für nicht-invasive Flüssigbiopsie in Kombination mit kompletten Workflows  Aktualisiertes ccfDNA-Kit mit urinbasiertem Protokoll für die Verwendung auf EZ1- und EZ2-Instrumenten verbessert Flüssigbiopsie-Workflows in der Krebsforschung  Neue QIAsymphony DSP-Circulating-DNA- und Maxi-Kits liefern hochwertige cfDNA für Downstream-Anwendungen",1
"QIAGEN N.V. to release results for Q3 2024 and hold webcast Venlo, The Netherlands, Oct.  10, 2024  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE QGEN) (Frankfurt Stock Exchange QIA) announced plans to release results for the third quarter 2024.",1
"Global TB Summit 2024 QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer QIAGEN’s leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission  Over 35 top tuberculosis experts to discuss critical topics such as advancements in diagnostics and new treatment strategies  CPD- and CME-accredited event highlights the need for renewed global efforts for tuberculosis control QIAGEN’s leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission  Over 35 top tuberculosis experts to discuss critical topics such as advancements in diagnostics and new treatment strategies  CPD- and CME-accredited event highlights the need for renewed global efforts for tuberculosis control",1
"Global TB Summit 2024 QIAGEN an vorderster Front im Kampf gegen Tuberkulose, eine der tödlichsten Infektionskrankheiten QIAGENs führender Tuberkulose-Bluttest QuantiFERON®-TB Gold Plus für den Nachweis latenter Tuberkulose-Infektionen trägt weiterhin dazu bei, den Kreislauf der Krankheitsübertragung zu durchbrechen  Mehr als 35 hochkarätige Tuberkulose-Experten diskutieren über wichtige Themen wie Fortschritte in der Diagnostik und neue Behandlungsstrategien  CPD- und CME-akkreditierte und damit als Weiterbildung anerkannte Veranstaltung unterstreicht die Notwendigkeit neuer globaler Bemühungen zur Eindämmung von Tuberkulose",1
"Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., Nov.  07, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy clinical study in lower-risk myelodysplastic syndromes (LR-MDS).",0
"Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting REDWOOD CITY, Calif., Oct.  24, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24-28, 2024, in Boston, Massachusetts.",1
"Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria REDWOOD CITY, Calif., Oct.  23, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of their initial follow up period. Additionally, Jasper also announced it has obtained regulatory clearance in the US and in the EU to further expand the BEACON study in CSU by adding a 360mg single-dose cohort (n=4), and that enrollment in this cohort has commenced. Jasper continues to plan to report initial data from all doses of the BEACON study up through 240mg in CSU during the week of January 6th, 2025. Data from the newly added 360mg single-dose cohort is expected to be reported in the first half of 2025.",1
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria 14 of 15 participants enrolled achieved a clinical response,0
"Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update SAN DIEGO, Nov.  05, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update.",1
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes,1
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet® Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives,1
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery,1
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of SSIs in Colorectal Resection Conducted in Over a Decade,1
"Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali PALO ALTO, Calif., Nov.  06, 2024  (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, and Denali Capital Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company (Nasdaq DECA, the “SPAC”), today announced the filing of a Registration Statement on Form S-4 (the “Registration Statement”) by Denali with the Securities and Exchange Commission (the ""SEC"") relating to the previously announced proposed Business Combination.",1
"Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms PALO ALTO, Calif., Oct.  30, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced it had a successful end of Phase II meeting with the FDA leading to an agreed path forward to NDA upon completion of Phase III trials for blockbuster product candidate, SP-103 (lidocaine topical system) 5.4%, a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain associated with muscle spasms.",1
"Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential PALO ALTO, Calif., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its board of directors has authorized management to explore ways to maximize the value of its wholly owned subsidiary, Scilex Pharma, including by way of conducting a spinoff or public listing of securities of Scilex Pharma in markets and on securities exchanges outside of the U.S., including Hong Kong, andor a potential strategic transaction or dividend of Scilex Pharma common stock to Scilex stockholders.  ",2
"Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion PALO ALTO, Calif., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it anticipates the filing of the Registration Statement with the SEC before the end of October 2024 relating to the previously announced proposed Business Combination with Denali Capital Acquisition Corp. (Nasdaq DECA) for a pre-transaction equity value of $2.5 billion which transaction is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025.",2
"Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024 PALO ALTO, Calif., Oct.  08, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for the quarter ended September 30, 2024.",0
"Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing PALO ALTO, Calif., Oct.  08, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering of new tranche B senior secured convertible notes (the “Notes”) in the aggregate principal amount of $50 million and warrants to purchase up to 7,500,000 shares of the Company’s common stock.",1
"Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile PALO ALTO, Calif., Oct.  07, 2024  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a definitive agreement with affiliates of Murchinson, 3i LP and with Oramed for the purchase and sale of new tranche B senior secured convertible notes in the aggregate principal amount of $50 million (the “New Financing”) and warrants to purchase up to 7,500,000 shares of the Company’s common stock in a registered direct offering.",1
"ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov.  01, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2024 (the “Grant Date”), ORIC granted a total of 61,800 non-qualified stock options and 10,400 restricted stock units to two new non-executive employees who began their employment with ORIC in October 2024.",1
"ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct.  23, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the company presented a poster highlighting certain best-in-class properties of ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFRHER2 inhibitor, to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.",2
"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct.  04, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NasdaqORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2024 (the “Grant Date”), ORIC granted a total of 92,400 non-qualified stock options and 16,300 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2024.",1
"T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform Pioneering a new frontier in antibiotic stewardship to combat the growing threat of antimicrobial resistance Pioneering a new frontier in antibiotic stewardship to combat the growing threat of antimicrobial resistance",1
"T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens LEXINGTON, Mass., Oct.  07, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel.",1
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results Achieved 35% increase in total revenue compared to prior year period Achieved 35% increase in total revenue compared to prior year period,1
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone,0
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates Conference call today at 1100 a.m. ET,1
"IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 LAWRENCEVILLE, N.J., Oct.  31, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 1100 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.",1
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance,1
"IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) LAWRENCEVILLE, N.J., Oct.  07, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options to purchase a total of 60,000 shares of the Company’s common stock to one individual hired by Imunon during the fourth quarter of 2024 and (ii) inducement stock options to purchase a total of 50,000 shares of common stock to Susan Eylward, hired by Imunon as General Counsel and Secretary effective October 7, 2024 (collectively, the “Inducement Option Grants”). The Inducement Option Grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) and were made on October 7, 2024, as a material inducement to each employee’s entry into employment with the Company.",2
"Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update Arcutis today reported financial results for the quarter ended September 30, 2024, and provided a business update.",1
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Nov.  04, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 50,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 50,000 shares of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of November 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting Arcutis today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients and families.",1
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.,1
"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Oct.  04, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 95,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 38,000 shares of Arcutis’ common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
Immunocore reports third quarter financial results and provides a business update Immunocore reports third quarter financial results and provides a business update,2
"Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostate Cancer SAN DIEGO, Oct.  22, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq ONCT) (the “Company”) today announced updated data from its Phase 12 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC).",0
"Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct.  22, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg26 mL (5 mgmL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara® (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025.",1
"European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® REYKJAVIK, Iceland, Oct.  10, 2024  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab).",1
"Evaxion announces business update and third quarter 2024 financial results COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results.",1
"Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of its AI platform.",1
"Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech AS (NASDAQ EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, continues to gather clinical evidence for the steady improvement of its AI-Immunology™ platform.",1
"Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update – Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter –",2
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update,0
"Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert",2
Spectral AI Announces 2024 Third Quarter Financial Results Revenue Rose to $8.2 MillionCompany Reaffirms Timeline for Regulatory Submission to U.S. FDA,0
Spectral AI Announces Last Patient Out in U.S. Burn Pivotal Study at Burn Centers Milestone Achievement Supports Planned FDA Submission of DeepView AI®-Burn in 2025,1
Spectral AI Completes Proof of Concept for Wound Measurement Technology Provides Clinicians with Superior Wound Size Measurement Information that Improves Patient Treatment Decisions Provides Clinicians with Superior Wound Size Measurement Information that Improves Patient Treatment Decisions,2
"Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, Oct.  29, 2024  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company’s common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 745,342 shares of common stock. The warrants have an exercise price of $3.90 per share, will be exercisable upon issuance, and will expire five years following issuance. The closing of the offering is expected to occur on or about October 29, 2024, subject to the satisfaction of customary closing conditions.",0
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 Expanded collaborations to support rapid testing in advanced animal models in Q4 2024,2
"Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension – Topline data now anticipated in mid first half of 2025 –",1
"Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 RADNOR, Pa., Oct.  22, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 1000 AM ET. To register for the event, please click here.",1
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) Longeveron presents clinical data for stem cell therapy in Alzheimer's disease.  Findings offer potential mechanistic and clinical insights.,1
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).,1
"Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements IRVINE, Calif., Nov.  07, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC (""Nasdaq"") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance.",2
"Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain IRVINE, Calif., Oct.  30, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods® IBS test directly from infoodsibs.com and consequently collect a sample in the comfort of their home. As part of this ordering process, a licensed physician remotely authorizes the test, ensuring professional medical oversight, without the need for visiting a doctor’s office.",2
"Biomerica Reports First Quarter Fiscal 2025 Financial Results IRVINE, Calif., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024.",1
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –,2
"Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors – Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects –",2
"Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease – KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks –",1
"Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results SAN DIEGO, Nov.  07, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided an update on its corporate activities and product pipeline.",1
"Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 SAN DIEGO, Oct.  16, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two upcoming presentations at IDWeek 2024, to be held October 16–19, 2024 in Los Angeles, CA. The presentations will highlight clinical data on the safety, pharmacokinetics, and prophylactic activity of Cidara’s clinical-stage influenza DFC asset, CD388.",2
"Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) SAN DIEGO, Oct.  04, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors (Compensation Committee) granted Dipesh Bhatt, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 1,110 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of September 30, 2024. The stock option has an exercise price of $10.75 per share, which is equal to the closing price of Cidara’s common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 14 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.",1
"Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., Nov.  07, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the third quarter ended September 30, 2024.",1
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Inducement Grant,0
"Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) CAMBRIDGE, Mass., Oct.  24, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive Phase 2 data from the ongoing Phase 12 study of NTLA-2002 in patients with hereditary angioedema (HAE), with results continuing to indicate that NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for HAE, a rare genetic condition that leads to potentially life-threatening swelling attacks. Results were published online today in The New England Journal of Medicine and will be presented on Saturday, October 26 at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Scientific Meeting in Boston, Massachusetts.",0
"Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) CAMBRIDGE, Mass., Oct.  07, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the initiation of HAELO, a global, pivotal Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is a wholly owned investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for this potentially life-threatening disease. Patient screening is active following Intellia’s successful end-of-Phase 2 meeting and submission of an Investigational New Drug Application amendment to the U.S. Food and Drug Administration (FDA).",1
"Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct.  03, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2024 it awarded inducement grants to nine new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.",1
"Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data NEW YORK, Nov.  01, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.",1
"Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million",1
"Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study NEW YORK, Oct.  30, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO), providing a potential novel approach to combat obesity-related inflammation, and liver inflammation and dysfunction.",2
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer,2
"Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -",1
"Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting SAN DIEGO and SUZHOU, China, Oct.  09, 2024  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024.",1
"Pacira BioSciences Reports Third Quarter 2024 Financial Results -- Conference call today at 430 p.m. ET -- PARSIPPANY, N.J., Nov.  06, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024.",0
"Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings -- Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act -- -- Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera° via product-specific reimbursement codes --",1
"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) TAMPA, Fla., Oct.  07, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors.",1
"Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct.  03, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for EXPAREL® (bupivacaine liposome injectable suspension). The new J-code for EXPAREL, J0666, becomes effective January 1, 2025, and will supersede the current C-code (C9290), which has been in place since 2019.",1
"BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress SAN DIEGO, Nov.  07, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the third quarter ended September 30, 2024, and provided highlights on its clinical programs. ",2
"BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting SAN DIEGO, Oct.  04, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.",1
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure,1
"Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient population",0
"Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World WARRINGTON, Pa., Oct.  23, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company has completed national phase filings of patent applications around the world, including in the United States, Germany, France, Italy, Japan and China.",0
"Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan WARRINGTON, Pa., Oct.  17, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.",2
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design The Company recently announced the positive topline results from the Phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock The Company recently announced the positive topline results from the Phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock,0
"Kraig Biocraft Laboratories Announces Successful Completion of Latest Recombinant Spider Silk Production Batch Kraig Labs (OTCQB KBLB) successfully completed its fourth 2024 production cycle, with record-setting performance across nearly every tracked metric",1
Kraig Biocraft Laboratories Nears Completion of Largest Production Batch of Parental Line Spider Silk Silkworms Kraig Labs (OTCQB KBLB) achieves key milestone for true commercial-scale production levels and great colony health,1
"InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Nov.  08, 2024  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System MIAMI, Oct.  07, 2024  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures.",0
Certara Reports Third Quarter 2024 Financial Results Updates Full Year 2024 Financial Guidance Updates Full Year 2024 Financial Guidance,1
"Certara Completes Acquisition of Chemaxon Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.",1
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research,1
"Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust",1
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update,1
Renovaro Issues Shareholder Letter and Provides Corporate Update Renovaro Issues Shareholder Letter and Provides Corporate Update,1
"RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing AMSTERDAM, Oct.  17, 2024  (GLOBE NEWSWIRE) -- (NASDAQ RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.",1
"Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure TORONTO, Oct.  31, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB RVVTF) (CSE RVV) (FRANKFURT31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury.",1
"Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications",1
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens,1
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study,1
"Elicio Therapeutics Reports Inducement Grants BOSTON, Oct.  16, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on October 15, 2024, Elicio granted an aggregate of 5,900 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.   ",1
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial Clinical Development Initiated in Greater China by Partner Betta Pharmaceuticals Clinical Development Initiated in Greater China by Partner Betta Pharmaceuticals,1
"C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Cemsidomide Phase 12 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA",1
"C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Oct.  28, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 345,600 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on October 28, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).",1
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure BioCardia announced today the completion of its last protocol specified follow-up visit in CardiAMP HF multi-center trial.,2
"MediciNova Announces Update of Phase 23 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) LA JOLLA, Calif., Oct.  23, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQMNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number 4875), today announced the lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN presented the update of an ongoing Phase 23 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients at the 2024 Annual NEALS Meeting being held virtually on Oct 21-24, 2024.",1
"Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares SAN DIEGO, Oct.  18, 2024  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 5,073,800 shares of its common stock, including the exercise in full of the underwriters’ option to purchase additional shares to cover over allotments, bringing the total gross proceeds to Capricor from the offering to approximately $86.3 million, before deducting underwriting commissions and other offering expenses payable by Capricor. All of the shares of common stock sold in the offering, including the over-allotment, were offered by Capricor. The closing of the offering occurred on October 18, 2024.",1
"Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock SAN DIEGO, Oct.  17, 2024  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the pricing of its underwritten offering of 4,412,000 shares of common stock at a public offering price of $17.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 661,800 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October 18, 2024, subject to the satisfaction of customary closing conditions.",0
"Capricor Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, Oct.  16, 2024  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",0
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress -Data Supports Deramiocel’s Sustained Efficacy and Safety in Treating DMD-,2
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-,0
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Nov.  01, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",1
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions,1
"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Oct.  04, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 501,600 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",1
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025,1
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update — First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH —,1
"Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 SOUTH SAN FRANCISCO, Calif., Oct.  21, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The presentations will highlight findings from the 96-week Phase 2b HARMONY study evaluating the efficacy and safety of lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3), along with insights from an analysis using AI and digital-based pathology.",1
Ocugen Provides Business Update with Third Quarter 2024 Financial Results Conference Call and Webcast Today at 830 a.m. ET Conference Call and Webcast Today at 830 a.m. ET,2
"Ocugen Secures $30 Million in Debt Funding MALVERN, Pa., Nov.  07, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024, the Company entered into a new $30 million credit facility with Avenue Venture Opportunities Fund, L.P., a fund of Avenue Capital Group. Proceeds from the facility are intended for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.",2
"Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 MALVERN, Pa., Oct.  28, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host an in-person Clinical Showcase on Tuesday, November 12, 2024. The event will take place from 10 a.m.-noon ET at the Nasdaq MarketSite in Times Square, New York City.",0
"Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease MALVERN, Pa., Oct.  22, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved enrollment for the second phase of the Phase 12 clinical trial. OCU410ST (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for Stargardt disease.",1
"Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial MALVERN, Pa., Oct.  09, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a recombinant fusion protein consisting of tumstatin and transferrin, for treating diabetic macular edema (DME).",1
"Oculis Reports Q3 2024 Financial Results and Provides Company Updates ZUG, Switzerland, Nov.  07, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS; XICE OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the quarter ended September 30, 2024, and provided an overview of the Company’s progress.",1
"Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees ZUG, Switzerland, Oct.  21, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the acceleration of patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in DME and expansion of the DIAMOND program committees with globally renowned retina experts.",2
"Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 ZUG, Switzerland, Oct.  15, 2024  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that an update on the DIAMOND Phase 3 program with OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, for diabetic macular edema (DME) will be presented by David Eichenbaum, M.D. at Innovate Retina. In addition, Riad Sherif, M.D., Oculis’ Chief Executive Officer, will be presenting at Eyecelerator 2024, ahead of the American Academy of Ophthalmology Annual Meeting where Oculis will be exhibiting (booth 5452).",1
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting Enhanced protection of vision with ANX007 treatment in healthier eyes,1
"Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).",1
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting ANX007 Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Photoreceptor Preservation in the Fovea Region Critical for Visual Acuity,1
"MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 Tissue-based test volumes increase by 36%, liquid-based test volumes by 24%",1
"Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024 SOUTH SAN FRANCISCO, Calif., Oct.  24, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine Congress Europe 2024 taking place in Barcelona, Spain on October 28-31, 2024.",1
"INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, October 31, at 430pm ET Company to Host Conference Call Today, October 31, at 430pm ET",2
"INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB “Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials” Webinar to be Held on November 7, 2024, at 1 PM ET. ",2
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell,1
"INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 Management to host conference call and webcast at 430 pm ET on that day",1
"INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit Boca Raton, Florida, Oct.  11, 2024  (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today announced that management will participate in the upcoming Maxim Healthcare Virtual Summit, to be held October 15-17, 2024.",1
Humacyte Third Quarter 2024 Financial Results and Business Update - FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing -,1
"Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024 – ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access –",1
"Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024 DURHAM, N.C., Oct.  23, 2024  (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will host a virtual KOL event on Thursday, October 31, 2024 at 800 AM ET. To register, click here.",1
"Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024 DURHAM, N.C., Oct.  08, 2024  (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its late-breaking abstract on the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients with end-stage renal disease was accepted for an oral presentation at the American Society of Nephrology’s (ASN) Kidney Week 2024. The late-breaking abstract titled “Prospective Randomized Trial of Humacyte's Acellular Tissue Engineered Vessel Versus Autologous Arteriovenous Fistula for Hemodialysis Access” will be presented at the ASN meeting in San Diego on October 26, 2024.",1
"Humacyte Announces Pricing of $30.0 Million Registered Direct Offering DURHAM, N.C., Oct.  04, 2024  (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $30.0 million worth of its common stock and warrants in a registered direct offering.",2
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue,0
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada-,0
Theriva Biologics seleccionada como finalista en el concurso internacional para las becas del programa Advance Biotech Grant en la región EMEA de Merck KGaA El ganador se presentará en BIO-Europe 2024 que se celebrará en Estocolmo (Suecia) El ganador se presentará en BIO-Europe 2024 que se celebrará en Estocolmo (Suecia),1
"Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant Winner to be Presented at BIO-Europe 2024 in Stockholm, Sweden Winner to be Presented at BIO-Europe 2024 in Stockholm, Sweden",2
"Theriva Biologics anuncia la designación de medicamento huérfano concedida por la Comisión Europea al VCN-01 para el tratamiento del retinoblastoma ROCKVILLE, Maryland, Oct.  16, 2024  (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American TOVX), («Theriva» o la «Empresa»), una empresa de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la Comisión Europea ha adoptado la recomendación de la Agencia Europea del Medicamento (EMA) de conceder la designación de medicamento huérfano al principal candidato clínico VCN-01, el adenovirus oncolítico sistémico, selectivo y degradador del estroma de Theriva para el tratamiento del retinoblastoma. La Administración de Alimentos y Medicamentos de EE. UU. (FDA) ya ha concedido previamente las designaciones de fármaco huérfano y de fármaco pediátrico poco frecuente para el VCN-01 para el tratamiento de niños con retinoblastoma.",0
"Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma ROCKVILLE, Md., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma. The United States Food and Drug Administration (FDA) has previously granted orphan drug designation and rare pediatric disease designation to VCN-01 for the treatment of retinoblastoma.",1
"Theriva™ Biologics anuncia el resultado positivo de la revisión del Comité de vigilancia y seguridad de los datos en el ensayo clínico de Fase 1b2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas El Comité de vigilancia y seguridad de los datos (DSMC) ha revisado los datos de seguridad de uso y farmacocinéticos de la Cohorte 2, y ha recomendado que el estudio proceda a inscribir pacientes en la Cohorte 3 El Comité de vigilancia y seguridad de los datos (DSMC) ha revisado los datos de seguridad de uso y farmacocinéticos de la Cohorte 2, y ha recomendado que el estudio proceda a inscribir pacientes en la Cohorte 3",1
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients into Cohort 3 DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients into Cohort 3,2
Editas Medicine Announces Third Quarter 2024 Results and Business Updates Achieved in vivo preclinical proof of concept of HBG12 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia,0
"Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia",1
"Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct.  21, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s proprietary LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets in Editas’ upregulation strategy.",1
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities,1
"Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 12 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 -- ",1
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance,1
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o,2
"TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology",1
"Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update NORWOOD, Mass., Nov.  07, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended September 30, 2024.",1
"Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 NORWOOD, Mass., Nov.  04, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agonist. The data are being presented as a Poster Presentation titled “Induction and Maintenance Regimens with CB1 Inverse Agonist CRB-913 and Semaglutide in DIO Mice”.",1
"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) NORWOOD, Mass., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined doses (1.8 mgkg, 2.7 mgkg, 3.6 mgkg and 4.5 mgkg) and will be followed by Part B (dose optimization) and Part C (dose expansion) that will determine recommendedoptimized doses and seek preliminary efficacy signals.",1
"Immutep Quarterly Activities Report Q1 FY25 SYDNEY, AUSTRALIA, Oct.  29, 2024  (GLOBE NEWSWIRE) -- Immutep Limited (ASX IMM; NASDAQ IMMP) (""Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 September 2024 (Q1 FY25).",1
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS 1) Head and Neck Cancer at ESMO Immuno-Oncology 2024 Media Release,1
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial Media Release,1
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit Media Release,2
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer Media Release,1
"Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates JERUSALEM, Nov.  08, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.",1
"Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement ADELAIDE, Australia and CAMBRIDGE, Mass., Nov.  08, 2024  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provides an update to the proposed re-domiciliation of Bionomics to the United States by way of scheme of arrangement between Bionomics and its Shareholders (“Scheme”) as announced on 1 October 2024.",1
"Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program ADELAIDE, Australia and CAMBRIDGE, Mass., Nov.  04, 2024  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it received a milestone payment of AUS$1M from Carina Biotech for BNC101, one of their partnered legacy oncology programs.",2
"Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct.  07, 2024  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon “Spyros” Papapetropoulos M.D.., Ph.D., President and Chief Executive Officer of Bionomics, issued the following letter to Bionomics shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company’s future.",1
"BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update Conference call and webcast scheduled for November 4, 2024, at 800 a.m. EST (200 p.m. CET)",1
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2024 sowie Informationen zur Geschäftsentwicklung Telefonkonferenz und Webcast sind für den 4. November 2024 um 1400 Uhr MEZ  (800 Uhr U.S. Eastern Standard Time) geplant,1
"BioNTech to Host Innovation Series R&D Day on November 14, 2024 MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 1030 a.m. Eastern Standard Time (1630 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.",1
"BioNTech veranstaltet am 14. November 2024 „Innovation Series Day“ zu Forschung & Entwicklung MAINZ, Deutschland, 31. Oktober 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“), veranstaltet am Donnerstag, 14. November 2024 um 1030 Uhr Eastern Standard Time (1630 Uhr MEZ) in New York City, USA, eine Ausgabe der „Innovation Series“ des Unternehmens mit Schwerpunkt auf Forschung & Entwicklung.",1
"BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024 MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 800 a.m. ET (200 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.",1
"BioNTech veröffentlicht am 4. November 2024 Ergebnisse für das dritte Quartal 2024 und informiert über operativen Fortschritt MAINZ, Deutschland, 21. Oktober 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 4. November 2024, die Ergebnisse für das dritte Quartal 2024 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 1400 Uhr MEZ (800 Uhr Eastern Time) eine Telefonkonferenz samt Webcast für Investoren, Finanzanalysten sowie die allgemeine Öffentlichkeit durchführen, um die Finanzergebnisse sowie ein Unternehmensupdate zu präsentieren.",1
"Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma NEEDHAM, Mass., Nov.  05, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The data will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, in Houston, Texas by Anne R. Diers, PhD, Senior Director of Research at Candel Therapeutics.",1
"Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) NEEDHAM, Mass., Oct.  28, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference (IOVC), taking place October 27-30, 2024, in Rotterdam, the Netherlands.",1
"Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting NEEDHAM, Mass., Oct.  04, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 6-10, 2024 in Houston, Texas and virtually.",1
"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Nov.  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on October 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 271,764 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",1
"BiomX Announces a Mandatory Unit Separation GAITHERSBURG, Md., Oct.  15, 2024  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share.",0
"HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024",2
"HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service",2
"Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction TUSTIN, Calif. and LONDON and BOSTON, Nov.  06, 2024  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP (""GHO"") and Ampersand Capital Partners (“Ampersand”) today announced they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at approximately $1.1 billion.",1
"NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results BELTSVILLE, Md., Nov.  07, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results.",1
"NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting BELTSVILLE, Md., Nov.  05, 2024  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today reports pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed in partnership with LigaChem Biosciences (LCB) (KOSDAQ 141080), and biomarker data from the NC410 combination study with pembrolizumab in patients with immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)microsatellite instability-low (MSI-L) colorectal cancer (CRC). The data will be presented during poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting.",1
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates – The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials –,1
"89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Oct.  11, 2024  (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 265,000 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on October 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).",1
"Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., Nov.  07, 2024  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2024.",1
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update,1
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders,0
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders,1
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update,2
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026,1
"Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18",1
"Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBFGLIS AML SOUTH SAN FRANCISCO, Calif., Nov.  01, 2024  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3GLIS2 (CBFGLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment.",2
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations,1
"Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology",2
"Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024 CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite",1
"Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024 Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale",1
"Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter Cytek has introduced the world’s first Enhanced Small Particle (ESP™) Detection Sorter, which opens the door to scientific discoveries.",1
"Cytek Biosciences Reports Third Quarter 2024 Financial Results FREMONT, Calif., Nov.  05, 2024  (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024.",1
"GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs",1
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-,1
"Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct.  29, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases.",1
"Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference CAMBRIDGE, Mass., Oct.  24, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid, Spain. The presentations will include updates on new scientific findings from Biogen’s Alzheimer’s portfolio, highlighting data on different aspects of treatment and data examining preclinical Alzheimer’s disease and race.",1
"Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients CAMBRIDGE, Mass., Oct.  09, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant patients. The FDA grants BTD to drug candidates for serious or life-threatening conditions and that have preliminary clinical evidence demonstrating potential to provide substantial improvement over existing therapies. The designation provides additional opportunities to engage the FDA and to support the drug development program through Fast Track designation features.",1
"New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA CAMBRIDGE, Mass., Oct.  08, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq BIIB) today announced detailed results from Part B and Part C of the Phase 23 DEVOTE study evaluating the safety and efficacy of an investigational higher dose regimen of nusinersen in spinal muscular atrophy (SMA), showing benefits in both individuals previously treated and treatment-naïve to nusinersen with infantile-onset or later-onset SMA. The investigational, higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®). Data to be presented during the World Muscle Society (WMS) 2024 Congress (Oct. 8-12, 2024 in Prague) highlight the potential of this investigational higher dose regimen to help address remaining unmet need in SMA.",1
"BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded CARSON CITY, Nev., Nov.  04, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is pleased to announce that the upcoming PD-202 A Double-Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkinson’s Disease is now fully funded.",1
"BioVie Inc. Announces Closing of Registered Direct Offering CARSON CITY, Nev., Oct.  29, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share.",1
"UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CARSON CITY, Nev., Oct.  28, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.",0
"BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CARSON CITY, Nev., Oct.  28, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.",1
"BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement CARSON CITY, Nev., Oct.  24, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share.",2
"BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules CARSON CITY, Nev., Oct.  23, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share, resulting in total gross proceeds of $6,000,750, before deducting the placement agent's fees and offering expenses.",0
"BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement CARSON CITY, Nev., Oct.  22, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 4,443,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $1.50 per share.",2
"BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules CARSON CITY, Nev., Oct.  21, 2024  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 4,443,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $1.50 per share, resulting in total gross proceeds of $6,664,500, before deducting the placement agent's fees and offering expenses.",0
"BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin Patents covering BioVie’s terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets",1
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -,2
"Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 SAN MATEO, Calif., Oct.  29, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the successful completion of end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), supporting the advancement of denifanstat into Phase 3 in metabolic-dysfunction associated steatohepatitis (MASH). The planned program will include two Phase 3 trials FASCINATE-3, evaluating patients with F2F3 (non-cirrhotic) MASH, and FASCINIT, evaluating patients with suspected or confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)MASH. The Phase 3 program is expected to initiate by the end of 2024.",2
"Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024 SAN MATEO, Calif., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor, denifanstat, and preclinical data demonstrating atherosclerosis improvement with FASN inhibitor treatment, will be highlighted in three presentations at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2024, taking place November 15-19, 2024 in San Diego, California.",1
"Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2F3 MASH in The Lancet Gastroenterology & Hepatology - Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -- Results support advancement of denifanstat into Phase 3 development -",1
"Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s potential and validating the VersAptx™ Platform technology",2
Aptose Reports Results for the Third Quarter 2024 Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML,1
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition All TSC-treated patients were relapse-free and MRD negative as of data cutoff,1
"Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results SEATTLE, Nov.  07, 2024  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024.",0
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL,1
"SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting – Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a median duration of therapy of approximately 3 years –",1
